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Abstract 
Membrane proteins, which reside in the membranes of cells, play a critical role in many important 
biological processes including cellular signaling, immune response, and material and energy transduction.  
Because of their key role in maintaining the environment within cells and facilitating intercellular 
interactions, understanding the function of these proteins is of tremendous medical and biochemical 
significance.  Indeed, the malfunction of membrane proteins has been linked to numerous diseases 
including diabetes, cirrhosis of the liver, cystic fibrosis, cancer, Alzheimer's disease, hypertension, 
epilepsy, cataracts, tubulopathy, leukodystrophy, Leigh syndrome, anemia, sensorineural deafness, and 
hypertrophic cardiomyopathy.
1-3
  However, the structure of many of these proteins and the changes in 
their structure that lead to disease-related malfunctions are not well understood.  Additionally, at least 
60% of the pharmaceuticals currently available are thought to target membrane proteins, despite the fact 
that their exact mode of operation is not known.
4-6
  
Developing a detailed understanding of the function of a protein is achieved by coupling biochemical 
experiments with knowledge of the structure of the protein.  Currently the most common method for 
obtaining three-dimensional structure information is X-ray crystallography.  However, no a priori methods 
are currently available to predict crystallization conditions for a given protein.
7-14
  This limitation is 
currently overcome by screening a large number of possible combinations of precipitants, buffer, salt, and 
pH conditions to identify conditions that are conducive to crystal nucleation and growth.
7,9,11,15-24
  
Unfortunately, these screening efforts are often limited by difficulties associated with quantity and purity of 
available protein samples. 
While the two most significant bottlenecks for protein structure determination in general are the 
(i) obtaining sufficient quantities of high quality protein samples and (ii) growing high quality protein 
crystals that are suitable for X-ray structure determination,
7,20,21,23,25-47
 membrane proteins present 
additional challenges.  For crystallization it is necessary to extract the membrane proteins from the 
cellular membrane.  However, this process often leads to denaturation. In fact, membrane proteins have 
proven to be so difficult to crystallize that of the more than 66,000 structures deposited in the Protein Data 
Bank,
48
 less than 1% are for membrane proteins, with even fewer present at high resolution (< 2Å)
4,6,49
 
and only a handful are human membrane proteins.
49
  A variety of strategies including detergent 
solubilization
50-53




In recent years, the use of a lipidic mesophase as a medium for crystallizing membrane proteins has 
been demonstrated to increase success for a wide range of membrane proteins, including human 
receptor proteins.
54,56-62
  This in meso method for membrane protein crystallization, however, is still by no 
means routine due to challenges related to sample preparation at sub-microliter volumes and to crystal 
harvesting and X-ray data collection.  This dissertation presents various aspects of the development of a 
 iii 
microfluidic platform to enable high throughput in meso membrane protein crystallization at a level 
beyond the capabilities of current technologies.   
Microfluidic platforms for protein crystallization and other lab-on-a-chip applications have been well 
demonstrated.
9,63-66
  These integrated chips provide fine control over transport phenomena and the ability 
to perform high throughput analyses via highly integrated fluid networks.  However, the development of 
microfluidic platforms for in meso protein crystallization required the development of strategies to cope 
with extremely viscous and non-Newtonian fluids.  A theoretical treatment of highly viscous fluids in 
microfluidic devices is presented in Chapter 3, followed by the application of these strategies for the 
development of a microfluidic mixer capable of preparing a mesophase sample for in meso crystallization 
at a scale of less than 20 nL in Chapter 4.  This approach was validated with the successful on chip in 
meso crystallization of the membrane protein bacteriorhodopsin. In summary, this is the first report of a 
microfluidic platform capable of performing in meso crystallization on-chip, representing a 1000x 
reduction in the scale at which mesophase trials can be prepared. 
Once protein crystals have formed, they are typically harvested from the droplet they were grown in 
and mounted for crystallographic analysis.  Despite the high throughput automation present in nearly all 
other aspects of protein structure determination, the harvesting and mounting of crystals is still largely a 
manual process.  Furthermore, during mounting the fragile protein crystals can potentially be damaged, 
both from physical and environmental shock.  To circumvent these challenges an X-ray transparent 
microfluidic device architecture was developed to couple the benefits of scale, integration, and precise 
fluid control with the ability to perform in situ X-ray analysis (Chapter 5).  This approach was validated 
successfully by crystallization and subsequent on-chip analysis of the soluble proteins lysozyme, 
thaumatin, and ribonuclease A and will be extended to microfluidic platforms for in meso membrane 
protein crystallization.  The ability to perform in situ X-ray analysis was shown to provide extremely high 
quality diffraction data, in part as a result of not being affected by damage due to physical handling of the 
crystals.   
As part of the work described in this thesis, a variety of data collection strategies for in situ data 
analysis were also tested, including merging of small slices of data from a large number of crystals grown 
on a single chip, to allow for diffraction analysis at biologically relevant temperatures.  While such 
strategies have been applied previously,
57,59,61,67
 they are potentially challenging when applied via 
traditional methods due to the need to grow and then mount a large number of crystals with minimal 
crystal-to-crystal variability.  The integrated nature of microfluidic platforms easily enables the generation 
of a large number of reproducible crystallization trials.  This, coupled with in situ analysis capabilities has 
the potential of being able to acquire high resolution structural data of proteins at biologically relevant 
conditions for which only small crystals, or crystals which are adversely affected by standard cryocooling 
techniques, could be obtained (Chapters 5 and 6). 
 iv 
While the main focus of protein crystallography is to obtain three-dimensional protein structures, the 
results of typical experiments provide only a static picture of the protein.  The use of polychromatic or 
Laue X-ray diffraction methods enables the collection of time resolved structural information.  These 
experiments are very sensitive to crystal quality, however, and often suffer from severe radiation damage 
due to the intense polychromatic X-ray beams.  Here, as before, the ability to perform in situ X-ray 
analysis on many small protein crystals within a microfluidic crystallization platform has the potential to 
overcome these challenges.  An automated method for collecting a "single-shot" of data from a large 
number of crystals was developed in collaboration with the BioCARS team at the Advanced Photon 
Source at Argonne National Laboratory (Chapter 6).  The work described in this thesis shows that, even 
more so than for traditional structure determination efforts, the ability to grow and analyze a large number 
of high quality crystals is critical to enable time resolved structural studies of novel proteins.   
In addition to enabling X-ray crystallography experiments, the development of X-ray transparent 
microfluidic platforms also has tremendous potential to answer other scientific questions, such as 
unraveling the mechanism of in meso crystallization.  For instance, the lipidic mesophases utilized during 
in meso membrane protein crystallization can be characterized by small angle X-ray diffraction analysis.  
Coupling in situ analysis with microfluidic platforms capable of preparing these difficult mesophase 
samples at very small volumes has tremendous potential to enable the high throughput analysis of these 
systems on a scale that is not reasonably achievable using conventional sample preparation strategies 
(Chapter 7).  In collaboration with the LS-CAT team at the Advanced Photon Source, an experimental 
station for small angle X-ray analysis coupled with the high quality visualization capabilities needed to 
target specific microfluidic samples on a highly integrated chip is under development.  Characterizing the 
phase behavior of these mesophase systems and the effects of various additives present in crystallization 
trials is key for developing an understanding of how in meso crystallization occurs.   A long term goal of 
these studies is to enable the rational design of in meso crystallization experiments so as to avoid or limit 
the need for high throughput screening efforts.   
In summary, this thesis describes the development of microfluidic platforms for protein crystallization 
with in situ analysis capabilities.  Coupling the ability to perform in situ analysis with the small scale, fine 
control, and the high throughput nature of microfluidic platforms has tremendous potential to enable a 
new generation of crystallographic studies and facilitate the structure determination of important biological 
targets.  The development of platforms for in meso membrane protein crystallization is particularly 
significant because they enable the preparation of highly viscous mixtures at a previously unachievable 
scale.  Work in these areas is ongoing and has tremendous potential to improve not only current the 
methods of protein crystallization and crystallography, but also to enhance our knowledge of the structure 
and function of proteins which could have a significant scientific and medical impact on society as a 
whole.  The microfluidic technology described in this thesis has the potential to significantly advance our 
understanding of the structure and function of membrane proteins, thereby aiding the elucidation of 
human biology, the development of pharmaceuticals with fewer side effects for a wide range of diseases.   
 v 
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Proteins are a class of biological macromolecules which play crucial roles in the internal machinery of 
a cell.  These proteins are composed of long chains of amino acids, the sequence for which is encoded 
by the DNA of a cell.  While genome
1,2
 and protein sequencing efforts
3
 have provided information about 
the primary structure of proteins and the genes that encode them, this information is obtained without any 
knowledge of the actual function of the protein.  Efforts to determine the mechanism whereby a protein 
performs a particular function involve coupling biochemical analyses with knowledge of the three-
dimensional structure of the protein.   
In 2000, the National Institutes of Health (NIH) launched the Protein Structure Initiative (PSI) with the 
goal of obtaining the three-dimensional structures of 10,000 proteins within a decade.
4
  One of the major 
achievements of this concerted effort was the development of improved, and often automated, high 
throughput methodologies for the cloning, expression, and purification of protein targets.
5
  A particular 
focus included the production of membrane protein samples for structure determination.  Membrane 
proteins are especially challenging because of their amphiphilic nature and the fact that they are grown 
within the confines of cellular membranes.  Once a sufficient quantity of high quality protein is obtained, 
protein structure determination is then pursued mainly by protein crystallography, though alternative 
techniques such as nuclear magnetic resonance (NMR) and electron microscopy are achieving 
increasing levels of success.
6,7
  Despite advances associated with protein expression and purification, the 
two most significant bottlenecks for protein structure determination continue to be the (i) obtaining 
sufficient quantities of high quality protein samples and (ii) growing high quality protein crystals.
7-33
  
1.1  Protein Crystallization 
The human genome has been estimated to encode for ~30,000 proteins of which roughly a third each 
are thought to be (i) soluble or globular proteins responsible for functions within the organism, (ii) 
membrane-bound proteins typically responsible for signaling and material and energy transduction across 
the cell membrane,
7,34-39
 and (iii) proteins with no intrinsic structure.
40
  Because protein crystallography 
requires the formation of crystals with repeating units of the protein in identical conformations, it is only 
the structured soluble and membrane proteins to which this method can be applied.   
Crystallization is a technique that has long been used as a purification procedure because crystals 
naturally exclude contaminants.  First a solution of the species of interest is made under conditions 
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favoring dissolution.  Crystallization is then achieved by altering the solution conditions so as to decrease 
the solubility of the desired product to the point where it will precipitate out of solution creating a solid 
crystalline form.  This decrease in solubility is typically achieved by changes in temperature, 
concentration, or by the addition of a precipitating agent such as a salt, an osmotically active molecule 
such as polyethylene glycol, or an anti-solvent.
41
   The growth of high quality protein crystals for X-ray 
analysis is achieved in a similar fashion; first through the identification of crystal forming 
conditions,
10,14,23,42-49
 followed by optimization of crystallization conditions to produce the highest quality 
crystals.
8,9,13-15,22,23,45,46,48,50-60
   
One of the main bottlenecks associated with protein crystallography is the identification of crystal 
forming conditions.
8-27,29,30,32,33,61
  Unfortunately, no methods currently exist to predict crystallization 
conditions a priori.
14,42,45,62-66
  Consequently, sparse matrix screening approaches have been adopted in 
order to explore multidimensional chemical space.
14,25,30-33,42,43,45,49,61,67,68
  In a sparse matrix screen a 
large number of possible combinations of precipitants with different buffer and pH conditions are 
screened to identify conditions that are conducive to crystal nucleation and growth.
10,14,23,31,42-49,68
  
However, while sparse matrix screening approaches provide a way to survey a wide range of chemical 
space, additional considerations such as the kinetic changes of species concentration with time are 
critical for controlling the nucleation and growth of crystals.  The exploration of chemical space and the 
impact of kinetic factors can be illustrated by examining the solubility phase diagram associated with 
crystallization and, once understood, can be affected by the choice of crystallization technique used.   
Figure 1.1 shows a generalized two-dimensional phase diagram, showing the conditions for 
crystallization as a function of protein and precipitant concentration.  However, determination and 
optimization of an actual crystallization condition can involve a large number of parameters including 
temperature, ionic strength, buffer identity and pH, additives, and protein purity.  For membrane proteins 
additional parameters such as detergent or lipid identity and concentration can also have a very 
significant effect.
69
  Furthermore, the areas of the phase diagram that are conducive for crystallization 




The portions of the phase diagram associated with crystallization can be divided into four regions 
(Figure 1.1).
25,41,70
  The solubility boundary separates the undersaturated region, where any crystals 
present would dissolve, from regions of supersaturation where crystal growth is possible.  Within this 
supersaturated region there are three zones: (1) the nucleation or labile zone, (2) the metastable zone, 
and (3) the precipitation zone.  In the nucleation zone the level of supersaturation is high enough to 
induce the nucleation of new crystals and to support subsequent crystal growth.  The metastable zone is 
at a lower level of supersaturation compared to the nucleation zone.  Thus while the level of 
supersaturation is not high enough to support the formation of new nuclei, growth of existing crystals is 
possible.  In the precipitation zone the level of supersaturation is very high, resulting in fast nucleation 
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and growth.  These processes occur so quickly that the resulting solid is amorphous rather than 
crystalline.  Thus, for a crystal to nucleate and grow, the solution needs to reach the nucleation zone first, 
after which it can continue to grow in either the metastable or the nucleation zone.  A wide variety of 
crystallization techniques to achieve first nucleation and then crystal growth have been developed over 
the years.  These are described in detail in Section 1.2. 
 
Figure 1.1. A generalized depiction of the solubility phase diagram for protein crystallization.  The solubility 
boundary defines the undersaturated from the metastable zone.  While crystal growth is possible in the 
metastable zone, higher levels of supersaturation are required for nucleation, as indicated by the nucleation 
zone.  At even higher levels of supersaturation, in the precipitation zone, the driving force to precipitate protein 
from solution is so high that there is not time for the formation of a crystalline solid, and an amorphous 
precipitate results. Thus for crystallization to occur the concentration of the solution must be such that the 
nucleation zone can be accessed, though subsequent crystal growth can occur in the metastable zone.  
Dynamic pathways for various common crystallization techniques are shown.  D = dialysis, VD = vapor 




1.1.1  The Challenge of Crystallizing Membrane Proteins 
While crystallization and structure determination of soluble proteins has been progressing swiftly, the 
structure determination of membrane proteins has lagged behind.  The amphiphilic nature of membrane 
proteins coupled with limited availability has hampered crystallization efforts.
26,39,71
  Amphiphilicity in 
particular is a challenge because crystal growth occurs from a solution of protein and dissolution occurs 
as an interaction of molecules with a like solvent (i.e. polar – polar or apolar – apolar).  Because 
membrane proteins have both hydrophobic and hydrophilic portions they will not readily dissolve into 
either a polar or an apolar solvent on their own.  To counteract this difficulty a variety of strategies have 
been developed such as (i) the in surfo detergent solubilization method which encapsulates the 
hydrophobic portions of the membrane protein in a detergent micelle to allow for dissolution,
36,39,72,73
 or (ii) 
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the in meso method which maintains the membrane protein in a membrane-like environment (see 
Chapter 2).
28,39,74,75
  Despite these strategies, membrane proteins have proven to be so difficult to 
crystallize that 25 years passed between the first structure determination of a soluble protein
76,77
 and that 
of a membrane protein.
78,79
  Furthermore, of the more than 66,000 structures deposited in the Protein 
Databank,
6
 less than 1% are for membrane proteins, with even fewer present at high resolution (< 2Å).
80-
82
  Of these known structures, only 15 are unique human membrane proteins (Figure 1.2).
80
  This 
disparity exists despite genomic analyses indicating that the number of soluble and membrane proteins 
should be similar.
34,83
  Even more critically, the malfunction of membrane proteins has been linked to a 
variety of diseases including diabetes, cirrhosis of the liver, cystic fibrosis, cancer, Alzheimer's disease, 
hypertension, epilepsy, cataract, tubulopathy, leukodystrophy, Leigh syndrome, anemia, sensorineural 
deafness, and hypertrophic cardiomyopathy,
37,38,84
 though the structure of many of these proteins and the 
corresponding malfunctions are not understood.  Furthermore, at least 60% of the drugs currently 
available are thought to target membrane proteins, the influence of a vast majority of which has only been 
guessed at because of  a lack of structural information.
81,82,85
  
In the following sections the traditional methods for protein crystallization will be discussed first 
(Section 1.2), followed by adaptations of these methods for use in microfluidic platforms for protein 
crystallization (Section 1.3).  The work presented in both of these sections is applicable to soluble 
proteins and to analogous strategies for the in surfo crystallization of membrane proteins.
26,73
  A more 
detailed description of the challenges associated with amphiphilic membrane proteins and the in meso 
crystallization of membrane proteins will be considered in Chapter 2.  Both traditional (Section 1.5) and 
microfluidic (Section 1.6) methods for X-ray crystallography will then be discussed in regards to obtaining 
structural information.   
 




1.2  Traditional Methods for Protein Crystallization 
Within the context of a sparse matrix approach where the identity of various precipitating agents are 
screened, a variety of crystallization methods have been developed which provide varying degrees of 
control over the concentration of the protein/precipitant mixture over time.
86
  The four most common 
techniques for protein crystallization are; (1) microbatch, (2) vapor diffusion, (3) dialysis, and (4) free 
interface diffusion.  Each of these techniques controls the change of concentration within the 
 5 
protein/precipitant solution differently, though with allowances for the different dynamics of each method, 




Figure 1.3. Schematic depiction of the generalized setups of typical traditional crystallization methods.  (a) 
Microbatch, (b) the hanging drop configuration of a vapor diffusion setup, (c) a dialysis button, and (d) free 
interface diffusion are depicted. 
Microbatch methods are based on the idea of identifying an initial condition which leads to 
crystallization.
61
  A small drop of protein solution is combined with precipitants or other additives and then 
incubated under Paraffin oil so as to prevent evaporation (Figure 1.3a).
86,90,91
  Thus the supersaturation of 
the droplet is constant with time and the conditions in the droplet will only change if the protein comes out 
of solution, either as a crystal or as an amorphous solid.  In reference to the phase diagram shown in 
Figure 1.1, crystals would only be observed if the initial combination of protein and precipitants resulted in 
a supersaturation high enough to be in the nucleation zone.  In a slight modification to this technique a 
mixture of Paraffin and silicon oils is used in the experiment.  This combination of oils is permeable to 
water vapor and would allow for the permeation of water from the sample and a change in 
concentration.
92
   In this variation, unless the experiment is performed under controlled environmental 
conditions to limit the extent of removal of water, the permeation of water away from the protein droplet 
will occur until the sample has completely dried out.  Microbatch crystallization is typically performed in 
well plates for high throughput analysis. 
Whereas microbatch crystallization involved a search for appropriate initial conditions, vapor diffusion, 
dialysis, and free interface diffusion methods are more dynamic, searching for a path through the phase 
diagram which leads to crystallization.
91
  Vapor diffusion is the most widely used protein crystallization 
technique
25,26,41,87,93,94
 and can be performed in a variety of geometries including hanging, sitting, and 
sandwich drop configurations.
25,26,30,41,86,95
  A droplet containing a mixture of protein and precipitants is 
placed in a sealed environment to equilibrate with a larger reservoir of the precipitant solution (Figure 
1.3b).  Evaporation from the droplet will then take place until equilibrium is reached.  In this method a 
single droplet is able to traverse a range of protein concentration values starting from an undersaturated 
solution, as indicated in Figure 1.1.  The concentration of the droplet will continue to increase until either 
equilibrium is reached or the protein comes out of solution.  Thus vapor diffusion is a more flexible 
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technique than microbatch, with a higher probability of obtaining crystals from a single set of 
crystallization conditions.  However, setting up vapor diffusion trials is more intensive than microbatch 
because of the need to individually seal each crystallization compartment.   
In dialysis the protein and precipitant solutions are separated by a dialysis membrane which is 
impermeable to the protein, but not to the precipitant (Figure 1.3c).
26,61
  As the concentration of precipitant 
changes with time the concentration of protein will remain constant until it comes out of solution.  The 
advantage of this technique is that the dialysis membranes allow for bidirectional changes in the 
concentration of precipitant species without significantly affecting the protein concentration (Figure 1.1).  
One could perform both salting in and salting out experiments, or sample a wide range of pH values.
41,86
  
While this method has similar flexibility to vapor diffusion, setting up crystallization trials is very intensive 
and is typically done using dialysis buttons,
86




In free interface diffusion a path through the phase diagram is traversed by allowing diffusion between 
a protein and a precipitant solution.  Initially the protein and precipitant solutions are placed into contact 
along a clearly defined interface.   The subsequent diffusion of protein into the precipitant solution and 
vice versa then creates a gradient of concentrations along which crystallization can occur (Figure 1.3d).
61
  
As the protein begins to diffuse into the precipitant solution the experiment samples conditions of low 
protein concentration and high precipitant concentration.  However, smaller precipitant molecules will tend 
to diffuse more quickly than larger proteins, allowing the experiment to also sample conditions of high 
protein and low precipitant concentration.  This flexibility gives free interface diffusion trials a tremendous 
capacity to sample a wide range of phase space in search of appropriate crystallization conditions (Figure 
1.1).  From an optimization perspective, protein crystals will grow along the length of the gradient, 
changing from showers of very small crystals or amorphous precipitates where the supersaturation is high 
enough to be significantly into the nucleation zone or into the precipitation zone to single larger crystals 
where the concentration is such that only a few nucleation events are adequate to lower the level of 
supersaturation from the nucleation zone into the metastable zone.  Despite its strengths, free interface 
diffusion is not commonly used on the macroscale due to difficulties in preventing convectional mixing in 
large scale devices.  It has, however, been used in microgravity experiments,
59,60,97,98
 and is ideally suited 
for scaling down to microscale dimensions where the geometries prohibit convectional mixing.  This 
technique and the related counter-diffusion method will be discussed further with respect to microfluidic 
strategies for protein crystallization in Section 1.3. 
The development of high throughput methods for preparing crystallization trials have developed to the 
point where an individual crystallization trial can be set up at volumes <50 nL in a fully automated 
fashion.
88
  Automated fluid handling robots have become a major workhorse of both high throughput 
crystallography facilities as well as smaller structural biology laboratories, with a single unit capable of 
setting up over 400,000 individual trials per month, or 500-600 trials per hour.
4,24
  Despite these advances 
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there is still potential to scale down the volume of crystallization trials further, to the <1nL range, through 
the use of microfluidics.   
1.3  Microfluidic Platforms for Protein Crystallization 
Efforts in developing microfluidic platforms for protein crystallization have focused on utilizing the 
high-throughput capability of microfluidic networks to screen a large number of crystallization conditions 
while relying on miniaturization to reduce the amount of sample needed per experiment.  Additionally, 
microfluidics can provide unique experimental approaches that would be difficult or impossible to 
implement on a larger scale.
61,89
  While the majority of these efforts have focused on miniaturizing 
traditional methods for crystallization including microbatch,
17,18,32,44-47,54,99-116
 and vapor diffusion,
16,44,51-
53,56,117,118
 others such as those focused on platforms for counter-diffusion
22,23,59,60,119-126
 and free interface 
diffusion
14,22,23,42,51,61,99,119-122,124-128
 have taken further advantage of the lack of convection and turbulence 
at the microscale to enable their technology.  In the subsequent examples microfluidics has been defined 
as any system where the characteristic dimension of the system is < 1 mm, such that turbulent effects 
can be neglected.  These "microfluidic" systems include examples ranging from simple capillaries, to 
nanoliter-scale droplets contained by two-phase flow, to highly integrated microfluidic networks created by 
multilayer soft lithography.   
1.3.1  Fabrication of Microfluidic Systems 
Soft lithography and replica molding have facilitated the development of a wide range of microfluidic 
technologies ranging from simple single layer devices to complex microfluidic networks.
129
  While 
fabrication methods such as hot embossing can be used to define device structures, soft lithography has 
the benefit of rapid prototyping for faster cycle time from concept to device.  A device design can be 
created in a computer aided design program and then printed on a high resolution transparency to serve 
as a mask.  A master for replica molding can then be fabricated from photoresist on a silicon wafer using 
standard photolithographic techniques.  Device fabrication is achieved by replica molding from a master.  
While a wide variety of materials including glass and various polymers have been used for simple 
structures, the use of elastomeric materials such as polydimethylsiloxane (PDMS) allows for the 
integration of valves and pumping mechanisms
130-132
 and is capable of replicating features down to sub-
micrometer length scales.
133
  Valving of fluid lines can be accomplished by the creation of a multi-layer 
device where a thin membrane can be pneumatically deflected by either positive pressure to seal off flow 
in the fluid layer below in an actuate-to-close configuration
130
 (Figure 1.4a) or negative pressure to allow 
flow in an actuate-to-open configuration (Figure 1.4b).
131,134
  A pump can be fabricated by placing a series 
of valves in series and actuating them a peristaltic fashion.
130,132
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Figure 1.4. Schematic showing operation of microfluidic valves by deflection of a thin membrane by (a) positive 
pressure in an actuate-to-close configuration, or (b) negative pressure in an actuate-to-open configuration. 
1.3.2  Examples of Microfluidic Platforms for Protein Crystallization  
In applying a microfluidic approach to microbatch crystallization the major benefit comes from the 
small volumes of fluid used.  Whereas the volume of fluid dispensed can be easily controlled for the 
traditional scale of crystallization trials, metering and controlling nanoliter-scale or smaller volumes is a 
significant consideration on the microfluidic scale.  The simplest method for metering fluids is filling of a 





  For a crystallization trial, wells containing protein solution must be brought into 
contact with those containing precipitant solutions.  In a very simple example, a series of wells on the 
glass bottom half of a device were aligned with a PDMS slab containing connecting channels.  Having 
degassed the PDMS slab by exposure to vacuum, the material retained enough internal pressure to fill 
the wells with either a protein or a precipitant solution.  Similar to traditional microbatch experiments, a 
silicone oil was used to protect filled wells as the PDMS slab was removed (Figure 1.5a).  Two half 
devices, one containing protein and the other containing precipitant solutions were then aligned under oil 
and allowed to incubate (Figure 1.5b).
18
   
A similar but more elegant microfluidic solution, termed SlipChip, begins with the various wells and 
connecting channels present in two half devices.  The two halves of the device can be slipped relative to 
each other to align wells and channels for loading of protein and precipitants and then to align and seal 
off wells to form a crystallization trial (Figure 1.6).
99,135
     
An alternative method of defining and controlling nanoliter volumes of fluid involves the use of two-
phase flow.
17,44-47,54,93,100-106,108,110,112,136-138
  By carefully controlling surface tension a series of droplets can 
be formed at a T junction where a carrier stream such as a fluorinated oil is used to disperse aqueous 
droplets (Figure 1.7a).  An advantage of this method over more static well-based strategies for 
microbatch crystallization is that the composition of an individual droplet can be easily varied by changing 
 9 
the flowrates of the various components over time (buffer, protein, precipitant, etc.).  Thus instead of 
merely screening a single protein/precipitant combination, the droplet-based approach allows for sub-
screening of a wide range of concentrations for each individual precipitant.  This allows for the 
simultaneous screening and optimization of crystallization conditions (Figure 1.7b).  The scale and ease 
of this method also vastly outstrips the current speed with which traditional microbatch trials can be set 
up.  Instead of 500-600 trials per hour at 50 nL/trial, using 25-30 µL of protein,
4,24
 the droplet-based 




Figure 1.5. (a) Schematic illustration of the process of removing the PDMS microchannel from a filled series of 
microwells.  Silicone oil has been applied to protect the microwells from evaporative losses.  (b) Illustration of 
the aligning of two half-devices under oil followed by diffusive mixing and incubation.  (Figure adapted from 




Figure 1.6. Schematic depiction of filling of the protein precipitant solutions.  Slipping of the chip allows for 
mixing by diffusion. (Image adapted from Li and Ismagilov, 2010).
61
 
While vapor diffusion at the macroscale involves controlling composition based on vapor/liquid 
equilibrium, we will expand our consideration of this technique at the microscale to include diffusion of 
solvent through any medium.  One of the difficulties in scaling down vapor diffusion while maintaining a 
vapor/liquid equilibrium is the difficulty in controlling separate volumes of fluid with merely an air gap.  
 10 
This can be a particular challenge in screening for crystallization conditions where the various chemicals 
present can create vastly different wetting properties and for membrane proteins where the presence of 
detergents significantly affects wetting.
46
   
 
Figure 1.7. A droplet-based microfluidic approach to microbatch crystallization.  (a) A schematic illustration of 
the droplet formation process where various precipitants combine with buffer and protein solution in various 
ratios.  (b) Optical micrographs of crystallization results for photosynthetic reaction center from Blastochloris 
viridis at two different crystallization conditions.  (Figure adapted from Li and Ismagilov, 2010).
61
 
Lounaci and coworkers have demonstrated two examples of traditional microscale vapor diffusion.  
Reservoirs containing the crystallization and reservoir solutions are separated by a microchannel through 
which vapor/liquid equilibrium is established.
16,117
  A secondary challenge with this method is the fact that 
in order for the two liquids to be in vapor contact with each other they cannot be isolated from the device 
materials or the external environment.  While PDMS has many benefits for microfluidic devices, including 
air permeability which allows for dead-filling of chambers, this same air permeability means that the 
PDMS is capable of both solvent absorption and evaporative solvent loss.  This can be controlled to a 
certain extent by controlling the environment around the device, but provides an additional complication.   
The droplet-based methods described earlier with respect to microbatch can be modified for vapor 
diffusion-type experiments.  Two phase flow can be used to generate and control individual crystallization 
trials while reservoir solutions are used to osmotically control the composition of the droplets by solvent 
diffusion through the carrier stream.  This strategy has been applied in several ways, the first of which is 
to generate a set of alternating droplets of a crystallization trial and "reservoir" droplet which acts as an 
osmotic bath.
44
  An alternative approach is to separate the crystallization trials and reservoir solutions in 
separate layers of the device.
53,56,118,137,138
 This strategy has the added benefit of allowing dynamic control 
over the composition of the reservoir solutions with time.  In fact, this has been used to decouple the 
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nucleation and growth of crystals.  By initially using a reservoir solution of high concentration Fraden and 
coworkers were able to first drive nucleation by concentrating the droplet until it reached the labile zone.  
Subsequent lowering of the concentration in the reservoir caused the concentration of the droplet to 
decrease to the point where nuclei smaller than a critical radius dissolved and crystal growth on the 
remaining nuclei could proceed (Figure 1.8).
56,118
   
 
Figure 1.8.  A crystallization droplet contained by a carrier fluid and connected to an osmotic reservoir.  (a) The 
initial state of the droplet.  (b) The droplet after equilibrating with a high concentration salt reservoir.  The 
volume of the droplet has shrunk and nucleation can be seen.  (c) The droplet after subsequent equilibration 
with a reservoir of lower salt concentration.  The droplet has increased in size with rehydration and many of the 





Figure 1.9. (a) Schematic of a gel acupuncture experimental setup for counter-diffusion.  The protein is loaded 
into capillaries and then punctured into a gel which prevents protein diffusion but through which precipitants can 
diffuse.  (Figure adapted from Garcia-Ruiz et al., 2002).
120
  (b) A counter-diffusion chip fabricated out of cyclic 
olefin copolymer (COC) by Greiner Bio-One. (Figure adapted from Ng et al., 2008).
122
  (c) A counter-diffusion 
chip manufactured by Microlytic. (Figure adapted from http://www.microlytic.com).
139
  (d)  A typical crystal 
growth profile in a counter-diffusion experiment using the device from (e) ranging from small crystals or 
amorphous precipitates on the right side which is closest to the precipitant reservoir to large single crystals on 
the left where lower levels of supersaturation are present.
124
  (e) A multichannel counter-diffusion chip 
fabricated out of COC.  (Figures adapted from Dhouib et al., 2009).
124
 
Free interface diffusion and counter-diffusion are the two crystallization methods most closely 
associated with microfluidic crystallization.  Counter-diffusion localizes the protein solution in a capillary or 
a microfluidic channel, oftentimes immobilized in a gel to reduce convective effects.  After filling the 
capillary or channel with protein solution, the precipitant solution is then introduced at one end.  The 
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precipitant solution then diffuses into the protein solution, creating a concentration gradient (Figure 
1.9).
22,23,26,59,60,93,98,119-126,139
  Free interface diffusion, on the other hand, establishes an interface between 
a protein and precipitant solution where diffusion of both species can occur.
14,22,23,42,51,61,98,99,119-122,124-128
  
Unlike counter-diffusion where a gel can be used to stabilize the protein solution and prevent convection, 
free interface diffusion requires either the convection-free conditions present in microfluidics or a zero-
gravity environment to be fully realized.   
Though elegant solutions such as the Slip-Chip have been recently developed,
61,99
 the free interface 
diffusion technique was truly enabled by multilayer microfluidic technology and the active valving and fluid 
control it provided (Section 1.3.1, Figure 1.4).  These valves were required because of the need to 
establish a clean interface between the protein and precipitant solutions and prevent premature contact 
during device filling.  In one of the best known examples, Quake and coworkers reported a microfluidic 
free interface diffusion crystallization platform comprised of an array of 144 10 nL chambers, capable of 
screening 48 precipitants, each at three different precipitant-to-protein ratios (Figure 1.10).
42,49,51,140
  
Pneumatic valves were used to isolate the chambers containing protein and precipitant solutions from 
each other during filling and then released to allow diffusion.  This method has been used to crystallize a 
number of novel targets,
13,127,141




Figure 1.10.  (a) Optical micrograph of a portion of a microfluidic device showing a set of three chambers used 
to create differing protein/precipitant ratios for free interface diffusion crystallization.  (b) A photograph of an 
integrated array chip containing 48 sets of three wells, each capable of screening a separate precipitant.  (c) 
Optical micrographs of protein crystals of type II topoisomerase ATPase domain/ADP (top), lysozyme (bottom 
left), thaumatin (bottom right) grown on-chip.  (Figure adapted from Hansen et al., 2002).
42
 
The advantage of both counter-diffusion and free interface diffusion as crystallization techniques is 
the range of phase space covered by a single trial.  Hybrid strategies that combine free interface diffusion 
with the osmotic control of vapor diffusion have also been reported to further extend this range.
51
   
Beyond conversion of existing crystallization to the microscale, microfluidic technology has also 
enabled high throughput pre-crystallization screening efforts.  Whereas crystallization screening 
experiments may need to incubate for days or weeks, a fast "solubility fingerprint" can be obtained in 
order to narrow down the window of phase space for further examination.  A highly integrated microfluidic 
chip was developed by the Quake group to efficiently meter in varying amounts of different precipitants or 
buffers, mix them quickly with the protein solution, and then examine the resulting droplet for precipitation 
(Figure 1.11).
15




  This strategy has been used numerous times as a pre-screening method which 





Figure 1.11.  (a) Optical micrographs of the microfluidic formulator and accompanying ring mixer used to 
screen for solubility.  (b) Metering of a chemical (blue) into the ring mixer.  (c) The ring mixer filled with several 
different chemicals, as indicated by the different colors present.  (d) The well mixed trial after ring mixer 
operation.  (Figure adapted from Hansen et al., 2004).
15
  
In summary, microfluidic strategies have been developed for a wide variety of crystallization methods.  
While the application of these methods to membrane proteins in particular was not discussed, their 
efficacy has been demonstrated in many cases.  One of the major challenges in adapting these platforms 
for the crystallization of membrane proteins is controlling wetting and surface properties of the devices in 
the presence of detergents and other amphiphiles.  This is a challenge not only from a fluid handling 
perspective, but also with respect to the crystallization trial itself.
61
  Because detergents and amphiphiles 
are critical for the solubilization and stabilization of membrane proteins unanticipated variations in their 
concentration due to adsorption onto the surface of the device could adversely affect a crystallization trial.  
Another challenge that will be addressed in Chapters 3 and 4 is the ability of microfluidics to work with 
highly viscous fluids, such as the lipidic mesophases used for in meso crystallization (Chapter 2).     
1.4  Protein Crystallography 
While obtaining high quality crystals is one of the major bottlenecks associated with structural 
biology,
8-28,30-33,61,82
 the harvesting and X-ray analysis of these crystals is also non-trivial.
31,144
  Protein 
crystallography makes use of the diffraction of X-rays through the lattice of the crystal.  The theoretical 
resolution limit on the level of structural detail that can be resolved by diffraction is equal to half of the 
wavelength of light used to probe the sample.
41
  Thus in order to extract atomic detail about the structure 
of a protein it is necessary to use X-ray radiation, the characteristic wavelengths for which are ~1Å.  In a 
typical crystallography experiment a crystal is exposed to a beam of X-rays and the subsequent 
diffraction image is recorded (Figure 1.12).  To fully characterize the molecular structure of the crystal the 
sample is rotated and additional diffraction images are taken.  The resultant diffraction data can then be 
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analyzed and a map of the electronic density present within the crystal extracted.  The three dimensional 
structure of a protein can be drawn from these electronic density maps.   
 
Figure 1.12.  Schematic depiction of a protein crystallography setup.  A loop mounted crystal has been placed 
on the goniometer and is exposed to the incident X-ray beam.  The resultant diffraction pattern is recorded on a 
detector.  The displayed diffraction pattern was taken of a thaumatin crystal under cryogenic conditions at the 
21-ID-F beamline at the LS-CAT at the Advanced Photon Source (APS) at Argonne National Lab.   
The strength and quality of the diffraction signal observed from a protein is a strong function of the 
internal perfection of the crystal, and cannot be determined by optical inspection.
93
  While the common 
perception may be that crystals have a rigid internal order, as is true for ionic crystals such as NaCl or 
crystals of smaller organic molecules, the strength of this ordering is much weaker in protein crystals due 
to a smaller number of stabilizing lattice contacts relative to the total number of atoms present.
25,41
  This 
problem is particularly exacerbated for crystals of membrane proteins grown in surfo where the protective 
band of detergent necessary for solubilizing the proteins interferes with intermolecular contacts.
145
  An 
additional challenge in dealing with protein crystals is their high solvent content.  Protein crystals typically 
contain 30 to 70% water, with some examples showing a water content as high as 95%.
25,41,105,145-162
  The 
fragility and high solvent content means that protein crystals can not only be easily damaged by physical 




As a result of this fragility and the need to insulate protein crystals from environmental effects, 
methods for harvesting and mounting crystals are a significant consideration for a crystallography 
experiment.  Section 1.5 presents traditional methods for harvesting and mounting protein crystals as well 
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as addressing strategies for minimizing radiation damage.  Section 1.6 discusses microfluidic strategies 
for protein crystallography that do not require harvesting crystals from a microfluidic device.   
1.5  Traditional Methods for Protein Crystallography 
Having overcome the challenges associated with growing high quality protein crystals, the geometry 
and materials of most crystallization setups prevent or limit in situ analysis of undisturbed crystals.
164-168
  
The limitations of crystallization trays come both from the geometry of the plates, the proximity of 
crystallization droplets and reservoir solutions, and the significant attenuation and scatter that would 
result from both the materials of the tray and the liquid surrounding the crystal.  Therefore harvesting 
individual crystals has proven necessary for any significant level of X-ray analysis.  
Harvesting and mounting of protein crystals is performed using either a crystal loop (Figure 1.13a) or 
a crystal mount (Figure 1.13b).
71,169-172
  Once isolated, handling and mounting of the crystal depends on 
how the X-ray analysis is going to be performed.  Initial screening to examine crystal quality was 
historically performed at room temperature, and while the collection of a complete dataset for structural 
analysis can be done at ambient conditions, it is more common to collect data at cryogenic conditions to 
minimize radiation damage and decrease molecular motion.
147,162,173-175
  While a vast majority of 
crystallography experiments today are done completely under cryogenic conditions, some crystals and 




One of the big challenges in mounting a protein crystal at ambient conditions is the need to protect it 
against environmental shock and dehydration.  Historically this has been done by mounting the crystal 
against the wall of a thin glass or quartz capillary using the surface tension of a thin film of mother liquor 
from the crystallization droplet.
169,181,182
  However, this method for mounting crystals is very challenging 
and has a series of disadvantages: (i) Fragile crystals must be carefully manipulated and may tend to 
conform to the cylindrical shape of the capillary, thereby increasing the crystal mosaicity.  (ii) Optical 
observations of a crystal in a capillary are hindered by scattering from both the capillary itself and the 
capillary-liquid interface.  (iii) The capillary itself results in significant signal attenuation, the effects of 
which may be non-uniform due to different path lengths through both the capillary and the liquid holding 
the capillary in place.  (iv)  Finally, capillary mounting methods are poorly suited for cryocooling due to the 
significant air gap and poor heat conduction.
169
   While some of these challenges can be overcome by the 
use of flattened capillaries or more advanced materials,
169,183
 mounting crystals remains a challenge.  
More recent methods for crystal mounting at room temperature couple the idea of a capillary containing a 




Sample mounting for cryogenic data collection has the distinct advantage of avoiding concerns of 
crystal dehydration.  Crystals are harvested either in a thin loop that holds the crystal in place via surface 
tension (Figure 1.13a)
147,169




  The goal here, as in room temperature mounting is to minimize both the scattering 
contribution of the mount itself and to minimize the volume of liquid remaining around the crystal.  Once 
mounted, the crystals are then plunged into a cryogen such as liquid nitrogen, a cold nitrogen gas stream, 
or liquid propane which cools the sample at a rate fast enough to vitrify the sample into an amorphous 
solid, avoiding the formation of ice.  However, the cooling rate necessary for vitrification is strongly 
dependent upon solution conditions.  Most crystals must be grown or treated with a cryoprotectant 
solution to help prevent the formation of ice during cryocooling.
67,147,162,175
   
 
Figure 1.13.  (a) An optical micrograph of a crystal of the membrane protein of bacteriorhodopsin mounted in a 
traditional crystal loop.  (b) An image of a polyimide-based crystal mount from Mitegen.
172
  (c) A photograph of a 
mounting setup for room temperature analysis.  The crystal is harvested using a standard mount as in (b) and 
protected from dehydration by a thin plastic capillary containing a small amount of mother liquor.  (Figures 
adapted from Qutub et al., 2004, Thorne et al., 2003, and Kalinin et al., 2005).
20,170,184
 
The methods for mounting crystals both at ambient and at cryogenic conditions require significant skill 
in manipulating small, fragile samples under a microscope.  These difficulties in handling are further 
compounded by the need to minimize handling time to avoid damaging the already sensitive crystals via 
environmental shock.  Additionally, as structural biology efforts continue, the remaining targets of interest 
are increasingly likely to be proteins which have resisted crystallization and analysis previously, and may 
only be available in miniscule quantities.  Crystallization trials for these difficult proteins may need to be 
performed at a very small volumetric scale and may produce only microcrystals.  While brighter X-ray 
sources and more tightly focused beams have enabled analysis of tiny, sub-10 µm crystals,
21,24,144,186
 the 
handling and mounting of these crystals remains a challenge.
144
   
1.6  Microfluidic Methods for In Situ Protein Crystallography 
As discussed in Section 1.3, a variety of microfluidic strategies for protein crystallization have been 
developed.  While much of the application focus for microfluidics in structural biology has been on the 
screening and optimization of crystallization conditions, mounting of crystals for analysis represents the 
only fully manual step remaining in the structure determination pipeline.
14,23,48,55
  Coupling in situ X-ray 
analysis with the high throughput screening ability of these platforms has tremendous potential not only to 
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decouple physical handling and environmental effects from crystal quality studies but also to enable the 
structure determination of otherwise recalcitrant targets.
28,29,51,63,93,125,141
 
The main consideration for enabling in situ analysis is simply minimizing the signal attenuation and 
scattering profile from the microfluidic device materials, as in traditional room temperature sample 
mounting.  However, unlike traditional mounting strategies, in situ analysis prevents removal of the 
surrounding mother liquor from the crystal.  Nevertheless, the benefits of avoiding sample handling have 
the potential to outweigh the additional scatter and signal attenuation resulting from this liquid.  Additional 
considerations for in situ analysis involve limitations on the device geometry with respect to sample 
mounting, translation, and rotation as well as cooling for cryogenic data collection, and the addition of 




Within the realm of microfluidic crystallization methods, those performed in capillaries are the simplest 
to use for in situ analysis because very little adaptation is necessary to mount the sample for analysis.  In 
the counter-diffusion method crystals are grown within an X-ray capillary.
22,23,93,98,119-121,123,191
  The use of 
a gel within a capillary helps to completely eliminate both convective effects and the potential for crystals 
to move within the capillary.
22,23,98,119,120
  While crystals grown via this method can be mounted directly for 
analysis at room temperature, cryogenic data collection requires the addition of a cryoprotectant.  
Because the cryoprotectant solution is added separately, rather than mixed in with the gel, the diffusive 
time necessary for crystals along the length of the capillary to become adequately cryoprotected can be 
significant.
23,93,98,119,120
  A similar strategy can be used to add not only cryoprotectant, but other additives 
such as heavy atoms for ab initio structure determination.
22,23,93,98
 
Crystallization in droplets can also be easily adapted for in situ analysis.  Droplet incubation is 
typically done in either a glass capillary or plastic tubing, thus mounting of samples is similar to traditional 
capillary-based experiments.
44-47,93,100,102,104,105,110,112,140
  In this example, unless the cryoprotectant is 
capable of diffusing through the fluorinated carrier, it would be necessary to grow the crystals under 
cryoprotected conditions. 
Despite the fact that X-ray capillaries have a long history of use in crystallography, the capillary or 
tube geometry which is most efficient for crystallization trials is most likely not optimal for diffraction 
experiments, particularly under cryogenic conditions.  For crystallization trials a long tube or capillary is 
desirable either to establish a long diffusive path for counter-diffusion, or to contain many droplets.  
However, for cryogenic data collection it is necessary not only to flash-cool the crystal of interest, but also 
to maintain the temperature of the crystal and the surrounding materials in order to prevent the formation 
of ice during data collection.  To this end a coaxial laminar stream of cold nitrogen surrounded by warm 
dry air is used to constantly cool the sample and prevent ice formation once mounted for analysis.  This 
cryostream is only a few millimeters in diameter and would only be able to cool a small section of a long 
capillary.  The remaining portions of the capillary will act as a heat sink, conducting heat towards the 
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crystal at a rate which the cryostream may or may not be able to overcome.  Therefore for long capillaries 
the chance for ice formation and poor cryocooling is substantially larger.  To overcome these problems or 




In situ crystallography has also been demonstrated for simple counter-diffusion and droplet-based 
microfluidic crystallization chips where the microfluidic channel has been molded into a planar plastic 
substrate.
98,110,122,124,126,139
  In these examples the crystallization method itself has not changed, though 
the physical geometry of the chip has been modified.  For instance, in the counter-diffusion chip shown in 
Figure 1.9e, a branching design was used to simplify loading of protein solution and minimize 
losses.
124,126
  In another example the CrystalCard manufactured by deCODE Biosystems combines a 
microfluidic droplet formulator and storage channel onto a single plastic chip, improving ease of use 
(Figure 1.14).
110
  In all of these cases the chip was fabricated from relatively thin organic plastic materials 
in order to minimize X-ray attenuation and scatter.  While in situ crystallography has been demonstrated 
for all of these microfluidic platforms, it has been limited to noncryogenic conditions due to even more 
significant geometric limitations in cooling than those discussed previously in reference to long capillaries. 
 
Figure 1.14.  (a) A picture of the plastic CrystalCard produced by deCODE Biosystems, combining a 
microfluidic formulator and a winding storage channel.  (b-c) The thin plastic cover being removed from the 
CrystalCard.  (d-e) Optical micrographs of a crystal grown on-chip being harvested with a cryoloop.  (f) A 
picture of the CrystalCard mounted on the goniometer head of an X-ray source for in situ analysis.  (Figure 
adapted from Gerdts et al., 2008).
110
 
In situ analysis has been demonstrated for a range of different platforms, but it has been mostly 
limited to simple microfluidic geometries.  For multilayer microfluidic devices such as the free interface 
diffusion chip developed by Quake and coworkers (Figure 1.10) it is necessary to use an elastomeric 
material such as polydimethylsiloxane (PDMS) to enable valve actuation.
13,14,42,51,130,141
  PDMS, however, 
is a silicon-based polymer, resulting in significantly higher X-ray attenuation than organic polymers.
192
  
Thus when performing in situ analysis of crystals grown in a chip made of PDMS, the thickness of the 
material becomes a significant consideration. 
While the functional areas of a multilayer microfluidic device (the fluid and control lines) are typically 
only 10 – 100 µm thick, typical fabrication procedures result in a much thicker device, up to several 
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millimeters, in order to provide stability and facilitate connections between the chip and external pressure 
control lines.  Therefore in order to perform in situ analysis of crystals grown in a PDMS-based free 
interface diffusion chip a section of the device of interest needed to be punched out and then excess 
material needed to be trimmed away.
29,51
  The resulting sample was small enough to allow both room 
temperature and cryogenic data collection.  Although this strategy has been successful in several 
cases,
13,51
 including the first in situ structure determination of a novel crystallization target using a 
microfluidic platform for protein crystallization,
141
 it still involves significant manual sample handling and 
the potential for damaging crystals.   
One potentially interesting application for in situ analysis using a multilayer microfluidic device would 
be for real-time crystallographic analysis that takes advantage of the active fluid control provided by 
microfluidic valves.  This kind of study could vary from an investigation of the effects of various 
cryoprotectants on crystal quality to time resolved structural studies as a result of a pH or concentration 
gradient.  However, X-ray transparency must be coupled with active microfluidic valving to enable these 
experiments.  Additionally, geometric considerations associated with mounting the device for analysis, 
and the subsequent need for translation and rotation during X-ray data collection, must also be dealt with. 
In summary, the ability to perform in situ X-ray analysis on crystals grown in microfluidic devices has 
been demonstrated.  In situ analysis has been shown to allow for data collection from higher quality 
crystals by avoiding the potential for both physical damage and environmental shock during mounting.  
However, in designing a microfluidic platform for in situ analysis both the properties and dimensions 
device and the operational needs of the experiment must be carefully considered.  As a result of scatter / 
absorption, device materials can have a significant impact on the quality of X-ray data which can be 
collected.  Additionally, the device geometry can potentially introduce limitations in terms of mounting, 
translation, rotation, and cryocooling.  However, the benefits of microfluidic platforms, both in terms of 
scale and in terms of precise fluid control, coupled with in situ crystallography have tremendous potential 
to enable the study of small fragile protein crystals for the next generation of structural biology efforts. 
1.7  Summary and Key Remaining Challenges 
One of the key bottlenecks in the structure determination of proteins still remains identification of 
appropriate crystallization conditions to grow high quality crystals for X-ray diffraction analysis.
8-25,29-33,61
  
Because no methods exist to predict crystallization conditions a priori, high throughput sparse matrix 
screening approaches have been adopted in order to screen a wide range of conditions.
14,30-
33,42,43,45,49,61,63,68
  Microfluidic platforms for crystallization have the potential to facilitate these screening 
efforts, not only by a reduction of the volumetric scale of the screen, but also through efficient fluid 
handling and by enabling crystallization methods that cannot be implemented on a larger 
scale.
14,15,17,32,42,44-46,49,51,53,54,61,99,100,102-105,124,126,193
   
While the crystallization and structure determination of both soluble and membrane proteins has been 
progressing at an exponential rate, the success rate for membrane proteins is significantly slower than 
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that of their soluble counterparts.
78
  The challenge in dealing with these membrane-bound proteins comes 
from their amphiphilic nature and difficulties in maintaining their functional structure upon removal from 
the membrane.  A variety of methods, including the in meso method of crystallization which "solubilizes" 
the membrane protein in an artificial membrane rather than a detergent micelle, have been developed to 
overcome these difficulties.  An in depth discussion of the in meso method will be given in Chapter 2.   
Coupled with the need to maintain amphiphilic proteins in a membrane-like environment is the 
challenge of preparing highly viscous crystallization samples.  This challenge presents particular 
difficulties when trying to adapt it for crystallization in microfluidic platforms.  Chapter 3 develops a series 
of design rules for overcoming the limitations of highly viscous fluids at the microscale and Chapter 4 
applies these results for the development of a microfluidic platform for in meso membrane protein 
crystallization.   
Although obtaining high quality protein crystals is a significant bottleneck for structural biology 
efforts,
8-33,61,82
 mounting crystals for X-ray analysis is also non-trivial.  Membrane proteins in particular 
have a tendency to form only very small and fragile crystals, and the size of crystals that can be analyzed 
at current synchrotron facilities is becoming smaller than the crystal size which can be reasonably 
mounted using present methods.
21,24,144,186
  Additionally, protein crystals have a very large solvent content 
and are particularly susceptible to dehydration and environmental shock once removed from the droplet 
they were grown in.
32,41,105,145-161
  The ability to perform in situ crystallographic analysis avoids many of 
these difficulties and would enable structural studies of difficult proteins by facilitating the analysis of 
higher quality crystals by avoiding potential damage.
13,44,45,51,100,102,104,105,110,140,141
  Coupling the 
advantages of microfluidic platforms for protein crystallization with in situ X-ray analysis has tremendous 
potential to enable not only traditional structural biology efforts, but also more advanced examinations of 
protein function through dynamic real-time and time resolved structural studies. 
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In Meso Membrane Protein Crystallization 
2.1  The Challenge of Amphiphilic Membrane Proteins 
Membrane proteins represent one of the most important classes of proteins.  These membrane-
bound proteins are typically responsible for material and energy transduction across cellular membranes 
as well as cell signaling.
1-7
  Because the function of these proteins is so critical for cellular operation, their 
malfunction can have serious consequences and has been linked to a variety of diseases including 
diabetes, cirrhosis of the liver, cystic fibrosis, cancer, Alzheimer's disease, hypertension, epilepsy, 
cataract, tubulopathy, leukodystrophy, Leigh syndrome, anemia, sensorineural deafness, and 
hypertrophic cardiomyopathy.
5,6,8
  Furthermore, modulation of cellular function by pharmacological 
treatment of membrane proteins has tremendous therapeutic potential.  In fact, at least 60% of the drugs 
currently available are thought to target membrane proteins.
9-11
  In all of these cases, knowledge of the 
three-dimensional structure of these proteins would dramatically improve our understanding of not only 
their biological function, but could also allow for the rational design of medical treatments.
12
  
Membrane proteins present significant challenges to the study of their function.  Obtaining large 
quantities of membrane proteins through over-expression is often difficult because these proteins are 
localized within the cellular membrane.
9,12-20
   These membranes have a limited capacity and are already 
crowded with naturally occurring membrane proteins that are necessary for cellular function.
14,21-24
  
Additionally, different organisms may have different membrane properties.  For instance, the simple 
peripheral inner membrane such as the one in E. coli provides a relatively small volume for the 
sequestration of over-expressed membrane proteins (Figure 2.1a).  This is particularly challenging 
because of the ease by which E. coli can otherwise be used for genetic manipulation and protein 
expression.
18
  Other organisms such as Rhodobacter have a much larger inner membrane structure, and 
are therefore able to accommodate much larger quantities of membrane proteins (Figure 2.1b), but might 
not be as commonly used for protein expression.
14,25
  Expression of membrane proteins at too high of a 
level can also result in aggregation of the expressed protein as inclusion bodies or even cell death,
9,14-
18,25-31
 and while strategies exist to refold aggregated proteins, there is no guarantee as to the quality of 
the refolding.
26-28,30
  Over-expression of proteins is also often done in a heterologous fashion, leading to 
additional potential challenges such as misfolding and post-translational modifications when the host 






Figure 2.1. Membrane morphologies of prokaryotic cells.  (a) The volume of the inner membrane in E. coli 
available for accommodating membrane proteins is relatively small (~3%), posing a serious limitation in the 
available membrane volume for over-expressed membrane proteins.  (b) Some organisms such as 
Rhodobacter have a much larger inner membrane area and are better able to sequester large quantities of 
over-expressed membrane proteins.  (Figure adapted from Hanson et al., 2009).
14
 
In addition to challenges with expression, the amphiphilicity of membrane proteins also causes 
difficulties with purification and crystallization.
4,20,32-34
  Because isolation of cellular membranes from the 
soluble portions of a cell is relatively straightforward, the main goal of purification is to separate the 
desired membrane protein from the many other proteins sequestered within the cellular membrane.
18
  
However, the majority of strategies to perform this separation require the dissolution of these 
proteins.
4,18,35-38
  Because membrane proteins have both hydrophobic and hydrophilic portions they will 
not readily dissolve into either a polar or an apolar solvent on their own.
13,16,20,34,37,39,40
  To overcome this 
challenge, membrane proteins are typically solubilized in detergent-containing solution.
11-13,16,18-20,31,32,34-
37,39,41,42
  The use of a detergent solution above the critical micelle concentration (CMC) allows for 
engulfment of the hydrophobic portion of the membrane protein within a protective detergent micelle while 
the hydrophilic ends of the protein and the external surface of the detergent micelle present a fully 
hydrophilic surface.  While this detergent micelle is capable of protecting the hydrophobic surface of a 
membrane protein from deleterious interactions with an aqueous solution, it does not replicate the native 
 29 
membrane environment of the protein.  Many membrane proteins suffer from denaturation upon removal 
from their native membrane because the solubilizing detergent micelles are unable to maintain the 




Although current methods for protein purification may make detergent solubilization of many 
membrane proteins unavoidable, the time spent in a detergent micelle or in the presence of a particular 
amphiphile can be limited.  For example, long-chain detergents may be more effective at extracting 
membrane proteins from cellular membranes.  However, the long-chain detergent can be exchanged for a 
shorter chain detergent which is able to better stabilize the protein and/or may be more amenable to 
crystallization.
18,35,39
  Alternatively the solubilizing detergent micelle can be exchanged for a lipidic 
environment.
7,11,13,16,20,26,27,31,32,36,40,43,45-92
  As discussed in Chapter 1, traditional methods for the 
crystallization of soluble proteins can be easily applied to detergent-solubilized membrane 
proteins.
4,11,12,31,39,43,93
  One of the disadvantages of these in surfo methods is that the protective band of 
detergent also limits the formation of protein-protein crystal contacts,
11,19,31,37,39,47,54,94,95
 thereby increasing 
the potential for crystal fragility and high mosaicity.  An analysis of crystal structures shows that in surfo 
grown crystals are typically Type II (Figure 2.2a), with crystal contacts forming almost exclusively from 
interactions between the polar head-groups of proteins and relatively large cavities between protein 
molcules.
4,11,16,19,32,37,38,41,50,54,95,96
  Type II crystals may suffer from a decreased diffraction signal 
compared to Type I crystals because of (i) lower packing density and (ii) an increased sensitivity to 




Figure 2.2.  Schematic depictions of (a) Type II and (b) Type I crystals of membrane proteins.  Lollipops denote 




While these in surfo methods have proven to be successful in numerous cases,
4,11,16,19,37-39,41,78,85,93-
95,97-126
 it has been unsuccessful for other proteins, potentially due to the lack of a membrane-like 
environment.
16,31,37,46,53
  To counter this difficulty, several different membrane-based crystallization 
methods have been developed.  These methods include the bicelle method,
11,31,37,43,81,86,96,127-129
 where a 
membrane-like disk of detergent is used to stabilize the proteins, as well as the in meso, or lipidic cubic 
phase (LCP) method,
7,11,13,16,20,26,27,31,32,40,43,45-86,92,130




 where proteins are crystallized directly from lipid bilayers.  In Section 2.2 a brief history followed by a 
detailed description of the in meso method for crystallizing membrane proteins is given.  Section 2.3 
presents the current mechanistic understanding whereby in meso crystallogenesis is thought to take 
place.  The relationship between this crystallization technique and the phase behavior of the lipid/water 
systems used to create the crystallization mesophases is then discussed in Section 2.4.  Key challenges 
related to this method are then addressed in Section 2.5.   
2.2  The In Meso Membrane Protein Crystallization Method 
The in meso method for crystallizing membrane proteins was introduced in 1996 by Landau and 
Rosenbusch with the crystallization of the membrane-bound proton pump bacteriorhodopsin.
7,45
  The 
method utilizes artificial self assembling membranous structures to "solubilize" amphiphilic membrane 
proteins while maintaining them in a more native environment throughout the entire crystallization 
process.  The in meso method relies on the self-assembly of liquid crystalline mesophase structures 
above a certain limiting concentration of certain lipids in water.  The amphiphilic nature of these lipids 
leads to the formation of various mesophase structures, including lamellar phases, bicontinuous cubic 
and inverted hexagonal phases (Figure 2.3).
11,26,27,32,66,130-133
  Lamellar phases are locally planar lipid 
bilayer structures with varying degrees of inter-bilayer hydration.  On a larger scale these lamellae can 
exist both as aligned bilayers and as uni-lamellar or multi-lamellar vesicles, though no connectivity exists 
between the various lamellae.
11,47
  Cubic phases can be described as networks of interconnected 
aqueous channels surrounded by lipid bilayers with negative curvature.  These phases are bicontinuous, 
allowing for diffusion in both the aqueous channels and the curved lipid bilayers.  The inverted hexagonal 
phase consists of highly curved long hexagonally packed rods of lipid surrounding an aqueous core.
11,47
  
Both lamellar and cubic mesophases are expected to allow for the reconstitution of amphiphilic 
membrane proteins, whereas the high curvature of the inverted hexagonal phase makes incorporation of 
membrane proteins less favorable.  This kind of phase behavior has been observed for numerous 
amphiphilic molecules including monoacylgylcerols (MAGs) such as the well-known monoolein (1-
monooleoyl-rac-glycerol).  These MAGs are commonly used for in meso crystallization.
26,132
  Extensive 
studies on the phase behavior of different lipids and screening for their suitability for in meso 
crystallization have been performed and will be discussed in Section 2.4. 
Crystals of membrane proteins are grown from these lipidic phases as follows:  An initial "solution" of 
protein is obtained by mixing a purified sample of membrane proteins with a MAG at the appropriate 
composition and temperature for the formation of a cubic phase (typically 60% w/w for monoolein with 
40% w/w aqueous solution).  Cubic phases are critical for successful in meso crystallization.
11,47,53
  
Crystallization requires first diffusion of a precipitant solution to induce nucleation and then the 
subsequent diffusion of proteins from a bulk "solution" to the nucleated crystal.  While the lamellar and 
cubic phases are both able to support reconstituted membrane proteins, the onion-like layering of a 
lamellar phase in a multi-lamellar vesicle would both prevent diffusion of polar precipitants across the 
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bilayer to induce nucleation and limit the quantity of protein which could diffuse to a growing crystal.  
However, the bicontinuous nature of a cubic phase allows for free diffusion of precipitant within the 
aqueous channels and protein diffusion within the cubic bilayer in an analogous fashion to that of a 
dissolved species in solution.  Reconstitution of membrane proteins can be done either from a detergent 
solubilized protein sample
11,32,47,49,53
 or from a highly pure membrane fraction, if such a source is 
available.
47,53,72
  The subsequent addition of an appropriate precipitant is then thought to drive a local 
phase change from a cubic to a lamellar phase where crystal nucleation and growth can occur (Figure 
2.4).
11,32,47,53,55,59,63,75,77,130,134
   
 
Figure 2.3.  Cartoon representations of various phases adopted by lipids.  Lipids are shown as lollipops: pop = 
polar head-group; wiggly stick = apolar chain.  The light blue, green, and red colored regions represent water.  
(Figure adapted from Caffrey, 2003).
26
 
This in meso crystallization procedure maintains the membrane proteins in an artificial membrane-like 
environment, thus reducing concerns about protein denaturation.  The method has also been shown to be 
extremely robust with respect to contamination.
62
  Furthermore, crystallization from aligned lamellar 
bilayers facilitates the formation of Type I crystals as a result of side-to-side interactions of the 
hydrophobic surface of the core of the protein as well as head-to-tail or tail-to-tail interactions between the 
extra-membranous regions (Figure 2.2b).
4,11,16,26,27,32,37,43,47,48,53,58,77,79,84,86,89,95,96,128,130,135-137
  The two 
major advantages of Type I crystals are (i) an increased number of crystal contacts compared to in surfo-
grown crystals, particularly with the polar regions of the protein, resulting in the potential for lower 
mosaicity and decreased fragility and (ii) increased packing density compared to in surfo-grown crystals, 
providing stronger diffracting power.
11,32,47,77,136,137
  For example, the packing density of in meso-grown 
light harvesting complex II (LH2) is twice that of in surfo-grown crystals.
50,54
  Also, the solvent content of 
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BtuB, an outer membrane cobalamin transporter from E. coli grown in meso is 53%, similar to what is 
observed for more robust crystals of soluble proteins, while the solvent content increases to 60% for in 




Figure 2.4.  Schematic depiction of the proposed in meso crystallization process.  Membrane proteins are 
reconstituted into a bicontinuous cubic phase (lower left).  Upon the addition of a precipitant such as salt 
(charged ions are shown) a local lamellar phase forms into which the membrane protein preferentially partitions, 
resulting in the nucleation and growth of a crystal (upper right).  Additional protein diffuses from the cubic phase 
to the growing crystal through a lamellar conduit.  The protein (lysozyme bound β2-andrenergic receptor, PDB 
code: 2RH1),
79
 monoolein bilayer, and aqueous channels have been drawn to scale.  The bilayer thickness is 
approximately 40Å.  (Figure adapted from Caffrey, 2008).
47
 
The preparation of aqueous/lipid mesophases, particularly at small volumes is challenging because of 
the high viscosity of the lipid solution (~30 times higher than the viscoity of water) and the non-Newtonian 
behavior and the extremely high viscosity (~10
5
 times higher than the viscosity of water at the shear rates 
employed) of the resulting mixture.
11,32,74,138,139
   Early on, samples were prepared by repeated 
centrifugation in a small tube such that the centrifugal forces can be used to fold the mixture over itself 
along with extended periods of equilibration (Figure 2.5c).
11,42,46,91,133,134,140-152
  More recently, a setup 
involving two microsyringes that are coupled through a small bore connector (Figure 2.5a) was 
developed,
11,32,49,63,66,68,132,152-157
 particularly for crystallization applications where a larger number of 
samples are needed.  Mixing is achieved by repeated actuation of the syringes back and forth such that 
the high shear stresses experienced by the fluids as they pass through the coupling bore facilitate mixing.  
After the crystallization mesophases are prepared in the coupled microsyringes, dispensing of 
material can be performed either manually or through the use of a robot.  Manual dispensing with a 50-
step repeat dispenser coupled to a 10 µL syringe (Figure 2.5b,d) enables dispensing of boluses on the 
order of 70 nL.
32,49,153
  Scaling to smaller syringes is not possible due to the high viscosity of the 
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mesophases.  A robotic system has also been developed which is capable of dispensing sub-nL boluses 
accurately.
32,56,158
  Robotically setting up a screen in a 96-well plate takes less than 15 min but the 
viscous nature of the mesophase first requires precise calibration for dispensing.
158
  In all of these cases, 
however, the flexibility of a crystallization screening experiment is not limited by the size of an individual 
crystallization trial, but rather the preparative scale at which mixing must be done.   
 
Figure 2.5. Photographs of (a) coupled microsyringes used to prepare lipidic membrane protein-containing 
mesophases by manual actuation; (b) manual dispenser used after mixing; and (c) mesophase prepared by 
centrifugation in a test tube from which bacteriorhodopsin crystals were grown.  (d) Depiction of the preparation 
of in meso crystallization trials.  A coupled syringe mixer.  A protein-containing mesophase (purple) has been 
prepared in a coupled-syringe mixer.  Dispensing of this mesophase can be done using a dispenser-driven 
microsyringe as shown.  A crystallization tray is prepared first by filling of the wells with a precipitant solution, 
and subsequent dispensation of a bolus of protein-containing mesophase.  The wells are then sealed with tape 
and allowed to incubate.  Over time the formation of crystals will result in the depletion of protein from the bulk 
of the bolus. (Figures (a) and (b) adapted from Caffrey, 2003.  Figures (c) and (d) adapted from Nollert, 
2004).
26,46
   
Harvesting of in meso grown crystals for X-ray analysis is done in much the same manner as with 
solution-grown crystals.  The only major difference in the harvesting procedure is that it is usually 
necessary to create a path through the viscous mesophase to the crystal in order to minimize damage 
from physical handling.  This can be done manually, through the use of enzymatic hydrolysis, or by 
dissolution in an oil or detergent solution.
13,32,49,75,159
  While it is advantageous to minimize the amount of 
bulk mesophase harvested along with the crystal, the mesophase has demonstrated cryoprotective 
abilities, so additional treatments are not typically necessary.
11,26,32,49-52,54,65,67,77,87,89,92,130
 
2.3  Current Mechanistic Understanding of In Meso Membrane Protein 
Crystallization 
As was described in Section 2.2, in meso membrane protein crystallization is thought to occur in the 
following three steps:  (1) reconstitution of the protein, (2) a phase change induced by the addition of a 
precipitant solution, and (3) crystal nucleation and growth from a lamellar phase.  The initial protein-




 with a MAG at the appropriate composition and temperature for the formation 
of a cubic Pn3m phase (typically 60% w/w monoolein with 40% w/w aqueous solution).  During 
preparation the membrane protein along with adventitious detergent and/or lipid molecules are 
reconstituted into the native-like lipid bilayer environment.
32,66,72,79,80,86,160
  The reconstitution of membrane 
proteins into a bicontinuous cubic phase creates a two-dimensional, membrane-bound analog of 
solubilized proteins.  Within the connected bilayers of the mesophase, membrane proteins are able to 
diffuse freely within the limited degrees of freedom for motion and curvature imposed by the membranous 
environment.
32,53,130,136
  It has been shown that the ability of reconstituted proteins to diffuse is a 
necessary but not sufficient condition for crystallogenesis, and that the rate of protein diffusion in the 
highly curved membranes can be altered based on how various additives such as lipids, detergents, salts, 
and other crystallization solutions alter the curvature of the mesophase.
136
 
The subsequent addition of an appropriate precipitant is then thought to facilitate crystallization in two 
ways.  As in traditional, solution-based crystallization methods the components of the precipitant solution 
may include salts to screen the repulsive interactions between proteins and/or osmotically active 
components that may draw the protein molecules together.
26,32,47
  The precipitant solution is also thought 
to drive a local phase change from a cubic to a lamellar phase in or from which crystal nucleation and 
growth can occur (Figure 2.4).
32,47,53,55,59,63,75,77,130,134
  This phase change is the culmination of a variety of 
effects including kosmotropic and osmotic effects of the precipitants on the mesophase (see Section 
2.4.2.1), but also the preference of the reconstituted membrane proteins for a flattened bilayer (see 
Section 2.4.2.3).
47,59,63,68,75,77,132-134,141,142,152,161
  The presence of adventitious detergent or lipids in the 




The clustering of membrane proteins in locally lamellar regions is energetically favored because it 
relieves strain associated with interactions between the membrane protein and the highly curved bilayer 
of the cubic phase, in addition to the energies associated with crystal nucleation.
53,59
  Thus while high 
curvature is conducive for protein nucleation in that it drives membrane proteins together in locally 
lamellar regions, these locally lamellar regions must increase in size in order to accommodate Type I 
crystals.  The lamellar phase is also thought to serve as a conduit for protein diffusion, connecting the 
growing crystal to the bulk cubic phase.
26,32,47,50,54,55,63,67,68
   The hypothesis for the lamellar conduit is 
supported both by the growth of Type I crystals and by freeze-fracture electron crystallography, atomic 
force microscopy (AFM), and microdiffraction analysis of the mesophase around a growing 
crystal.
32,47,53,55
   
2.4  The Role of Lipid Phase Behavior in In Meso Membrane Protein 
Crystallization 
The in meso crystallization of membrane proteins has tremendous potential to enhance the rate of 
structure determination since it avoids many of the key issues that currently plague crystallization efforts.  
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The amphiphilic nature of membrane proteins that is crucial to their role in the transduction of 
energy/information across cell membranes also makes them difficult to treat in solution.  Solubilization of 
membrane proteins can be accomplished using detergents,
12,13,16,18-20,31,35-37,39,41
 but the resulting 
detergent micelles around the hydrophobic part of the membrane proteins are often unable to maintain 
the necessary level of lateral pressure on the protein to maintain its functional conformation.
6,7,12,14,31,35-
37,40,43,44
  Furthermore, the spherical nature of micelles hampers the formation of protein-protein contacts 
needed to form a crystal.
19,31,39,54,94
  As explained in Section 2.2, the in meso strategy overcomes these 
issues by embedding the membrane proteins in a cubic phase comprised of a complex network of curved 
lipid bilayers.  The subsequent formation of a locally lamellar phase drives embedded membrane proteins 




Figure 2.6.  The structure of the 18-carbon monoacylglycerol monoolein (1-monooleoyl-rac-glycerol, 9.9 MAG).  
A glycerol head-group is attached to an 18-carbon chain with a single unsaturated C-C bond located halfway up 
the chain in the cis conformation.   
Successful in meso crystallization has been reported for a variety of membrane proteins, but most 
commonly using the 18-carbon MAG known as monoolein (Figure 
2.6).
7,13,32,45,50,51,53,54,57,61,64,66,72,73,79,80,82,84,85,92,129,130,134,135,159,162-171
  Monoolein exhibits rich phase behavior, 
comprised of several cubic phases (Ia3d and Pn3m) that will transition into lamellar phases (Lc and Lα) 
upon lowering the water content and/or lowering the temperature (Figure 2.7).
27,157,172
  Depending on the 
temperature and water content it is possible to obtain coexisting phases, such as Lα+Ia3d, or a fully 
hydrated phase in the presence of excess water, such as Pn3m+water.  Interestingly, the phase behavior 
of these MAG/water systems shows significant metastability, particularly with respect to changes in 
temperature (Figure 2.7b).
26,27,32,42,47,49,68-70,77,131,132,137,152,157,172-174
  This metastability represents a kinetic 
trapping of a non-equilibrium state upon cooling of the system.   
While the vast majority of in meso crystallization experiments have been performed using monoolein, 
consideration of only a single lipid imposes a serious limit on the accessible phase space for in meso 
crystallization of membrane proteins.  A library of many lipids and/or lipid mixtures suitable for in meso 
crystallization needs to be developed to expand the range of accessible temperatures and mesophase 
properties such as bilayer thickness, curvature, and water channel dimension in order to capitalize on the 
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promise of this method.
32,66,67,69,70,157
  Additionally, recent studies have begun to elucidate the importance 
of native lipids from the source organism in maintaining the function and stability of membrane 
proteins.
79,80,86,92,160
   
 
Figure 2.7. Temperature/composition phase diagram for the monoolein/water system.  (a) Equilibrium phase 
diagram.  (b) Metastable phase diagram.   Legend:  Lamellar phases start with an “L;” Cubic phases contain a 




2.4.1  The Phase Behavior of MAG/Water Systems 
To increase the number of lipids available for in meso crystallization of membrane proteins, Caffrey 
and coworkers have systematically explored the phase behavior of various MAGs.
32,67,69,70,157
  MAGs have 
a simple molecular structure of a glycerol-based head-group and a single unsaturated bond in their 
hydrophobic alkyl chain (Figure 2.6).  They exhibit phase behavior that can access the full range of 
temperature and concentration induced mesophases while remaining within biologically relevant 
constraints such as temperature and water content.
26
  An examination of the behavior of a variety of 
MAG/water systems has demonstrated that decreasing chain length results in a decreased thickness of 
the lipid bilayer and an increase in the diameter of the aqueous channel.
32
  Additionally, the chain length 
and position of the single unsaturated bond can be easily shifted to further alter the phase behavior.   
The MAG homologs are classified using a so-called N-T matrix.
67,69,70
  The lipid is assigned a 
coordinate in N-T space defined by the length of the carbon chain on either side of the olefinic bond.  The 
region between the double bond and the glycerol head-group is referred to as the neck (N) while the 
region extending from the double bond to the terminal methyl group is the tail (T).  For the commonly 
used 18-carbon monoolein, the N-T matrix designation is 9.9 MAG, describing a monoacylglycerol with 9 
carbons in the neck region and 9 carbons in the tail region.  Other lipids that have been reported on 
include the 18-carbon lipid monovaccenin (11.7 MAG),
83









Determination of the phase diagram for a MAG is highly labor intensive, involving preparation of all 
individual compositions, followed by transfer into X-ray capillaries and analysis.  To determine the phase 
diagram for an individual MAG, mesophase samples of specific concentrations are prepared using the 
coupled syringe mixer (Figure 2.5a).
154
  The phase identity of each sample is then analyzed by a variety 
of techniques including small angle X-ray diffraction and differential scanning calorimetry.
69,70,157,172,173
  X-
ray analysis provides direct insight into the dimensions of the mesophases: for example, a fully hydrated 
cubic Pn3m phase of monoolein and water has a bilayer thickness of 32Å and water channels with a 
diameter of 40Å.
67
  Temperature-controlled sample holders are also limited in the number of samples 
which can be mounted at one time.  The metastable character of the various mesophases requires long 
incubation times in excess of 3 hours at each temperature increment to minimize these 
effects.
42,67,69,70,152,157,172
  Actual diffraction data collection takes between 15 minutes to 24 hours using a 
„bench-top‟ X-ray source
69,150,157
 or less than a minute when a synchrotron source is used.
152,173
   
The temperature dependence of the microstructure of various lipidic mesophases has proven to be a 
critical factor for crystallization of membrane proteins.  While monoolein (9.9 MAG) has been used 
preferentially for in meso crystallization trials thus far, it is unable to accommodate a cubic phase at lower 
temperatures such as 4°C without relying on metastable phase behavior (Figure 2.7b).
26,27,32,49,68,77,132
  
While it is possible to perform crystallization at lower temperatures,
70,76
 these metastable phases cannot 
be counted on for reproducible results in crystallization experiments lasting many hours.
26,27,32,68,70,77,157
  
Instead, Caffrey and coworkers utilized rational design based off of the phase behavior for various MAGs 
for which the phase diagrams are known to identify 7.9 MAG as a potential candidate for low temperature 
in meso membrane protein crystallization.
32,70
  Following synthesis, characterization of the phase 
behavior for 7.9 MAG/water systems showed mesophases which are not only stable at much lower 
temperatures than those of monoolein, but which matched the predicted behavior from rational design 
very closely.  Successful in meso crystallization of the membrane protein bacteriorhodopsin was 
performed in 7.9 MAG at 6°C.  This demonstration of a rationally designed alternative lipid suitable for in 
meso crystallization exemplifies the potential for dramatic success in crystallizing membrane proteins that 
are only stable at lower temperatures.    
Stability and crystallizability can also be affected by the thickness and curvature of the lipid bilayer 
within the mesophase.  The mesophase must be able to accommodate the membrane protein, but the 
curvature should also provide a sufficient driving force for crystallization to occur without preventing the 
protein from diffusing.
59,77,136
  Combining the ideas of mesophase curvature and thickness, Caffrey and 
coworkers proposed the use of a shorter-chained lipid in order to decrease the “degree of comfort” 
experienced by the protein in the mesophase and increase the driving force for crystallization.
32,67
  Their 
hypothesis was that the standard 16 or 18-carbon MAGs used previously formed membranes that 
accommodated membrane proteins to the point where the driving force favoring protein-protein 
interactions and the formation of stable nuclei was not significant.  A 14-carbon MAG was chosen with the 
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idea of 14-carbons being a short enough chain to better facilitate crystallization, but not so short as to 
prevent reconstitution of the protein into the membranes of the mesophase.  
In an attempt at rational design,
32,70
 existing phase behavior information for longer chain MAGs was 
extrapolated to determine the optimum location for the single unsaturated C-C bond in the carbon chain.
67
  
The 14-carbon 7.7 MAG was chosen to have the desired overall chain length and the ability to form a 
cubic phase at room temperature.  This shorter chain length resulted in both a thinner membrane and a 
lower degree of curvature for the cubic mesophases used for in meso crystallization as compared to the 
standard monoolein mesophases (Figure 2.8).
67
  In crystallization trials using the membrane protein 
bacteriorhodopsin, the difference in lipid composition both required different crystallization conditions and 
resulted in a different crystallographic space group.  It is also particularly interesting to note that in trials 
using the smaller 7.7 MAG the size of the resultant crystals was significantly larger than that for 
monoolein (maximum dimension of 200 µm vs. 80 µm) and were of better visual quality.  This 
corresponds directly with their hypothesis of improving the driving force for crystallization via a smaller 
chain lipid.  7.7 MAG was also used to crystallize BtuB, a colorless E. coli outer membrane cobalamin 
transporter, which represents the first β-barrel membrane protein to be crystallized by the in meso 
method.
32,67
   
 
Figure 2.8.  Cartoon representation of bacteriorhodopsin (PDB ID: 1C3W) in the highly curved cubic lipidic 
phase of fully hydrated 9.9 MAG (monoolein) and 7.7 MAG at 40°C.  (Figure adapted from Misquitta, 2004).
67
 
2.4.2  The Effect of Additives on the Phase Behavior of MAG/Water Systems 
The reported successes for in meso crystallization have all hinged on prior characterization of the 
phase behavior of the various water/lipid systems; such as lattice parameters and structural data from X-
ray diffraction studies as a function of both temperature and composition (i.e. water content).
172,173
  While 
rational design of MAG/water systems has demonstrated powerful predictive abilities, it will remain 
necessary to experimentally characterize the phase behavior of various lipid mesophases.  In addition to 
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understanding the phase behavior of binary MAG/water mixtures, it is important to consider the effects of 
a variety of additives which might be present during an in meso crystallization trial, in addition to the 
membrane protein itself.  These contaminating agents can include detergents and native lipids carrying 
through from protein purification or intentionally added, precipitants, and other biologically relevant 




As will be discussed in more detail in Section 2.3, the in meso crystallization method requires the 
formation of a bicontinuous cubic phase to create a "fluid" environment through which the reconstituted 
membrane proteins can diffuse.
32,47,49,53,55,132,136
  One of the first concerns in a crystallization trial is the 
tendency of the various components of the crystallization screen such as salts and precipitating agents to 
destabilize the cubic phase.
32,132
  A detailed examination of the effects of two commonly used sparse 
matrix screens, Hampton Screen and Hampton Screen 2, was made.
132
  Based on the binary 
monoolein/water phase diagram, samples were prepared at a ratio of monoolein to aqueous phase to 
produce both fully hydrated and water-stressed cubic phases using the precipitant solution both at full 
strength and at a 50% dilution.  The diluted precipitant was tested because in traditional crystallization 
methods the precipitant solution is typically diluted in a 1:1 ratio with the protein solution, and so the 
precipitant solutions as supplied by the manufacturer might simply be too strong.  A variety of 
observations were made including the tendency of salts to decrease the lattice parameter, thus increasing 
the curvature of the cubic phase, and a phase change from cubic Pn3m to cubic Ia3d followed by a 
decrease in the lattice parameter due to the water withdrawing effects of higher molecular weight 
polyethylene glycols (PEGs).  However, the overall level of hydration in the mesophase remained a key 
factor in determining the phase behavior.  Based on the results of this study a new crystallization screen 
designed to be compatible with in meso crystallization, the Cubic Screen, was developed by Emerald 
Biosystems.
178
  While an examination of the effects of a sparse matrix screen provided direct insight into 
the design of crystallization trials, the complex mixture of chemicals present in a screening solution make 
isolating the effects of individual classes of chemicals difficult.  A variety of additive-specific studies have 
been performed, but the breadth of information in the literature is no doubt limited by the sample and 
labor-intensive nature of the experiments.   
2.4.2.1  The Effect of Salts on the Phase Behavior of MAG/Water Systems 
An examination of the effect of salts on the phase behavior of MAG/water mesophases is particularly 
interesting in the context of protein crystallization.  Salts are commonly used in crystallization experiments 
and have also been well studied with respect to their interaction with proteins.  The Hofmeister or 
lyotropic series was generated based on the efficiency of ions in precipitating proteins.
133,142,161,179-184
  The 
series for anions and cations are expressed as follows, though the position of polyvalent ions may vary 








































For the anionic series, species to the left of Cl
-
 are referred to as kosmotropes and are strongly 
hydrated ions that structure the water around them and have a stabilizing effect on proteins.  
Kosmotropes also display salting-out effects on proteins where the solubility of the protein decreases with 
increasing salt concentration.  The species to the right of Cl
-
 are termed chaotropes and destabilize the 
structure of water and folded proteins.  Chaotropes typically result in salting-in behavior where protein 
solubility increases with increasing salt concentration.
181
   
An examination of the effects of a series of sodium salts on the phase behavior of MAG/water 
systems with roughly 30% w/w lipid demonstrated that changes in the energetics of phase transitions due 
to the presence of salt are consistent with the anionic Hofmeister series.
133,142,161
  This observation 
corresponds to the stabilization of one phase over another.  Chaotropic solutes (NaSCN) were found to 
increase the lattice constant of the cubic phase while kosmotropes (NaBr, NaCl, and Na2SO4) decreased 
the lattice constant.  These trends were explained by the effect of the various ions on the amount of 
interfacial water present at the bilayer surface.  Because kosmotropes stabilize the structure of bulk 
water, they tend to be excluded from interfacial regions and therefore reduce the amount of interfacial 
water present.  A decreased amount of interfacial water would then be expected to cause a 
corresponding decrease in the interfacial area present, resulting in changes in curvature and/or 
preferential stabilization of one phase over another (Figure 2.9).  For example, the decreased lattice 
constant observed for the kosmotropic salts corresponds to an increase in curvature and a decrease in 
the interfacial area present, agreeing with this hypothesis.  Similar trends have been observed in the 




Figure 2.9.  Depiction of the effects of a kosmotropic salt on the curvature of a cubic phase.  Addition of the salt 
results in a decrease of the interfacial area between the lipidic phase and the aqueous channel, shrinking the 
size of this channel and increasing the curvature.  Increases in the curvature of this interface beyond the 




Separate studies utilizing fully hydrated cubic phases also demonstrated that increasing 
concentrations of salt consistently decreased the lattice parameter of the cubic phase, thus increasing the 
curvature.
141,152
  A trend of decreasing lattice parameter with increasing temperature was also 
observed.
152
  These trends were again consistent with the Hofmeister series for both anions and cations 
(Figure 2.10).  At constant pH and cation (ammonium), sulfate anions resulted in a more significant 
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decrease in the lattice parameter of the cubic phase than did phosphate anions.  With constant anion 
(phosphate) the combination of the sodium and potassium anions resulted in a more significant decrease 
in the lattice parameter than did ammonium.  As before, the decrease in lattice parameter is associated 
with an increase in curvature and a concomitant decrease in the interfacial area.    
A variety of other studies have commented on the effects of salt in the literature, though the effect of 
salts were not studied explicitly.  From an examination of the effects of detergents on the cubic phase of 
monoolein it was demonstrated that the presence of ammonium sulfate results in a significant decrease in 
the lattice parameter of cubic phase, even in the presence of 10% mol/mol octyl glucoside.  In direct 
agreement with the anionic Hofmeister series, the presence of equivalent levels of sodium and potassium 
phosphate resulted in a much smaller decrease in the lattice parameter of the cubic phase than did 
ammonium sulfate.
68
   
From the study focused on the effects of the Hampton Crystallization Screens on the cubic phase, 
trends in the effect of salts on the lattice parameter of the cubic phase were also observed.  Although 
cationic and pH effects were neglected, the ability of salts to shrink the lattice parameter of the cubic 
phase was reported in the order of citrate ≈ sulfate > tartrate > phosphate > formate > acetate > 
chloride.
132
  While some of the ordering here reflects the Hofmeister series, such as the relative 
positioning of sulfate, phosphate, and chloride, many of the other ions are seemingly out of place.  It is 
possible that the overall difference in behavior observed between the various studies is a result of 
variations in both the different MAG/aqueous phase compositions and the solution pH used for the trials.  
However, more extensive testing is needed to investigate this.   
 
Figure 2.10.  Plot of the lattice parameter of the fully hydrated cubic Pn3m phase of monoolein in the presence 
of salts of varying concentrations at pH 6.5.  Trends consistent with the Hofmeister series are observed.  In the 
presence of the ammonium cation, sulfate anions showed a larger decrease in the lattice parameter of the cubic 
phase than did phosphate ions.  In the presence of phosphate anions sodium and potassium showed a more 




2.4.2.2  The Effect of Amphiphiles on the Phase Behavior of MAG/Water Systems 
In addition to the salts and precipitants which are added during the course of a crystallization trial, it is 
also critical to understand the effects of detergents, lipids, and other amphiphiles which can be 
incorporated into the cubic phase during the reconstitution of the membrane protein.  Naturally occurring 
lipids and detergents in particular may have a significant impact on the phase behavior of the 
MAG/aqueous solution mesophase because of the differences in the preferred curvature of these 
amphiphiles as compared to the curvature adopted by the mesophase (Figure 2.11).
42,47,91,134
   
 
Figure 2.11.  Schematic depiction of the geometric shape and resultant curvature for typical detergents and 
lipids. (a) Detergents typically have a single aliphatic tail, resulting in a cone shape and the preference for areas 
of positive curvature, such as micelles.  (b) Naturally occurring lipids often have two aliphatic tails, imparting a 
cylindrical or wedge shape to the molecule which prefers areas of negative or flat curvature. 
A variety of studies have investigated the effects of common crystallization detergents on the stability 
of the cubic phase.  The cubic phase itself can be characterized as an infinitely periodic minimal surface 
(IPMS) with negative Gaussian curvature and zero mean curvature.
37,42,53,59,66,91,133,134,144-147,150-152,157,175,185
  
However, detergents preferentially self assemble into structures with positive curvature.
37,42,47,134
  
Therefore it is reasonable to expect that with increasing loading, detergents will eventually destabilize the 
cubic phase in favor of a structure with less negative curvature.   
An examination of the alkyl glucoside family of detergents in a monoolein mesophase showed a 
tendency for the detergent to destabilize the Pn3m phase in favor of cubic Ia3d and lamellar Lα 
phases.
32,42,68,134,140
  Increasing detergent concentration at constant temperature resulted in a slight 
increasing of the lattice parameter of the cubic phases while increases in temperature at constant 
detergent loading resulted in a decrease in the lattice parameter.  Similar results were observed for a 
series of maltosides, alkyl fos-cholines, lauryldimethylamine-oxide (LDAO), sodium dodecyl sulfate (SDS), 
heptyl thioglucoside, and Cymal.
32,63,68,77,155
  Whereas the effects of salts and dissolved precipitants must 
be coupled with interactions between water and the polar head-groups of the MAGs, amphiphilic 
molecules like detergents can interact with both the apolar aliphatic and polar head-groups and aqueous 
channel aspects of the mesophase.  It is interesting to consider the effects of these two contributions 
separately. 
 43 
The polar detergent head-group is expected to interact with both the glycerol head-groups of the 
MAG and also the water within the aqueous channel.  The effects of these head-groups can be simulated 
by considering the effects of dissolved sugars on the cubic phase.  The addition of a variety of dissolved 
sugars, including glucose and maltose, resulted in a decrease in the lattice parameter of the cubic 
phase.
91,142,155,175
  These sugars were also observed to stabilize the Pn3m cubic phase to very low values 
of lattice parameter without undergoing a phase transition.
175
  This can be explained as a water 
withdrawing effect where dissolved sugar molecules order the water around them, thus sequestering it 
away from the lipid head-groups.  This behavior is that of a kosmotropic agent from the Hofmeister series 
and a similar ordering based on the strength of the interaction can be made, with the number of 
monosaccharide rings present in the sugar molecule (shown in parenthesis below) having a significant 
impact on the level of interaction observed with the cubic phase:
155,175
  
Saccharides:  maltotriose (3) > trehalose (2) > maltose (2) > sucrose (2) > glucose (1) 
With respect to the effects of detergent head-groups, the larger disaccharide maltoside head-group 
resulted in a more significant decrease in lattice parameter and a larger degree of destabilization than did 
the monosaccharide glucoside head-group.
42,155,175
   
The tendency for a detergent to destabilize the cubic phase can be related to the length of its aliphatic 
tail.
42,68
  In the study of the alkyl glucoside family of detergents the shorter-chain detergents (i.e. hexyl 
glucoside) facilitated a phase change from the cubic Pn3m to the cubic Ia3d and lamellar Lα phases at 
lower concentrations than did the longer-chain detergents (i.e. decyl glucoside).  This trend can be 
observed by the shifting of the phase boundaries as a function of detergent chain length (Figure 2.12).  In 
this sense the geometric argument associated with the shape of the detergent molecule agrees with 
experimental observations.  For a given head-group, the cone shape of shorter-chain detergents will tend 
to impart a stronger need for positive curvature and thus a stronger destabilizing effect on the negatively 
curved cubic phase than would longer-chain detergents.  Based on the opposing nature of the 
interactions between the head-group and the aliphatic tail of the detergent, the tail effects appear to 
dominate the observed changes in phase behavior. 
Having understood the effects of the various components separately, it is interesting to return to the 
context of a crystallization experiment and understand the balance between the effects of the various 
precipitants and amphiphiles.  For instance, the addition of detergent has been shown to increase the 
lattice parameter and destabilize the cubic phase in favor of lamellar phases,
32,68,155
 while the addition of 
salt has been shown to decrease the lattice parameter of the cubic phase with eventual destabilization in 
favor of the inverted hexagonal phase.
132,133,141,142
  These opposing effects can be used to stabilize a 
cubic phase using increasing salt concentration in the presence of increasing detergent concentration.
32,68
  
For instance, the cubic Pn3m phase of monoolein could be stabilized up to a detergent concentration of 
1.18 M octyl glucoside by using 2 M sodium/potassium phosphate at pH 5.6 and 20°C.  This is a 





Figure 2.12.  Plot of the metastable phase behavior of four monoolein/water/alkyl glucoside systems as a 
function of detergent mole fraction, temperature, and detergent chain-length.  Samples were prepared using a 
60% w/w monoolein, 40% w/w detergent solution for hexyl, octyl, nonyl, and decyl glucosides.  A shift in the 
location of the phase boundaries to increasing detergent concentration is seen with increasing chain length.  
(Data replotted from Misquitta, 2003).
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While membrane protein crystallization is most commonly associated with detergents, lipids and other 
amphiphiles may be present in the crystallization mixture, either adventitiously despite purification 
procedures, or intentionally to stabilize the protein in its natural conformation.
37,66,72,79,80,86,160
  For 
instance, the detergent-free in meso crystallization of bacteriorhodopsin has been performed via the 
direct reconstitution of naturally occurring purple membranes into a monoolein mesophase.
72
  Purple 
membrane is composed of phosphatidylglycerol (PG), phosphatidylglycerophosphate (PGP-Me), 
phosphatidylglycerosulfate (PGPS), and squalene, all of which can promote the formation of a lamellar 
phase over the cubic phase that is desired for in meso crystallization.
24,134
  Phosphatidylcholine (PC) is 
also a common component of cellular membranes and causes a decrease in the curvature of cubic 
phases in favor of the formation of low curvature lamellae.
32,47,66
  Phosphatidylethanolamine (PE), on the 
other hand, increases the curvature of cubic phases in favor of the formation of inverse hexagonal 
phases.
32,66
  Anionic lipids such as phosphatidylserine (PS) and cardiolipin resulted in the formation of a 
cubic Im3m phase, followed by a lamellar Lα on continued loading.
32,66
  Cholesterol is also a naturally 
occurring component of many membranes and has been proven necessary for the crystallization of 
several human G-protein coupled receptors.
32,79,80,86,160
  While cholesterol occurs naturally in a lamellar 
phase, the cubic Pn3m phase was capable of accommodating relatively large amounts of the steroid 
through an increase in the lattice parameter before triggering a conversion to the cubic Im3m phase.
66
  In 
 45 
each of these cases the geometric shape and charge of the additive molecule can be used to rationalize 
the observed changes in phase behavior.
66
   
In addition to adventitious or stabilizing lipids, it is also possible to intentionally dope MAG/water 
mesophases with lipids in order to tailor the geometric properties of the mesophase.
32
  The anionic lipid 
distearoylphosphatidylglycerol (DSPG) can be used to decrease the curvature of the cubic phase, thereby 
increasing the dimensions of the aqueous channels to better facilitate membrane protein reconstitution 
and diffusion.
134,145,151
  This modification to the traditional monoolein preparation of the in meso 
crystallization method resulted in crystals of bacteriorhodopsin growing faster, more readily, and to a 
larger final size.  However, diffraction analysis on the crystals was not performed, so no comparison of 
crystal quality can be made.  Also, the use of a mixture of the commonly used 1-monoolein with its 
isomer, 2-monoolein, has been suggested for fine-tuning of the cubic phase lattice parameter while 
holding the chemistry of the MAG/water interface constant.
66
   
As in the case of detergents, the effects of lipid and salt additives can be balanced in order to 
stabilize a particular phase.
32,146
  For instance, the addition of the charged lipid dioleoylphosphatidic acid 
(DOPA) to a fully hydrated monoolein-based cubic phase caused an increase in lattice parameter that 
resulted in a transition from the cubic Pn3m to the cubic Im3m and finally to the lamellar Lα phases.  
However, the addition of NaCl stabilized the cubic Pn3m phase over a much broader range of DOPA 
loading.
146
  These observations were rationalized based on a charge density argument where significant 
electrostatic interactions at the membrane surface from the DOPA stabilize the less highly curved Im3m 
and Lα phases whereas charge screening from the addition of salt to the solution enables the recovery of 
the cubic Pn3m phases.   
2.4.2.3  The Effect of Membrane Proteins on the Phase Behavior of MAG/Water Systems 
In addition to all of the various precipitants, additives, and other chemicals that can be present in an 
in meso crystallization trial the effect of the reconstituted membrane protein should also be considered.  
The lipid bilayers that form cellular membranes are only a few nanometers thick and because local 
curvature is on the order of a few tens of nanometers the cellular membrane can be approximated as a 
flat bilayer for a majority of cases.
186
  Membrane proteins are thus well adapted to a flat bilayer 
environment.
24
  The incorporation of a membrane protein into a highly curved cubic phase results in a 
hydrophobic mismatch between the length and shape of the membrane-spanning portion of the protein 
and the hydrophobic region of the lipid bilayer.
59,63,75,77,134
  This mismatch is energetically unfavorable and 
can result in distortion of the bilayer to cover up exposed hydrophobic patches on the membrane protein 
(Figure 2.13).
53
  This distortion can be thought of as a locally flattened region in the saddle of the highly 
curved cubic phase, creating an energetic driving force for membrane proteins to cluster together in 
flattened regions of the membrane and stabilizing the formation of a lamellar phase.
53,59,134
  This 
preference of the reconstituted membrane protein for the lamellar phase is a key aspect of the proposed 
mechanism whereby in meso crystallization occurs. 
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Figure 2.13.  Hydrophobic matching of the protein-membrane interface in bilayers of varying curvature.  
Membrane proteins are shown as cylinders with their hydrophobic portions highlighted in green and their polar 
portions colored in blue.  Lipid bilayers are shown as planar structures with purple polar surfaces and a green 
embedded hydrophobic region.  A solubilizing detergent micelle is shown as a purple torus around the protein.  
For each structure a rolled out depiction of the membrane protein surface is shown.  Overlap of the hydrophobic 
areas of the membrane protein and lipid bilayer are shown in green.  Areas of hydrophobic mismatch are 
indicated in red.  (a)  A membrane protein interacting with a planar lipid bilayer (top), a detergent micelle 
(middle), and neighboring protein molecules (bottom).  No hydrophobic mismatch is observed in these cases.  
(b)  A membrane protein interacting with a negatively curved bilayer such as the bicontinuous cubic phase.  The 
saddle shape of the membrane results in significant hydrophobic mismatch.  (c)  Relief of the hydrophobic 
mismatch in a highly curved bilayer can be achieved by local distortion of the membrane.  (Figure adapted from 
Nollert et al., 2001).
53
  
2.5  Key Challenges 
In summary, the in meso method for crystallizing membrane proteins has tremendous potential to 
enhance the rate of current structure determination efforts.  This method has been demonstrated to be 
successful for a wide range of membrane protein types.
7,32,45,50,51,54,64,79,80,83,84,130,159
  However, a number 
of remaining challenges associated with this method could be overcome by novel approaches.   
One of the foremost challenges associated with both the in meso method and the characterization 
and development of new mesophase systems is the scale at which samples can be prepared.  Methods 
have been developed which allow for sample dispensing at sub-nanoliter volumes, although it is still 
necessary to prepare a minimum of ~10 µL of mesophase due to challenges associated with the mixing of 
a viscid and an inviscid solution to form a highly viscous and non-Newtonian mesophase.  Variations in 
the lipid composition of a crystallization mesophase is one potentially powerful variable that could be 
investigated during in meso crystallization screening experiments, in addition to more traditional variables.  
However, the introduction of such a variable would require intensive sample preparation and relatively 
large volumes of both protein and lipid.  Similar difficulties are encountered during the characterization of 
lipidic phase behavior.  Transitioning from syringe-based mesophase preparation methods to a 
microfluidic approach would enable not only an increase in the number of samples while using less 
material, but would also allow for a significant decrease in the actual preparative scale of an individual 
sample.   
While the viscosity of the mesophases used with the in meso method has been a challenge for 
traditional methods of sample preparation,
32,74,138,139
 these difficulties have presented a significant barrier 
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for the translation of the in meso method to the microscale.  Chapter 3 develops a series of design rules 
for overcoming the limitations of highly viscous fluids at the microscale and Chapter 4 applies these 
results for the development of a microfluidic platform for in meso membrane protein crystallization.   
In transitioning to microscale platforms for in meso crystallization and lipidic phase behavior studies, 
the benefits of scale and sample handling cannot be fully accessed without the ability to perform in situ 
analysis on the resultant samples.  However, the traditional materials used for many microfluidic platforms 
are incompatible with X-ray analysis, and thus new materials and fabrication methods must be identified 
and optimized.  Chapter 5 presents the development of a microfluidic platform for in situ X-ray analysis.  
This efficacy of this platform is then validated using both traditional monochromatic (Chapter 5) and Laue 
(Chapter 6) crystallographic techniques for protein structure determination.  In Chapter 7 this device 
architecture is applied to microfluidic studies of lipid phase behavior and the effects of additives.  Finally, 
Chapter 8 summarizes the results described in this dissertation and directions for further research are 
discussed. 
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Chapter 3  
Overcoming the Challenge of Pumping Viscous 




The use of fluids that are significantly more viscous than water in microfluidics has been limited due 
to their high resistance to flow in microscale channels.  This chapter reports a theoretical treatment for 
flow of highly viscous fluids in deforming microfluidic channels, particularly with respect to transient 
effects, and discusses the implications of these effects on the design of appropriate microfluidic devices 
for highly viscous fluids.  Theory describing flow in a deforming channel is coupled with design equations, 
both for steady-state flows and for the transient periods associated with the initial deformation and final 
relaxation of a channel.  The results of this analysis allow for the description of these systems and also an 
assessment of the significance of different parameters on various deformation and/or transient effects.  
To exemplify their utility, these design rules were applied to two applications: (i) pumping highly viscous 
fluids for a nanoliter scale mixing application and (ii) precise metering of fluids in microfluidics. 
 
  
                                                     
*
 Part of this work has been published:  S.L. Perry, J.J.L. Higdon, and P.J.A. Kenis, Design Rules for 
Pumping and Metering of Highly Viscous Fluids, Lab on a Chip 2010 Vol. 10(22), 3112-3124. 
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3.1  Introduction 
Microfluidic approaches have been demonstrated for a wide variety of applications ranging from virus 
detection
1




 and fuel cells.
4
   The idea of a "lab on a chip," capable 
of performing ever more complex chemical and/or biological processes, has been realized in numerous 
examples through the integration of multiple unit operations such as mixing, reaction, separation, and 
detection on a single chip.  Soft lithography continues to spur the development of microfluidic technology 
by providing a fast and easy method for the rapid prototyping of highly complex networks of channels with 
integrated pneumatic valves and peristaltic pumps.
5
  The elastomer polydimethylsiloxane (PDMS) has 
been used in particular for this purpose because of its ability to replicate features down to sub-micrometer 
length scales, such as photolithographically defined channel networks, and the ease by which the 
resulting molded layers can be assembled into fully functional microfluidic chips.
6
  Additional advantages 
of PDMS over other materials include its optical transparency and its elasticity.  The bulk properties of 
PDMS are equivalent to an incompressible rubber-like elastic material, with a Young‟s modulus E typically 
in the range of 0.5 to 4 MPa and a Poisson ratio of σ = 0.5.
7,8
  The pneumatic valves and peristaltic pumps 
that are now being used in many microfluidic devices would not be possible without the high level of 
deformability of PDMS.
9-11
  A number of models for these pneumatic valves and pumps have been 
reported to describe and predict their operation.
12-14
   
To date microfluidic applications have been mostly limited to systems where the fluid viscosities are 
similar to that of water because of the challenges associated with pumping highly viscous and/or non-
Newtonian flows.  In fact, the pressures that would be required to drive highly viscous fluids (i.e., ~10
5
x 
more viscous than water) through a typical microfluidic channel can be extreme, to the point of exceeding 
the ability of most pumping systems used for microfluidics, and/or the capacity of the materials to sustain 
such high pressures.
15-17
  Thus, strategies that overcome these challenges are needed to enable the 
pumping of viscous fluids.  In designing a microfluidic device for use with highly viscous fluids the single 
most important consideration is the viscous resistance to flow.  Microfluidic devices are typically operated 
under conditions of low Reynolds number flow.  Steady-state operation at low Reynolds number requires 
ρuh/η << 1 while for unsteady flow we have the additional requirement that ρωh/η << 1, where ρ is the fluid 
density, u is the linear flow velocity, h is the channel height, is the η fluid viscosity, and ω is the frequency 
of oscillation.  For the laminar flows encountered in microfluidic devices, resistance to flow scales linearly 
with viscosity and the length of a channel and with the inverse square of the cross-sectional area of a 
channel.
18
  Thus for a specified maximum pressure, flow resistance can be decreased by decreasing the 
length over which the fluid is flowing, and especially by enlarging the cross-sectional area of the channel.  
While these geometric modifications can be used to facilitate flow of viscous fluids, the pressures required 
for flow in a given microfluidic configuration may cause the microfluidic channels to deform, particularly if 
elastomeric materials such as PDMS are used.  Channel deformation occurs if the applied pressure 
exceeds the stiffness of the material.  Channel geometry will vary as a function of pressure, which in turn 
varies as a function of position along the channel.  Deformation will be larger at the inlet of the channel 
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where the pressure is highest, and will decrease towards the outlet.  Previous studies have discussed the 
effects of channel deformation in microfluidic configurations, but these studies were limited to externally 
driven, steady-state flow.
7,19,20
  Channel deformation has also been useful experimentally.  Hardy et al. 
developed a microfluidic analog for the study of blood vessels by exploiting the deformability of 
microchannels in PDMS.
19
  Channel deformation as a result of viscous fluid flow in non-rigid channels 
also introduces a variety of transient phenomena that may have a profound effect on the operations 
performed on-chip, such as the precise metering of fluids which is required in many microfluidic 
applications.  For these and several other on-chip operations, transients as a result of viscous fluid flow 
must be taken into account, yet mathematical descriptions to estimate these transients are presently not 
available.  
This chapter develops relevant theory for the flow of highly viscous fluids in deforming microfluidic 
channels, particularly with respect to transient effects, and discusses potential implications on the design 
of appropriate microfluidic devices for such highly viscous fluids.  A simple model for a pneumatic valve 
will be introduced to characterize the efficiency whereby an applied valve actuation pressure is translated 
into a driving force for fluid flow, and scaling relationships between valve actuation and flow effects will be 
identified to aid the design of microfluidic chips for viscous flows (Section 3.2.1).  Next the effects of 
channel deformation on viscous flows will be considered.  After a steady-state analysis similar to prior 
work (Section 3.2.2.1),
7,19,20
 relevant theory will be derived for the fully transient problem (Section 3.2.2.2).  
The results of the theoretical analysis will then be applied to (i) the challenges of pumping and precise 
metering of viscous fluids despite channel deformation effects, and (ii) the design of a microfluidic device 
for the mixing of highly viscous and non-Newtonian fluids. 
3.2  Theory 
3.2.1 The Effect of Valve Membrane Actuation on Pressure-Driven Flow in a Rigid Channel 
The use of integrated microfluidic pneumatic pumps, comprised of three peristaltic valves in 
series,
2,9,11
 has become increasingly common, particularly in highly complex microfluidic networks.  This 
kind of on-chip method to drive fluid flow is desirable because it enables complex fluid routing while 
providing better precision and flexibility than external pressure sources.  In a multilayer microfluidic 
device, a valve can be defined by an area where a microfluidic feature from one layer overlaps with that 
of a second layer, either above or below.  A thin membrane of elastomeric material separates these two 
layers and deflects upon the application of pressure to the valve layer, translating an externally applied 
pressure to an internally applied pressure via deflection of the membrane and eventually sealing off flow 
in the fluid layer (Figure 3.1a).  An on-chip pump can be created by placing three or more of these valves 
in series and actuating them in a sequence to create a peristaltic pumping action (Figure 3.1b).
9
  
A linearized model, valid for small deflection of a thin membrane was used to understand the effects 
of various design parameters on the operation of these valves and the resultant downstream pressure on 
the fluid.
21




the linear model captures the essential scaling needed for the initial design of microfluidic valves.  For the 











         (3-1) 
where the Young‟s modulus E and Poisson‟s ratio σ characterize the deformability of the valve material, 
and the valve membrane is of radius s, thickness a, and experiences an applied pressure Pappl (Figure 
3.1d).  Deflection of the membrane is taken to be in the z-direction and is characteristic of the amount of 
deflection of the center of the membrane.  Full actuation of the valve is defined when z = hv, the height of 
the valve chamber.  Within the valve chamber, the assumption is made that the only pressure losses are 
those due to deflection of the membrane, resulting in a pressure in the valve chamber of Pin.   
 
Figure 3.1.  (a) Depiction of the actuation of a push-down type pneumatic valve.  (b) Depiction of a 3-phase 
peristaltic pump where a set of three pneumatic valves are actuated in sequence to drive fluid flow.  The (100) 
actuation phase is shown.  (c) Schematic depiction of a microfluidic channel of length L, width w, and height h.  
Inlet pressure is Pin, pressure at outlet is Pout.  (d) Depiction of a theoretical pneumatic valve with circular 
membrane (highlighted in blue) of radius s and thickness a to be deflected a height hv.  Applied pressure is Pappl, 
pressure inside of the valve is Pin. 
Eq. (3-1) can be used to consider the pressure driving force available for pumping after valve 
actuation, assuming a pressure difference across the valve of ΔP =Pappl – Pin.  Eq. (3-1) can be normalized 
by the applied pressure Pappl and a parameter α can be defined that describes the pressure losses 















        (3-2) 
From Eq. (3-2) it follows that the term  approaches zero when the pressure losses due to the valve 
are small.  The case where actuation of a pneumatic valve has a negligible effect on the pressures 
associated with fluid flow can be defined in the limit of ( → 0).  This limit can be approached physically 
 58 
by modifying the stiffness (E/Pappl) and/or the geometry (a
3
hv/s
4) of the valve.  When the ratio of E/Pappl is 
small, the applied pressure is able to easily overcome the resistance of the valve material to deformation.  
The thickness of the valve membrane a along with the extent of deflection hv can be modified along with 
the radius of the valve s in order to minimize the geometric term a3hv/s
4.   
A method to determine Pin, the pressure available for pumping at the inlet of a microfluidic channel, 
has now been established, whether it is directly applied by an external source or determined using Eq. (3-
1).  Fluid flow in a long microfluidic channel of length L, width w, and height h (Figure 3.1c) can now be 
considered.  Typically microfluidic channels have a low aspect ratio such that w >> h, and the channel can 
be treated effectively as an infinite slit.  Furthermore, the small dimensions of these channels lead to a 
small Reynolds number and thus laminar flow.  The driving pressure Pin is dissipated over the length of 
the channel to an outlet pressure of Pout.  The z-axis is taken to be in the direction of flow along the length 
of the channel. 
The hydrodynamics of viscous flow in an infinite slit of rigid geometry are well understood and an 
expression for the volumetric flowrate V can be easily derived in terms of the channel dimensions, 








            (3-3) 
For a channel of set dimensions, termed a „rigid‟ channel, a linear pressure drop (ΔP/L) is realized 
over the length of the channel with ΔP = Pin – Pout.  Note that since the pressure front is assumed to 
transfer instantaneously through an incompressible fluid, this result is valid for all times. 
3.2.2 The Effect of Channel Deformation on Viscous Flow 
In using elastomeric materials, deformation of the bulk material defining a channel is possible (Figure 
3.2).  Thus, rather than considering a thin membrane as in Section 3.2.1, the deformation of an infinite 
slab subject to an applied surface pressure will now be considered. 
 
Figure 3.2.  Schematic depiction and optical micrograph of (a) an undeformed PDMS microfluidic channel and 
(b) a highly deformed PDMS channel under the influence of 207 kPa (30 psi) applied pressure.  Schematic 
depictions are not drawn to scale. 
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3.2.2.1 Steady-State Viscous Flow in a Deformed Channel 
Deformation of the channel can be modeled as a distributed pressure over an infinite slab.
22
  For a 
typical PDMS device on a stiff glass substrate, it is only necessary to consider deformation of the top wall 
of the microfluidic channel so long as the aspect ratio of the device does not approach unity (also a 
requirement for viscous flow in an infinite slit).
7,22
  The maximum deformation of a slab can be written in 
terms of the ratio of pressure to Young‟s modulus P/E, a characteristic length which for a low aspect ratio 
channel is the width w, and a proportionality constant c which takes into consideration the geometry of the 
deforming area and is of order of magnitude ~ 1.
7,19,22







           (3-4) 
Previous work has demonstrated that this deformation is parabolic across the width of a microfluidic 
channel.
7,19
  Owing to the nonlinear dependence on the channel height h in Eq. (3-3), the change in V  
with variable h cannot be captured by using an average value for h.  Nonetheless, it is convenient to 
compute <Δh> = 2/3Δhmax, as has been done previously, 
7,19
 and thus an expression for an effective height 
h(z) along the length of the channel as a function of P(z) and the initial channel height h0 can be written.  
Note that the relevant coefficient for the effective height may differ from 2/3 in practice. 
 














        (3-5) 
Substituting this function for the channel height into our expression for volumetric flowrate from Eq. (3-3), 
the following expression for the volumetric flowrate in a deformed channel as a function of the pressure 




















       (3-6) 
At steady-state the volumetric flowrate is constant, and Eq. (3-6) can be integrated over the length of 
the channel assuming an inlet pressure of Pin and letting Pout = 0.  Combining the integrated form of Eq. 
(3-6) with Eq. (3-3) and defining a non-dimensional parameter β, which characterizes the tendency of a 
channel to deform, an analytical form of the steady-state volumetric flowrate for a deformed channel can 
be obtained in terms of the volumetric flowrate for a rigid channel and a correction term that depends on 



























         (3-8) 
 
Figure 3.3.  (a) Steady-state pressure profiles for different values of β along the microfluidic channel.  
Pressures in the deformed channels are larger than the linear rigid case at all points in the channel.  (b) Steady-
state volumetric flowrate normalized by the flowrate in a rigid channel as a function of the deformation 
parameter β.  (c) The change in the channel volume normalized by the rigid channel volume as a function of β.  
In the limit of small this curve can be approximated as 0.5, as shown. (d) Depiction of the effects of steady-
state channel deformation based on the results of the MATLAB simulation.  Image is drawn to scale with h0 = 10 
µm. 
β describes the tendency of the material to deform given the ratio Pin/E.  The larger the applied 
pressure compared to the Young‟s modulus, the larger the deformation.  For the purposes of the analyses 
presented here – particularly given the approximation of flow in an infinite slit – an examination of 
deformation behavior over only the range of β < 3 will be made.  This threshold for analysis was 
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established based on the aspect ratio of the deformed device such that the assumption of an infinite slit is 
still valid.  For example, if a channel of width w = 100 µm and initial height h0 = 10 µm is considered, the 
initial aspect ratio is 0.1, indicating an order of magnitude difference between the two dimensions.  
However, for the case of β = 3, channel deformation results in an average channel height of h = 40 µm 
and an aspect ratio of 0.4, indicating that the height and width of the channel are of nearly the same order 
of magnitude.  
To obtain an expression for P(z) Eq. (3-6) is integrated and substituted into Eq. (3-7): 
     
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             (3-9) 
Owing to the deformation of the channel, a 4
th
 root decay of pressure along the channel length is 
observed, rather than the linear dependence seen in the rigid case (Figure 3.3a).  In the limit of small β, 
Eq. (3-9) reduces to the rigid limit described by Eq. (3-3). 
Combining the expressions for channel height in Eq. (3-5), and pressure in Eq. (3-9), integration over 
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       (3-10) 
Having developed the mathematics behind steady-state flow in a deformed channel, the physical 
meaning behind some of these results can be considered.  As described by Eq. (3-9), and shown in 
Figure 3.3a, the pressure profile along the length of the channel is nonlinear, which corresponds to the 
channel deformation.  At the beginning of the channel where the large applied pressure results in a large 
deformation (Figure 3.3d), relatively small pressure losses occur resulting in pressure gradients that are 
lower than for the purely rigid case.  However, near the end of the channel where deformations are small 
(Figure 3.3d), much steeper pressure gradients are observed.  Both channel deformation and steeper 
pressure gradients combine to enhance the volumetric flowrate.  At steady-state, the most significant 
result of channel deformation is the 3
rd
 order polynomial dependence of the volumetric flowrate on β 
described by Eq. (3-7) and plotted in Figure 3.3b.  While for small deformations this effect can be 
neglected, a dramatic increase in flowrates is seen at larger deformations.  For example, at a value of β = 
1, typical for many microfluidic systems, the volumetric flowrate resulting from the deformed channel is 
375% higher than the corresponding flowrate expected for a rigid channel.  (See Appendix A.1 for 
calculated values of β as a function of various microfluidic device geometries).  An additional effect of 
channel deformation is an increase in the total volume of the channel.  While the precise dependence of 
the swell volume with respect to deformation given in Eq. (3-10) is complicated, one can approximate the 
relationship depicted in Figure 3.3c as Vswell/Vrigid ~ 0.5 from a Taylor series expansion for small .  The 
effect of the swell volume should have little impact on steady-state operation of a device but can become 
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significant when considering unsteady effects where the channel volume changes with time, causing the 
inlet and outlet volumetric flowrates to be unequal. 
3.2.2.2 Unsteady Viscous Flow in a Deforming Channel 






          (3-11) 
Assuming that  h changes slowly with z, we can combine Eq. (3-11) with the expression for volumetric 
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      (3-12) 
The initial condition is P = 0 at t = 0, and boundary conditions are P = Pin at z = 0; P = 0 at z = L. 
The expression is non-dimensionalized using the core variables: applied pressure Pin, the channel 
length L, and the fluid viscosity η.  These variables are chosen because they are physical parameters 
which can be easily controlled and which define resultant quantities in our system such as volumetric 
flowrate.  The non-dimensional forms of the variables are: 
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Applying this non-dimensionalization and the definition for β from Eq. (3-8), the following partial differential 














        (3-14) 
The non-dimensionalized initial condition is U = 0 at τ = 0, the boundary conditions are U = 1 at Z = 0 and 












           (3-15) 
  
The form of Eq. (3-14) is analogous to that of a diffusion equation with a variable diffusivity of 
 
3
1 U  .  Because γ is related to this variable diffusivity it can be used to define a dimensionless 
diffusive time τ*. 
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* inP t 

            (3-16) 















        (3-17) 
The modified non-dimensionalized initial condition is U = 0 at τ = 0, and the boundary conditions are U = 
1 at Z = 0 and U = 0 at Z = 1. 
The boundary value problem defined by Eq. (3-17) with associated initial and boundary conditions 
was solved numerically in MATLAB (Mathworks Inc., version 7.6.0.324).
23
  A variable grid mesh was used 
to capture the increasingly steep behavior of the function near the outlet at Z = 1.  Details of the variable 
mesh can be found in Appendix A.3.  At long times the solution is observed to approach the steady-state 
values predicted from the analytical solutions.  Results are shown below for β = 1, which is typical for a 
PDMS channel (Figure 3.4).  A copy of the code used can be found in Appendix A.6. 
As mentioned previously, the form of the boundary value problem is the same as nonlinear diffusion 
in a channel.  It is intuitive to think of a large slug of concentration entering the channel and then slowly 
diffusing along its length.  In an analogous fashion, the pressure profile within the channel develops first 
as a sharp impulse at the entrance of the channel and then spreads down the length of the channel as 
deformation occurs and steady-state is reached (Figure 3.4a).  From Eq. (3-5) the channel height scales 
directly with pressure.  Deformation or “inflation” of the channel due to the applied pressures thus 
matches the changes in pressure profile. 
The initial impulse of pressure also translates to the initial generation of steep pressure gradients.  
These steep gradients allow for rapid filling at the start of the deforming channel.  However, the pressure 
gradients take time to propagate down the length of the channel, resulting in a lag between the start of 
flow at the inlet and the observation of flow at the outlet.  This lag time can be more clearly observed by 
examining a plot of normalized volumetric flowrate at the outlet as a function of time (Figure 3.4c).  
A similar analysis can be used to examine the case where a deformed channel is allowed to relax in 
the absence of an inlet pressure.  In this instance the pressure driving force for flow comes from the 
deformed channel as it relaxes.  Referring again to the diffusion analogy, the steady-state concentration 
(or in this case pressure) profile slowly decays to zero as material diffuses to the outlet (Figure 3.4b).  
However, the driving force for this diffusion decreases with time as the concentration profile levels out in 
the channel.  Translating this analogy to pressure and fluid flow, an initially high flowrate at the outlet is 




Figure 3.4.  Results from the MATLAB simulation of the fully transient problem of pressure-driven viscous flow 
in a deforming channel using parameters that are typical for flow in a PDMS channel giving a value of β = 1.  
Here the channel is deforming to reach a steady-state profile over time.  Dimensionless pressure over the 
length of the channel Z (a) at intervals from τ  = 0 to τ  = 0.1 for the filling case, and (b) over intervals from τ  = 
0 to τ  = 1.0 for the emptying case.  (c) Volumetric flowrate at the outlet normalized by the flowrate for a rigid 
channel as a function of time for both filling and emptying.  (d) Time to fill or empty 99% of the channel volume 
for the transient filling and emptying cases, respectively, as normalized to the rigid case. 
The trends in the pressure driving force for flow are very different between the filling and emptying 
cases.  For the filling case there is a constant inlet pressure that then propagates along the length of the 
channel.  This results in a fairly rapid approach to steady-state.  However, for the emptying case the 
pressure driving force decreases with time, asymptotically approaching zero.  A comparison of the outlet 
volumetric flowrate curves for the two cases in Figure 3.4c shows that the time to reach steady-state is 
significantly longer for the emptying case. 
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Variations in the rate at which a deforming channel approaches steady-state varies with β can also be 
examined (Figure 3.4d).  The time for filling is characterized as the swell volume divided by the volumetric 












         (3-18) 
In the limit of small β, the filling time scales linearly with β.  This relationship is the result of roughly linear 
increases in the swell volume that dominates over negligible increases in the volumetric flowrate.  
However, in the limit of large β, the time scales as the inverse square of β as increases in the channel 
volume are balanced by the geometric increases in the volumetric flowrate. 
While it is more difficult to extract trends for the emptying case, Figure 3.4c and Figure 3.4d clearly 
show that the time for the emptying case to reach steady-state is significantly longer than that of the filling 
case.  Despite this difference, similar trends with β are observed. 
3.3  Design Rules 
In Section 3.2 a theoretical analysis of various aspects of the microfluidic system yielded key 
equations to describe flow in rigid and deforming channels as well as the ability to induce pressure-driven 
flow by the actuation of microfluidic pneumatic valves.  Here these key equations will be analyzed to 
establish practical design rules for use in the design of microfluidic devices.  First the effects of pneumatic 
valves on pressure-driven flow will be summarized (Section 3.3.1).  The case of steady-state pumping in 
a channel will then be considered, including the possible effects of channel deformation (Section 3.3.2).  
Next metering applications will be considered, and three different strategies to achieve precise metering 
will be presented while accounting for both steady-state and transient channel deformation effects 
(Section 3.3.3).  In Section 3.3.4 these design rules will be applied to cases in actual microfluidic 
applications. 
Note that the expressions given here reflect only the scaling behavior of the various parameters.  For 
applications where high precision is required, the values predicted here may not be sufficiently accurate.  
In those cases, the device should either be calibrated under actual operating conditions, or the theory 
should be modified to more accurately describe such cases. 
3.3.1 Effective Pneumatic Valves for Pumping Viscous Fluids 
This chapter is concerned with the idea of handling viscous fluids in a microfluidic device.  
Overcoming the resistance of highly viscous fluids typically necessitates a high pressure driving force.  
Therefore, it is important to minimize ancillary pressure losses associated with the transfer of pressure to 
the fluid, as with the actuation of a pneumatic valve.   
In Eq. (3-2) the parameter  was established which describes pressure losses associated with 
stiffness during the actuation of the valve.  This provides a design equation for the effective incorporation 
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of microfluidic pneumatic valves to drive fluid flow.  In the limit of an ideal valve that actuates without 
pressure losses the parameter  → 0.  In designing a valve for pumping, the parameters in Eq. (3-2) can 
be optimized corresponding to the geometry (a3hv/s
4) and the relative stiffness of the valve (E/Pappl) to 
minimize the value of .  
Using typical physical constants for PDMS (E = 700 kPa, and σ = 0.5)
7,8
 and typical valve 
configurations ( = 10 µm and hv = 10 µm), the value of α is small (< 0.05) for valves sizes s > 100 µm at 
actuation pressures as low as 10 kPa (1.45 psi).  Similar values for α can be obtained with smaller valves 
through the use of higher pressures.   
The results presented here are similar to work done by Quake et al. concerning the design of a 
valve.
12
  While the goal of their work was the creation of a valve that could be actuated successfully, here 
their ideas have been extended to design a valve with minimal pressure losses. 
The simplest pumping scenario is the constant pressure case where steady-state can be reached and 
maintained.  This can be achieved through the use of an external syringe pump or pressure source.  
However, on-chip pumping by a series of pneumatic valves is inherently a discrete process which can be 
characterized as a fluctuating pressure source.  As shown in Figure 3.1b, a pneumatic pump can be 
created by arranging three or more valves in series, and actuating these valves in a peristaltic sequence 
(100, 110, 010, 011, 001, 101 where 1 refers to the actuation or closing of a valve and 0 refers to the 
opening of a particular valve in the series).
9
  Thus, six sequential valve actuations must take place for a 
discrete unit of fluid to be pushed through the pump.  For such a pump to maintain a pseudo-steady-state 
in a deformed channel, the timescale of the pumping cycles must be smaller than the timescale for 
relaxation of the deformed channel.  However, the timescale for pumping must also be longer than the 
timescale for relaxation of the small segments of deforming channel between valves.  Fortunately, the 
distance between pump valves is typically small and since the relaxation time scales with channel length, 
the relaxation time for these small channel segments is not significant. 
While balancing pump design against deformation of the channel may need to be considered in 
extreme cases, the advantage of moving fluid within a peristaltic pump as opposed to down a long 
channel is the difference in length-scale.  The distance between sequential valves in a pump can be 
made very short, allowing for a high driving force.  Flow between valves can be further facilitated by 
considering the dimensions of the valves as compared to the fluid channel as per Eq. (3-3).  Increasing 
the width or height of the valve allows for easier flow.  In fact, if the design rules associated with Section 
3.3.1 and Eq. (3-2) have been used to design an efficient valve, the thin membrane forming the “roof” of 





3.3.2 Steady-State Pumping in a Microfluidic Channel 
Eq. (3-3) provides a design equation in which parameters such as the applied pressure, flowrate, and 
channel geometry can be optimized to facilitate flow of a fixed volume of a viscous fluid.  Using an initial 
channel design and specifying a volumetric flowrate, an initial estimate of the applied pressure that would 
be needed to drive flow can be made and then the design and/or operation of the device can be adjusted 
to lower this pressure if the estimated pressure is not feasible.   
However, while large applied pressures can be used to drive flow, such increases also affect the 
potential for channel deformation to occur.  Thus the combined effects of changing a particular parameter 
first on the pressure using Eq. (3-3), and then the total effect of both the parameter and the pressure 
change on β using Eq. (3-8) were examined.  As an example, consider the parameter h.  The pressure 
scales as 1/h3 and β scales as P/h, thus the total effect is β~ 1/h4.  The scaling of these parameters is 
given in Table 3.1.   
Table 3.1 provides a 1
st
 order estimate of the scaling relationships that various geometric, materials, 
and operational parameters have on the applied pressure necessary to drive flow and on the resultant 
deformation.   For small deformations (β << 1), these scaling relationships constitute a rigorous 
quantitative estimate.  For β ~ 1, these estimates may be refined to give quantitative predictions using Eq. 
(3-7), the full expression for volumetric flow in a deformed channel.   It is interesting to note that for the 
same initial microfluidic geometry (identical w, h, and L) and fluid, a larger extent of channel deformation 
(i.e. lower E) will result in a higher steady-state volumetric flowrate for a given applied pressure.  Thus 
while analysis of the resultant system is more complicated, the deformation itself could be beneficial. 
Table 3.1.  Scaling relationships for steady-state pumping of a fixed volume of a viscous fluid developed from 
Eqs. (3-3) and (3-8). 
Parameter Flow Effect Deformation Effect 
w ΔP ~ 1/w β ~ constant 
h ΔP ~ 1/h3 β ~ 1/h4 
L ΔP ~ L β ~ L 
t ΔP ~ 1/t β ~ 1/t 
E No effect β ~ 1/E 
 
3.3.3 Precise Metering Operations 
In many microfluidic applications it is necessary not only to pump fluids but to do so with precise 
control over the volumes metered.  Pumping fluids in a rigid channel is simple because flow achieves 
steady-state instantaneously.  Thus the simplest strategy to design a device for precise metering is to use 
the scaling relationships in Table 3.1 such that β is small and deformations can be neglected.  If design of 
a microfluidic device such that channel deformation is negligible is not possible, it becomes necessary to 
carefully account for transient periods associated with the starting and stopping of flow.  Here three 
strategies for precise metering in a deformed channel are presented which balance the speed of a single 
metering operation against simplicity of operation. 
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3.3.3.1 Steady-State Metering with a Shunt 
For flow in a deforming channel, transient effects are associated only with the initial filling of the 
channel before steady-state is reached and the relaxation of the channel once the applied pressure is 
removed.  While the behavior of these transient periods can be accounted for, the device design and 
operation can be modified to decouple these transient periods from the actual metering operation by 
establishing a shunt to which flow can be directed during these transient periods or between metering 
instances.  In this manner, steady-state flow as predicted by Eq. (3-7) can be established in the channel, 
and then flow can be switched from the shunt to the desired outlet as needed (Figure 3.5). 
This method can provide very fast metering but requires more complicated control over the various 
flow streams.  Additionally, it is potentially wasteful with respect to the material shunted. 
 
Figure 3.5.  Depiction of a metering operation using a shunt in order to avoid concerns associated with the 
initial and final transients.  (a) Flow is directed to the shunt during the period associated the initial deformation of 
the channel.  (b) Once steady-state has been reached flow is switched from the shunt to the desired outlet.  (c) 
Once metering is finished flow is returned to the shunt and the inlet to the channel is sealed, allowing the 
excess fluid present in the channel because of the deformation to drain out.   
3.3.3.2 Metering with an Initial Transient (Half-Shunt) 
To avoid the complications of switching between shunting and metering operations while maintaining 
steady-state, the initial transient behavior could instead be accounted for while using a shunt to avoid 
transient associated with channel relaxation.  Beginning with a fully relaxed channel and the fluid at rest, 
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a lag is observed during metering between the start of pumping and the evolution of flow at the outlet 
which can be treated as a correction to the steady-state solution.  Once the desired quantity of fluid has 
been metered the outlet of the channel can simply be sealed off to prevent excess fluid associated with 
the channel deformation from affecting the metering precision.  The excess fluid present in the deformed 
channel can then be drained away as the channel returns to its rest state (Figure 3.6). 
A correction can be defined in terms of a lag time or a lag volume which is the difference between the 
actual, or transient, curve and the volume of fluid which would be metered at steady-state (Figure 3.7a).  
This value can then be added as a constant correction term to the steady-state solution predicted by Eq. 
(3-7). 
   lag sst V t V t           (3-19) 
   lag ssV t V V t           (3-20) 
 
Figure 3.6.  Depiction of a metering operation using a half-shunt to avoid concerns associated with the final 
transient.  (a) Metering is performed during the initial deformation of the channel and on into steady-state 
operation, depending upon the volume of fluid to be metered.  (b) Once metering is finished, flow is directed to 
the shunt and the inlet to the channel is sealed, allowing the excess fluid present in the channel because of the 
deformation to drain out. 
While Figure 3.7a provides a graph of the lag volume for β = 1, developing a universal relationship for 
all values of β is more useful.  Because the lag volume increases exponentially during the transient period 
before asymptotically leveling off at steady-state it is useful to normalize the lag volume to that of the 
steady-state value, Vlagss.  The dependence of lag volume on time is more complicated.  However, an 
effective time can be defined based on a 2
nd
 order polynomial scaling for the dimensionless diffusive time.  
* *2 *
scale A B             (3-21) 
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Figure 3.7.  Results from the MATLAB simulation of the fully transient problem of pressure-driven viscous flow 
in a deforming channel.  (a) The volume passing through the outlet normalized by the volume of a rigid channel 
as a function of time for the transient case and for hypothetical instantaneous steady-state flow.  (b) The 
steady-state lag time normalized by the time to for flow in the rigid case to accomplish a total rigid channel 
volume and the steady-state lag volume normalized to the channel volume for metering as a function of β.  (c) A 
plot of normalized lag volume vs. a scaled dimensionless time.  The solid curve is an exponential fit to the data 
which is universal for all β.  (d) A plot of the fit parameters A and B for reversing the normalization the universal 
lag volume curve as a function of β.  Polynomial fits are shown. 
The fit parameters A and B were obtained by matching values of the effective time for each value of β 
to the case of β = 0.001 when the lag volume parameter = 0.4 and 0.9.  Additional details associated with 
this fitting are given in Appendix A.2.  Plots of both A and B as a function of β are given in Figure 3.7d 
along with the associated polynomial fit of the curves.  The R
2
 values for each of these curves were  
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> 0.999.  The resulting data was then fit to a simple exponential curve by least squares analysis with a 
value of k = 8.39 for the fitting constant.  A plot of both the data and the resulting curve fit are given in 
Figure 3.7c.  
Examining variations of the steady-state lag time and lag volume as a function of β (Figure 3.7b) is 
also useful.  Similar to the trends observed in the swelled volume of the channel (Figure 3.3c), the steady-
state lag volume increases in a nearly linear fashion as a function of β.  This similarity is expected since 
the lag volume is directly related to the extra volume of fluid needed to fill the deformed channel.  Actual 
values for the lag time and lag volume are calculated and discussed in Section 3.3.4.2 below. 
The trends in the relationship of lag time vs. β are identical to those observed for the time to fill a 
channel vs. β from Eq. (3-18) and Figure 3.4d.  At small deformations a nearly linear relationship between 
lag time and β exists because increases in the channel volume dominate over the relatively small 
increases in the volumetric flowrate.  However, as deformation becomes more pronounced, the benefits 
of an increased volumetric flowrate are counteracted by increases in channel volume, resulting in an 
inverse square dependence of lag time with β. 
As demonstrated in Figure 3.4c, the timescale for the transient period associated with filling a 
deforming channel is significantly shorter than the timescale associated with relaxation of the channel.  
Thus while the half-shunt metering strategy described here is slower than the fully steady-state shunt 
method (Section 3.3.3.1), it is faster than the fully transient strategy presented in Section 3.3.3.3 below. 
3.3.3.3 Fully Transient Metering 
The simplest method for precise metering is also the slowest and involves considering the fully 
transient problem.  In this case the pressures associated with pumping will first cause the channel to 
deform.  Thus the time associated with this initial transient can be estimated using the plots of lag volume 
(Figure 3.7).  If the volume to be metered is such that the system reaches steady-state, Eq. (3-7) can be 
used as previously to determine the time needed for pumping.  However, it is now necessary to also 
consider the time needed to fully relax the channel and thus empty out the desired volume of fluid. Figure 
3.4d provides an estimate of the time needed for the channel to fully relax as a function of β. 
In determining a metering protocol for this fully transient case, the previously described strategies can 
be used to determine the time for the desired volume of fluid minus that of the swell volume to reach the 
outlet.  At this point the pumping must be shut off and the inlet of the channel sealed to prevent backflow. 
3.3.4 Applications of the Design Rules 
Thus far the physics behind various phenomena present in a microfluidic device have been described 
and associated design rules were developed.  These design rules will now be applied to two examples in 
actual microfluidic applications: (i) a microfluidic device for mixing highly viscous fluids and (ii) the precise 
metering of fluid using a pneumatic on-chip pump over a range of fluid viscosities. 
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3.3.4.1 Creating a Mixer for Highly Viscous Fluids 
Microfluidic applications involving highly viscous fluids have lagged behind their less viscous 
counterparts mostly due to the difficulty in flowing high viscosity fluids on the microscale.  The simple 
scaling relationships that resulted from the work presented above (Table 3.1) enable the design of 
microfluidic devices capable of driving flow for fluids that are not only highly viscous but also non-
Newtonian.  These design rules were coupled with strategies for mixing to create a microfluidic mixer 
capable of operating with fluids of both differing and high viscosities.
2
  Additional details on the design 
and operation of this mixer are given in Chapter 4.   
The majority of microfluidic mixers, such as the ring mixer devised by the Quake group
11,24,25
 or the 
herringbone mixer devised by Stroock and coworkers,
26,27
 require driving flow over relatively long 
distances.  These mixer designs have difficulty operating with higher viscosity fluids, especially when 
trying to mix fluids of significantly different viscosities.  Thus instead of striving to establish complex flow 
patterns in a long channel, a mixing strategy that is compatible with the need to pump higher viscosity 
fluids was developed (Figure 3.8).  Chapter 4 describes the operation and application of this device to mix  
a viscous lipid (monoolein) and an inviscid aqueous solution.
2
  Here a description is given as to how the 
scaling relationships were used in its design.  The viscous fluid mixer is composed of three microfluidic 
chambers connected by small microfluidic channels.  In this two-layer PDMS device, isolation valves are 
located both over the inlet lines used to fill the device and over the channels connecting each of the three 
chambers.  Large microfluidic injection valves are also located over each of the three large chambers 
containing the fluids to be mixed.  These injection valves are used to pump fluid from one compartment to 
another while the various isolation valves on the connecting channels control the direction of fluid flow.  
Mixing is achieved by first driving flow in a linear fashion from the side chambers into the center chamber 
through all of the available injection lines.  Two recirculating loops of flow are then created on the two 
halves of the device by using first one injection line for flow to the side chambers, then two lines to return 
to the center chamber, and then again a single line to refill the side chambers.  These straight-line and 
recirculating flow patterns are repeated to drive fluid mixing in a tendril-whorl fashion.
28
  This mixer was 
used to prepare self-assembling aqueous/lipid mesophases where the viscosity of the initial aqueous and 
lipid solutions differed by a factor of ~30 (2.45 × 10
-2
 Pa-s for the lipid phase versus 7.98 × 10
-4
 Pa-s for 
the aqueous phase).  Furthermore, the resulting mixture had a viscosity ~10
5
 times larger than that of 
water (~48.3 Pa-s at a shear rate of 71.4 s
-1
) and displayed non-Newtonian fluid behavior.  These 
mesophases are of interest particularly in structural biology applications, including membrane protein 
crystallization, (see Chapter 2).
29
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Figure 3.8.  Optical micrograph of a microfluidic mixer designed to mix highly viscous fluids or fluids of vastly 
different viscosities.  Pneumatic valves are outlined in green and are located as isolation valves over inlet lines 
leading into each of three larger chambers as well as over lines connecting the three chambers.  Valves used to 
drive fluid flow are located over each of the three large chambers.  (a) The injection of an aqueous solution from 
the side chambers into the center chamber containing a highly viscous lipid.  (b) Injection of fluid from the 
center chamber to the side chambers through a single injection line.  See Chapter 4 for more details on the 
mixing sequence.  
In designing this microfluidic mixing device, the first challenge that needed to be overcome was 
pumping fluids with viscosities several orders of magnitude higher than water.  This increased viscous 
resistance was countered by designing the geometry of the device based on the design rules in Table 
3.1, such that operational parameters including the applied pressure to drive flow, could be optimized (i.e. 
minimized to attainable pressure levels).  Instead of trying to pump a highly viscous fluid over a long 
distance in a narrow channel, the mixer was configured such that (i) the distance for flow L is short and (ii) 
the width w of the device is large.  The use of large fluid chambers allow for minimization of the distance 
over which fluid was pumped in a narrow channel.  These large chambers have the added benefit of 
ensuring, as per the scaling relationships associated with the parameter α in Eq. (3-2), that the pneumatic 
valves located over each chamber are able to efficiently drive flow without pressure losses.  Including 
these chamber valves in our design provided two additional benefits:  (i) Whereas the actual height of the 
fluid chambers in the device is a constant, the presence of an easily deflectable valve over each of the 
chambers allows each of the chambers to be effectively considered as having a much larger height than 
was initially designed.  The design rules derived here (Table 3.1) show that the required pressure to drive 
viscous flow scales with the cube of the channel height, meaning that even small increases in height 
significantly decrease the pressure needed to drive fluid flow.  (ii) The entire contents of each individual 
chamber are pumped with a single actuation, rather than by repeated pumping steps to move smaller 
portions of fluid around.  (iii) Lastly, the device was operated relatively slowly such that adverse effects of 
the increased fluid viscosity which had not been overcome through device design could be compensated 
for by accepting a lower flowrate.  The mesophase that is formed upon mixing in this study also displayed 
viscoelastic behavior.  An additional benefit of the decreased flowrate was adequate compensation for the 
relaxation timescales associated with the fluid. 
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Based on the geometry of the device and the large applied pressures needed to drive flow, the 
calculated value of β ~ 2 indicates that deformation of the channels connecting the compartments will be 
significant.  As discussed previously (Section 3.2.2), this kind of deformation decreases pressure losses 
along the length of a channel and can provide further benefits for moving highly viscous fluids between 
chambers.  While deformation is only an issue for the short channels connecting the larger microfluidic 
chambers, the short length of these channels means that the lag time and volume will be relatively small 
compared to the total volume of fluid to be pumped.  Additionally, relaxation of the extra volume in these 
channels is not a concern because microfluidic isolation valves over each of these channels are actuated 
as part of the mixing sequence and will expel fluid remaining in the channel. 
3.3.4.2 Peristaltic Fluid Metering 
The Case of a Rigid Channel 
The ability to precisely meter out picoliter-scale (or smaller) quantities of fluids has been clearly 
demonstrated in microfluidic devices, usually by the peristaltic actuation of a series of pneumatic valves.
24
  
This method typically assumes that the volume of fluid displaced under the valve will be moved down the 
channel without losses due to channel deformation.  For a given driving pressure ΔP, Eq. (3-3) gives the 
maximum flowrate through a channel based on the channel geometry and fluid viscosity.  When using a 
peristaltic pump, an average volumetric flowrate can be calculated based on the volume displaced by a 
single cycle of the pump Vvalve and the pumping frequency f.   
valveV fV           (3-23) 
The pump should be capable of pumping at any flowrate up to the maximum flowrate specified by the 
channel geometry and fluid viscosity at which point the viscous resistance to flow will dominate over 
pumping rate.  The maximum pumping rate associated with a given frequency can be calculated for a 
given system by combining Eqs. (3-3) and (3-23).  In the interest of examining viscosity effects on 
pumping, a system parameter ksystem can be defined which captures the geometric and operating 
















        (3-24) 
Hansen and coworkers describe the exact problem resulting from a limiting pump speed in their work 
on a microfluidic formulator.
24
  In this formulator they use a three valve peristaltic pump to precisely meter 
out small volumes (~80 pL) of fluid.  While for aqueous solutions (η ~ 0.001 Pa-s) they are capable of 
successfully operating their pump at a very fast rate of 100 Hz, they observe a drop-off in metering 
accuracy for more viscous fluids (η ~ 0.4 Pa-s) even at a pump rate of 10 Hz.  They determined that it 
was necessary to decrease the pump speed to 5 Hz in order to accurately meter out the more viscous 
fluid. 
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Using the analysis provided by Eq. (3-24) with the geometry of the microfluidic formulator used by 
Hansen and coworkers (h = 9 µm, w = 80 µm, L = 4712 µm, Vvalve = 80 pL), and an estimated value for the 
pressure applied by the valve of ΔP = 207 kPa, one calculates a value of ksystem = 2.7 Pa.  From this value 
for ksystem, the limiting pumping frequency was calculated as a function of viscosity, and plotted in Figure 
3.9.  The curve defined by Eq. (3-24) provides an upper bound on the range of pumping frequencies and 
viscosities for which  accurate metering based on incremental increases in the volumetric flowrate can be 
accomplished, thus defining an “accurate metering window.”  Beyond this window the relation between 
the frequency and the volumetric flow rate is unclear, hampering accurate metering.  Note that this 
analysis assumes that the channel or chamber into which the fluid is being pumped is rigid, thus transient 
effects can be ignored.  
 
Figure 3.9.  Pump rate curves for peristaltic metering systems characterized by different values of ksystem.  
These curves indicate the upper bound of an “accurate metering window.” The black curve represents the 
system described by Hansen et al. with ksystem = 2.7 Pa.
24
  The associated metering window is highlighted in 
grey.  Two points are shown, corresponding to the limiting case of 10 Hz ( ) which could not accurately meter 
a fluid with a viscosity of 0.4 Pa-s, and 5 Hz ( ) which falls within the metering window. 
In their work, Hansen and coworkers reported that metering of a viscous fluid (η ~ 0.4 Pa-s) could not 
be accomplished at a pumping rate of 10 Hz, whereas accurate metering could be done at a slower rate 
of 5 Hz.  If these two points are examined graphically, it can be observed that the faster pumping rate of 
10 Hz falls outside of the metering window (Figure 3.9, ) whereas adjusting the pumping rate to 5 Hz 
shifts the condition so that it falls within the accurate metering window (Figure 3.9, ).  In other words, 
the simple approach to indicate what ranges of operational parameters for a given system will allow for 
precise metering that is reported here, based on Eq. (3-24),  is able to accurately describe these 





The Case of a Deforming Channel 
The fluid metering described above assumes that the channel or chamber into which the fluid is being 
pumped is rigid and that transient effects do not need to be taken into account.  To examine the extent to 
which the initial transient can affect metering, the metering example from Hansen and coworkers
24
 can 
also be considered while taking channel deformation into account.  The assumption that β = 1 and that 
the timescale for actuation of the peristaltic pump is much faster than the timescale for channel 
deformation are made such that the discrete nature of peristaltic pump actuation can be neglected.  Given 
the value of β, the analysis regarding the effect of channel deformation on viscous flow provided in 
Section 3.2.2 allows for the determination of a variety of parameters for the system.  For this metering 
example, the most important parameters are the steady-state volumetric flowrate, the lag time, and the 
lag volume.  As was mentioned previously (Section 3.2.2.1), for a value of β = 1 the volumetric flowrate 
resulting from the deformed channel is 375% higher than the corresponding flowrate expected for a rigid 
channel.  Thus if a limiting pumping rate analysis from Eq. (3-24) is performed, the deformation of the 
channel is observed to reduce the resistance to flow and thus allow for the system to operate at a faster 
steady-state pumping rate than in the limit of the rigid case.  In fact, for the same viscous fluid (η ~ 0.4 Pa-
s), a maximum pumping rate of 25 Hz is predicted, a 5x increase over that of the rigid case. 
The lag time and lag volume are also very important when taking the initial transient of a metering 
operation into account.  For a system with β = 1, Figure 3.7b can be used to read off normalized values 
for these two parameters with respect to a rigid system (Vlagss/Vrigid = 0.254 and τlagss/τrigid = 0.0679).  While 
the values of these normalized parameters are applicable to any system, the actual dimensional values 
for the lag time and volume will depend on the system parameters involved in the normalization variables 
Vrigid and τrigid.   











         (3-26) 
As can be seen in Eqs. (3-25) and (3-26), Vrigid scales linearly with the channel length L, whereas τrigid 
scales with the length squared.  If two channels are considered where one is twice the length of the other 
and the lag behavior associated with the initial transient is analyzed, a significant difference between the 
two channels will be observed.  The lag volume for the longer channel will be twice that of the shorter one 
while the lag time will be four times longer.  A summary of these scaling relationships is given in Table 
3.2.  
The effects of this lag period can now be considered with respect to the metering example from 
Hansen and coworkers.  For this system the accuracy of metering was taken to be equal to the volume 
pumped by a single cycle of the peristaltic pump, 80 pL.  However, a lag volume of 0.863 nL was 
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determined, which corresponds to nearly 11 cycles of the pump.  While the magnitude of this lag volume 
depends upon the channel geometry as shown in Table 3.2., it is important to note the potentially 
significant error in the volume of fluid metered that can result from channel deformation. 
Table 3.2.  Scaling relationships for the lag volume (Vlag) and lag time (tlag) associated with the initial transient 
resulting from channel deformation.  These results were developed from the definitions for Vrigid and τrigid. 
Parameter Lag Volume Lag Time 
w Vlag ~ w No effect 
h Vlag ~ h tlag ~ 1/h
2
 
L Vlag ~ L tlag ~ L
2
 
ΔP No effect tlag ~ 1/ΔP 
η No effect tlag ~ η 
 
3.4 Conclusions 
In summary, key equations for the actuation of microfluidic pneumatic valves and pressure-driven 
viscous flow have been derived for both rigid and deforming microfluidic channels at steady-state and 
unsteady conditions.  These mathematical expressions were then translated into a series of scaling 
relationships which can be used in the design, construction, and operation of microfluidic devices.  Here 
the focus was on pumping and precise metering.  These design rules were then applied to two specific 
tasks: (i) the design of a microfluidic device to mix highly viscous fluids and (ii) the precise metering of 
fluids over a range of viscosities using an on-chip pneumatic peristaltic pump. 
The analysis performed here focused on Newtonian fluids to clearly lay out the various scaling 
relationships that exist.  However, similar rules can also be developed for non-Newtonian fluids.  The two 
most commonly considered types of non-Newtonian fluid behavior are shear thickening and shear 
thinning, related to how the fluid reacts to different shear stresses.  At a single flow condition, a non-
Newtonian fluid can be described by an apparent viscosity, which can be used with the design equations 
developed here.  Additional non-Newtonian behaviors such as viscoelasticity are characterized most 
importantly by a characteristic timescale.  In the case of a viscoelastic fluid, actions that occur faster than 
this characteristic timescale for relaxation cause the material to respond elastically rather than as a 
viscous fluid.  Thus by operating a device at a timescale longer than this relaxation time the non-
Newtonian behavior will be negligible and the equations derived here for steady and unsteady flow of 
viscous fluids in microfluidic channels will still apply. 
The design rules in this work will aid the design of microfluidic systems that involve a significant 
challenge, such as the need to handle high fluid viscosities or the need to meter fluids precisely.  
Furthermore, the results in this work for the first time quantify the transient effects that deforming 
channels have on the performance of microfluidic systems.  This analysis will enable the design of 
devices whereby transient deformation effects can be minimized to a level that is acceptable for the 
intended application or the transient effects can be accurately accounted for. 
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Chapter 4   
Design and Application of Microfluidic Platforms 




This chapter describes a microfluidic method for the formation of aqueous/lipid mesophases to enable 
screening of suitable crystallization conditions of membrane proteins from a membrane-like phase in sub-
20 nL volumes.  This integrated microfluidic chip and the employed mixing strategy address the specific 
challenges associated with the mixing of fluids of highly different viscosities (here a factor of 30) as well 
as the non-Newtonian character of the resulting mesophases.  The chip requires less than 20 nL of 
material per condition screened whereas typically on the order of 10 µL or more is needed for a batch 
preparation in the present screening methods.  This approach was validated with the successful 
crystallization of the membrane protein bacteriorhodopsin. 
  
                                                     
*
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4.1  Introduction 
As was described in Chapters 1 and 2, membrane proteins are critical components of many 
fundamental biological processes, enabling cell signaling and material and energy transduction across 
cellular boundaries.
1-7
  As such, their malfunction has been linked to numerous diseases and they are 
common targets for pharmacological treatments.
6-11
  However, an understanding of the mechanisms 
whereby these proteins operate and attempts at rational drug design have been limited by difficulties in 
obtaining high resolution structural information.
12
 
Two of the most significant bottlenecks for membrane protein structure determination are (i) obtaining 
sufficient quantities of high quality protein samples and (ii) growing high quality protein crystals.
2,13-39
  
These challenges are exacerbated for amphiphilic membrane proteins because of difficulties with over-
expression
9,11,35,40-46
 and stability once removed from their native membrane environment.
1,7,11,26,41,47-53
  As 
a result of these difficulties, a tremendous disparity has developed between the number of known 




In recent years, microfluidic technology has been successfully utilized for high throughput screening 
of crystallization conditions at the sub-nanoliter scale.
56,57
  The small volumetric scale of microfluidics 
coupled with significant benefits related to fluid handling and control have the potential to enable the next 
generation of structural biology studies.  However, crystallization of membrane proteins in microfluidic 
systems thus far has been limited to in surfo methods where detergents are used to solubilize membrane 
proteins
11,33,35,40,43,45-47,50-52,58-60
 and crystallization is attempted as for soluble proteins.
5,11,47,48,56,58,61,62
 
The in meso crystallization method, as described in Chapter 2, is an alternative to the in surfo 
method.  It uses an artificial aqueous/lipid mesophase to maintain membrane proteins in a membrane-like 
environment.
1,25,26,33,40,43,46-48,60,63-106
  This method exploits the complex phase behavior of aqueous/lipid 
systems (e.g. lamellar, bicontinuous cubic phases),
33,60,73,74,86,106-110
 creating local variations in the 
curvature of the lipid bilayers to drive crystal nucleation and growth.
1,26,64,65,74,79,106,108
  Despite its benefits, 
implementation of the in meso approach to crystallization on the microscale has been particularly difficult 
because of the challenges associated with mixing fluids of vastly different viscosities.
33,94,111,112
  Thus far, 
the aqueous/lipid mesophases necessary for the in meso approach have been prepared either by 
centrifugation
52,60,64,110,113-127
 or using coupled microsyringes.
33,60,67,83,86,88,108,127-132
  Unfortunately the 
preparative scale of both of these methods requires the creation of relatively large amounts of 
mesophase (10-500 µL) due to the scale at which mixing can be performed.   
While many microfluidic strategies for mixing have been reported,
20,133
 they are limited to the mixing 
of fluids which have similar and have relatively low viscosities, such as two aqueous solutions.   The 
viscosities of the solutions to be mixed here differ by a factor of ~30; 2.45×10
-2
 Pa-s for the monoolein 
lipid phase, versus 7.98×10
-4
 Pa-s for the aqueous phase.  Furthermore, the resulting mesophase has a 
viscosity that is a factor of ~10
5
 larger (~48.3 Pa-s at a shear rate of 71.4 s
-1
, see Section 4.3.1) than the 
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viscosity of the aqueous phase.  Moreover, the resulting mixture exhibits highly non-Newtonian 
behavior.
111,112
  The highly viscous and non-Newtonian nature of the fluids render previously reported 
microfluidic mixing approaches ineffective.  
As described in Chapter 3, the pressure required to move increasingly viscous fluids through a 
channel of set dimensions scales with viscosity.  In microfluidic chips where flow is driven by the actuation 
of pneumatic valves, the maximum achievable pressure is limited by the actuation pressure supplied to 
the valves, which in turn limits the viscosity a fluid can have to be used in a given microfluidic network.  To 
still be able to pump fluids of high viscosities, for example, the lipids used here, an adjustment of channel 
dimensions, specifically the reduction of channel length and/or enlargement of the cross-sectional area, 
was used to overcome pressure limitations, as per the design rules established in Chapter 3.  
Additionally, non-Newtonian fluid behavior, such as the viscoelastic properties of the lipidic mesophases 
created here, needs to be accounted for.  For pneumatic pumping to be effective, the rate of individual 
valve actuation needs to be reduced to a timescale longer than the timescale of viscoelastic relaxation 
present in the fluid.  Otherwise the fluid will deform and bounce back elastically as opposed to actual flow.  
This chapter describes an integrated microfluidic chip (Figure 4.1) capable of mixing lipids with 
aqueous solutions to enable sub-microliter screening for crystallization conditions in meso.
94
  The 
principles of chaotic mixing were employed via time-periodic flow in a tendril-whorl fashion to prepare 
homogeneous aqueous/lipid mesophases.
134
  Each experiment consumes less than 20 nL of material with 
the potential to scale down further to the 0.1 nL level.  This approach was validated by the successful in 




Figure 4.1.  Optical micrograph of a microfluidic chip capable of mixing lipids (L) and aqueous protein (Pr) 
solutions by pneumatic actuation of the isolation valves (black) between the chambers and the injection valves 
(purple and blue) on top of the three large chambers (2-Pr, L).  Crystallization occurs in a separate 
crystallization chamber where the mesophase is combined with a precipitant solution that is introduced from a 
separate circular chamber at the top.  The fluidic layer is filled with a green solution and is partially covered by 
various valves (purple, blue, black, orange) in the control layer. 
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4.2  Materials and Methods 
4.2.1  Device Fabrication and Operation 
The microfluidic chip was fabricated out of polydimethylsiloxane (PDMS, General Electric RTV 650) 
bonded to a glass substrate using standard multi-layer soft lithographic procedures reported 
previously.
57,136
  Briefly, the various control and fluid layers were designed using Macromedia Freehand 
MX (Macromedia Inc.).  Based on this design, photolithography was used to fabricate replica masters 
using high resolution transparencies (5080 dpi, University of Illinois at Urbana-Champaign Printing 
Services) as masks.  The positive-tone photoresist SPR 220 (Rohm and Haas Electronic Materials) was 
used to fabricate the master for the fluid layer with ~10 µm tall features.  A reflow step at 120°C for 2 min 
was used to create rounded features in order to facilitate valving.  The master for the control layer was 
fabricated using the negative-tone photoresist SU-8-25 (Microchem).  The fabricated masters were then 
treated with (tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane (Gelest, Inc.), a silanizing agent, to allow 
for easy release of PDMS subsequent replicas.  
Fluid and control layers were fabricated via replica molding from these masters.  Spin-coating was 
used to control the thickness of PDMS for the fluid layer.  A spin rate of 2400 rpm was used to obtain a 
total PDMS film thickness of 40 µm, resulting in a valve membrane thickness of ~30 µm.  A much thicker 
control layer (~5 mm) was fabricated in order to facilitate connections for fluid and valve lines.  The fluid 
and control layers were prepared using PDMS with different ratios of monomer to cross-linking agent.  
The control layer was prepared using an excess of cross-linker (5:1 ratio) while the fluid layer was 
prepared with a 20:1 ratio, creating a deficiency in cross-linker.  The two layers were partially cured for 
~40 minutes at 65°C and then aligned and allowed to fully cure.  The differences in cross-linking 
concentration facilitates bonding between the two layers creating a monolithic structure.  Inlet holes were 
punched using a 27 AWG needle with a thin wire plunger.  The finished PDMS device structure was then 
bonded to a glass substrate using an oxygen plasma treatment to create a chemical bond.   
Fluids (protein and precipitant solutions and lipid) were supplied to the device using 30 AWG 
polytetrafluoroethylene (PTFE) tubing (Cole-Parmer Instrument Co.).  Pneumatic connections for valves 
were made using 24 AWG PTFE tubing coupled with a thin metal tube.  Pneumatic control for the various 
valve lines was accomplished using a computer-controlled bank of solenoid valves coupled to a nitrogen 
tank (Fluidigm Corp.).  The 32 individual control lines are separated into two banks of 16, enabling the 
use of two different pressures.  Typically, one bank is set at a lower pressure for driving fluid flow and the 
other is set to a higher pressure for actuation of isolation valves at a higher pressure.  
4.2.2  Crystallization Experiments 
Crystallization experiments were set up and visualized using a stereomicroscope (Leica, MZ12.5) 
with an attached digital camera.  The camera was operated using Micrometrics SE software.  For 
visualization of the various lipidic mesophases and protein crystals, images were taken with the use of 
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cross-polarizers.  Incubation of crystallization experiments was performed in a dark box at room 
temperature. 
4.2.3  Protein, Lipid, and Precipitant Solutions 
The membrane protein bacteriorhodopsin was purified from isolated purple membranes from 
Halobacterium salinarium using standard procedures reported in the literature.
64,137
  Briefly, a sample of 
purple membrane was removed from the freezer, thawed, resuspended in 10 mL of 150 mM KCl (Sigma) 
and then collected by centrifugation (15 min, 50,000 rpm, TLA 100.3 rotor, 4
°
C).  The collected pellet is 
then resuspended in 6 mL of 25 mM NaH2PO4 (EMD Chemicals), pH 6.9.  Solubilization of the 
bacteriorhodopsin was performed by the addition of 1 mL of 20% (w/v) β-octylglucoside (anagrade, 
Anatrace), sonication for 1 min, and then an overnight incubation in the dark at room temperature without 
stirring.  Following incubation the pH of the solution is adjusted to 5.5 using 0.1M HCl (Fisher), and 
centrifugation for 45 min at 15
°
C at 50,000 rpm (TLA 100.3 rotor) is used to isolate the solubilized protein 
from the membrane fraction.  The sample was then filtered through a 0.45 µm syringe filter (Fisher) and 
concentrated to < 2 mL with a Centriprep YM-50 filtration device (Millipore).  The protein sample was then 
treated by size exclusion chromatography using a Superdex 200 10/300 GL (GE Healthcare) gel filtration 
column on an Äktabasic Fast Protein Liquid Chromatography (FPLC) instrument (Amersham Biosciences) 
with 1.2% β-octylglucoside in 25 mM NaH2PO4, pH 5.5 as the running buffer.  All solutions used for gel 
chromatography were degassed and filtered (0.2 µm, Millipore) prior to use.  Fractions were pooled based 
on the ratio of absorbance at 280 nm compared to 550 nm (A280/A550 = 1.5 – 2.0).  The purified sample 
was then concentrated with a Centriprep YM-50 filtration device to the desired concentration and filtered 
through a 0.1 µm (Ultrafree-MC, Millipore) spin filter.  Protein concentration was determined by 






  SDS-PAGE 
analysis of samples taken throughout the purification procedure show a single protein band (Figure 4.2).   
2.5M Sørenson phosphate buffer pH 5.5 was prepared from a mixture of 16.06g of dibasic 
Na2HPO4•7H2O (EMD Chemicals) and 1.90g of monobasic KH2PO4 (Sigma) for 50 mL of solution.  Prior 
to setting up a crystallization experiment, precipitant solutions were filtered through 0.22 µm (Steriflip, 
Millipore) filters.   
Monoolein (1-monooleoyl-rac-glycerol, Fluka) was purchased and stored at -12°C.  Small aliquots of 
lipid were used at a time in order to limit the potential for oxidation.
67
  For a crystallization experiment a 
small aliquot of lipid was gently melted to facilitate loading into a microfluidic chip.   
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Figure 4.2.  Image of an SDS-PAGE urea gel stained with Coomasie Blue used to investigate the quality of the 
bacteriorhodopsin throughout the purification process.  From left to right a molecular weight standard (STD) is 
shown, followed by a reference sample from a previous purification.  Additional aggregate peaks are seen in 
this sample because of long term storage and repeated freeze/thaw cycles.  The subsequent columns on the 
gel show the purity of the sample after solubilization, and before and after size exclusion chromatography.  In all 
of these columns a single peak is seen, corresponding to bacteriorhodopsin at a molecular weight of 26.8 kDa. 
4.3. Results and Discussion 
4.3.1  Design and Operation 
The microfluidic chip shown in Figure 4.1 was designed to perform metering and mixing solutions 
followed by crystallization.  Fluid flow in the bottom, fluid layer is controlled pneumatically.  Isolation 
valves (black) over lines connecting the various chambers are used to control the direction of fluid flow 
while injection valves located over each fluid chamber (purple, blue, and orange) are used to drive the 
movement of material from one chamber into the next.  The short length of the injection lines between 
fluid chambers as well as the larger size of the fluid chambers compared to the injection lines allow for the 
pumping of highly viscous and non-Newtonian fluids.  Protein solution and lipid are introduced into the 
side (4.9 nL each) and center chambers (9.6 nL), respectively (Figure 4.4a), displacing air, which escapes 
by permeation through the PDMS.  In the present configuration some additional volume is lost in the 
supply lines and inlets (~40%), however this design has not been optimized.   
For protein crystallization it is necessary to screen  a range of conditions.  Thus a microfluidic array 
chip was created to facilitate higher throughput crystallization screening.  In these devices a total of eight 
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individual mixing units with attached crystallization and precipitant chambers, as in Figure 4.1 are 
operated using a single set of pneumatic valve (Figure 4.3).  Protein and lipid solutions are filled in 
through a single set of lines.  However, separate inlets for precipitant solution were included to allow for 
testing of different crystallization conditions.  This scaled-out configuration reduces the relative losses 
within the chip (18% loss for lipid and 30% loss for protein) as compared to a single crystallization unit 
and could be further optimized.  
 
Figure 4.3.  Optical micrograph of a scaled out 4x2 array of in meso crystallization devices.  All eight devices 
are connected by a single set of inlets for protein and lipid and a single set of control valves.  Isolation valves 
are shown in black.  Injection valves on top of the three mixing chambers are shown in purple and blue.  
Separate inlets feed into the dark green precipitant chambers to allow for precipitant screening.  Crystallization 
occurs in a separate crystallization chamber (light green) in which  the mesophase is combined with a 
precipitant solution that is introduced from a separate circular chamber by the actuation of a pneumatic valve 
(dark green).   
One important consideration in working at the microscale is whether the amount of material contained 
within the device is adequate to the task at hand.  While bacteriorhodopsin has been crystallized in meso 
from sub-nanoliter boluses of mesophase,
76
 it is interesting to investigate the number of crystals which 
could be reasonably expected to result from the amount of material present in a single lipid mixer.  From 
the literature, conservative estimates for the dimensions of typical in meso-grown crystals of 
bacteriorhodopsin result in a single crystal volume of ~12.5 pL (50 x 50 x 5 µm).
1,64,138
  Comparing this 
value with an estimate for the volume of a single protein molecule, as calculated from unit cell parameters 
(a = b = 60.63Å, c = 108.16Å and  =  = 90
°




 gives on the order of 3 x 10
10
 protein 
molecules/crystal.  Assuming a protein concentration on the order of 15 mg/mL, for the volume of protein 
used in a single crystallization trial roughly 3 x 10
12
 molecules of bacteriorhodopsin should be present, 
allowing for the formation of ~100 crystals per device.  
Mixing in microfluidic devices is a significant challenge.  In order to create chaotic mixing in a system 
dominated by laminar flow the fluids must be stretched and folded upon themselves until the thickness of 
the lamellae is such that diffusion dominates.  For mixing of aqueous mixtures in a batch system, a 
microfluidic ring mixer has been reported previously that operates at high Péclet numbers such that a 
band of fluid is wrapped repeatedly around on itself.
139
  Without invoking such symmetry arguments, 
another way to kinematically drive mixing is through the use of multiple mixing motions.
134
  A simple back 
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and forth motion, as in the coupled syringe mixer used traditionally for preparing in meso crystallization 
samples,
33,67,83,86,88,108,127-132
 is ineffective at small length scales because the fluid motion resulting from 
the first actuation will be identical to all subsequent repetitions.  However, if the fluid is translated in one 
direction, and then a different motion, such as a rotation is included, mixing is improved.  The addition of 
asymmetries to a system with respect to fluid flow or mixing times can give further improvements.   
 
Figure 4.4.  Optical micrographs of an aqueous 13.5 mg/mL bacteriorhodopsin solution (left and right 
chambers) being mixed with the lipid monoolein (center chamber) in a microfluidic chip.  The blue lines 
delineate the edges of the fluidic channels.  (a) Filling of chambers with protein solution and lipid through inlet 
channels (arrows); (b) straight-line injection of protein into the lipid-containing center chamber; (c-e) 
consecutive, chamber-to-chamber injection of the fluid mixture through different sets of inlets to create a net 
circulatory motion.  The mixing cycle then repeats starting at (b). (f) The slightly birefringent mixture (observed 
through partially crossed polarizers) after 1 min. of mixing.  Scale bars: 500 µm. 
The mixing chambers are designed to produce different types of fluid motion on two scales of 
operation.  At the larger scale of fluid flow between chambers, flow proceeds alternately in a linear 
fashion from the side chambers to the center chamber through all of the available injection lines (Figure 
4.4b), and then by two recirculating loops that utilize one injection line for flow directed into the side 
chambers and the remaining two lines to return to the center chamber (Figure 4.4c-e).  These two 
motions are used to avoid issues associated with the reversibility of laminar flow.  The asymmetric 
arrangement of the side chambers enables offset fluid injection into the center chamber.  The rounded 
chambers also reduce dead volume (fluid not involved in mixing).  Additionally, the injection lines between 
chambers only represent a short distance over which the pressure drop in the fluid is dissipated, thus 
avoiding further difficulties associated with moving highly viscous fluids over long distances.  A complete 
mixing cycle is composed of a sequence of 12 different valve actuations (Figure 4.5).   
The sequence of valve actuation for filling the chip is shown in Figure 4.5a-c.  First protein solution 
and lipid are filled through inlet channels into their respective chambers (Figure 4.5a).  The channels 
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connecting chambers are shut with microfluidic valves to prevent different liquids from coming into contact 
during the filling process.  Once filling is complete, the inlet isolation valves over the inlet channels are 
actuated, isolating the reagents within the microfluidic chambers (Figure 4.5b).  The isolation valves over 
the injection lines are then opened upon start of the computer-driven mixing program (Figure 4.5c).   
The 12-step sequence of valve actuation for the mixing program is shown in Figure 4.5d-o. Cycles of 
this sequence are run with equal time spacing per step at speeds varying from 5 to 25 seconds per cycle.  
(1) Injection of fluid from the side chambers into the center chamber through all six injection lines by 
actuation of the pneumatic valve over the center chamber (Figure 4.5d).  (2) The diagonally opposed 
isolation valves covering two injection lines each are closed (Figure 4.5e).  (3) The valves over the side 
chambers are opened (Figure 4.5f).  (4) The mixture is directed back into the side chambers through two 
of the six fluid channels by utilizing valves over the center chamber and a set of diagonal injection lines 
(Figure 4.5g).  (5) The diagonal isolation valves covering two injection channels each are opened and the 
opposite set of isolation valves, covering only a single injection line each, are closed (Figure 4.5h).  (6) 
The valve over the center chamber is opened (Figure 4.5i).  (7) Actuation of the side chamber valves 
pushes the mixture is pushed into the center chamber through two injection lines on a side (Figure 4.5j).  
(8) The isolation valves over the single injection channels are opened and those over the double injection 
channels are closed (Figure 4.5k).  (9) The valves over the side chambers are opened (Figure 4.5l).  (10) 
The mixture is injected into the side chambers by actuation of the valve over the center chamber (Figure 
4.5m).  (11) The isolation valves over all of the injection lines are opened (Figure 4.5n).  (12) The valve 
over the center chamber is opened.  Figure 4.5o shows the state of the mixture after a single mixing 
cycle.  A homogeneous mixture can be achieved after mixing for <1 min (Figure 4.5p), though the mixture 
tends to be slightly birefringent.  This birefringence decreases with time, as shown in Figure 4.5q after 1 
min of mixing. 
Based on the rate of pumping achieved using this 12-step sequence and observations of the flow, the 
viscosity and shear rate of the mesophase during mixing can be estimated.  The largest shear rates will 
be present in the injection lines, therefore the calculation will utilize this particular geometry, 
approximating the system as two-dimensional flow through a slit.  Defining the system as in Figure 4.6, 
laminar fluid flow occurs in the x-direction.  The height of the channel is defined with respect to y, with the 
coordinate axis centered in the channel.  Thus the deformation rate of the fluid, or change in the angle α 
with time can be described in terms of the shear rate, where u is the fluid velocity along the channel.
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Figure 4.5.  Schematic depiction of mixing device operation.  Optical micrograph are of an aqueous solution of 
13.5 mg/mL bacteriorhodopsin solution being mixed with the lipid monoolein on a microfluidic device acquired 
through a cross-polarizer.  Blue lines delineate the edges of the channels which contained reagents, green lines 
delineate valves.  (a-c) Protein solution and lipid loading sequence.  (d-o) The step-by step mixing sequence.  
(p) The slightly birefringent mixture after <1 min of mixing.  (q) The less birefringent mixture after 1 min of 
mixing.  Scale bars: 500 µm. 
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An estimation of the fluid velocity in the channel can be made based on the length and height of the 
channel (δl = 300 µm, δy = 10 µm) and the time for valve actuation.  For the 12-step mixing sequence 
actuated at a rate of 5 s/cycle a single step occurs in δt = 0.42 s.  Although actuation of the valve is much 
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Figure 4.6.  Schematic depiction of the geometry and parameters used in the estimation of shear rate and 
mesophase viscosity during mixing.  Flow occurs in the x-direction and the channel height is defined with 
respect to y.  The deformation of a fluid element at a particular height y can be described by the change in angle 
δα, which translates to a deformation length δl at height δy.  The inlet pressure P0 is assumed to equal the 30 
psig supplied by the pneumatic lines and this pressure is assumed to be spent at the out let of the channel PL = 
0 psig.
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Although lipidic mesophases have been clearly demonstrated to have non-Newtonian fluid 
properties,
111,112
 as a simple estimate the viscosity (µ) of the mesophase fluid at the above shear rate 
(71.4s
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where L is the length of the channel in the x-direction and P0 and PL describe the inlet and outlet 
pressures respectively.  Thus for the microfluidic geometries defined here the shear stress τxy = 3447 Pa.  
Using this model the viscosity of the mesophase is estimated to be 48.3 Pa-s during mixing.  This value 
for the fluid viscosity is approximately 60,000x larger than that of water at 30°C and 2,000x larger than 
that for pure monoolein lipid at 30°C. 
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During mixing each point of injection leads to mixing by tendril-whorl type flow (Figure 4.7).
134
  In this 
manner chaotic mixing is done by stretching and folding the two fluid components until the length-scale of 
the individual fluid lamellae is on the order of the diffusion length.  Tendril-type flow occurs as the fluid 
stretches upon moving from one fluid chamber to another through a narrow injection channel (Figure 
4.7c).  Whorl-type flow occurs as fluid leaves the injection channel and enters a fluid chamber where it 
then folds around in an eddy-like fashion (Figure 4.7b).  This whorl motion is further enhanced when fluid 
enters a chamber from multiple injection lines.  Birefringence (or the lack thereof) was used to visualize 
the extent of mixing in the chip.
26,33,40,48,64,67,71,73-75,77,79,88,89,92,95,96,103,113,114,125,142-146
  The aqueous/lipid 
mixture was observed to be homogeneous and mostly non-birefringent within 1-2 min. of mixing (Figure 
4.4f and Figure 4.5q), indicating the formation of the desired cubic phase. 
 
Figure 4.7.  Optical micrographs of an aqueous 13.5 mg/mL bacteriorhodopsin solution being mixed with the 
lipid monoolein in the center chamber of a microfluidic chip.  (a1-a5) Injection of protein solution into the lipid 
such that tendril-whorl flow occurs; (b) eddying (whorl) flow within the injected protein solution indicated by 
divergent arrows; (c) stretching (tendril) flow, indicated by convergent arrows, as the contents of the center 
chamber are pushed through a the narrow injection line.  Scale bars: 150 µm. 
4.3.2  Validation of the Platform Using Bacteriorhodopsin as a Model Protein 
After mixing is complete, the mesophase is transferred to a crystallization chamber via actuation of 
the chamber valves.  This is done in order to provide better control over the interaction of the mesophase 
and a precipitant solution.  The movement of the mesophase itself is achieved by actuation of the 
chamber valves in the mixer to first concentrate material in the center chamber (Figure 4.8b), and then 
drive it out of the mixer and into the circular crystallization chamber of defined geometry upon opening of 
an isolation valve over the line connecting the two portions of the device (Figure 4.8c).  A specific amount 
of a precipitant solution, e.g. 2.5 M Sørenson phosphate buffer, can then be injected from the precipitant 
chamber (Figure 4.8d).   
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The amount of a precipitant solution can be metered by dead filling of the precipitant chamber.  One 
isolation valve is used to prevent the precipitant solution from leaking into the crystallization chamber until 
desired.  A second isolation valve is used to seal the precipitant chamber inlet once filling is complete.  
With this inlet valve closed, the outlet valve connecting the chamber to the mixing chambers is opened 
and actuation of the valve over the precipitant chamber is used to drive in the precipitant solution (Figure 
4.8d).  This injection can be performed either before the mesophase is moved to the crystallization 
chamber or afterwards, as shown here.  Injection of the precipitant prior to moving the bolus is preferred 
in order to avoid air bubbles, as shown in Figure 4.8d. 
 
Figure 4.8.  A series of optical micrographs under cross polarization depicting the preparation of an in-meso 
crystallization trial on chip using 13.5 mg/mL bacteriorhodopsin solution and monoolein. (a) The 
homogeneously mixed mesophase.  (b) Valves over the side chambers are used to concentrate the mixture into 
the center chamber.  (c) The valve over the center chamber is used to drive the mesophase trial into the 
crystallization chamber.  (d) A precipitant solution of 2.5M Sørenson buffer, pH 5.5 is injected into the 
crystallization chamber from the precipitant chamber by actuation of a valve over the precipitant chamber.  
Scale bars: 1 mm. 
Alternatively, a chip where a large well has been punched through the PDMS over the crystallization 
chamber can be used for crystallization trials to facilitate harvesting of crystals (Figure 4.9a).  In this 
punched-hole chip the precipitant solution is pipetted directly into the well prior to preparation of the 
mesophase, and the well is sealed with Crystal Clear tape (Hampton Research) for the duration of the 
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crystallization experiment.  The size of this precipitant reservoir is large enough that evaporative losses 
through the PDMS would be insignificant during the course of an experiment. 
As a proof-of-concept, in meso crystallization of the membrane protein bacteriorhodopsin was 
performed using this chip.  A precipitant solution of 2.5 M Sørenson phosphate buffer at pH 5.5 was 
pipetted into the precipitant reservoir and sealed. The lipid monoolein and a solution of bacteriorhodopsin 
(13.5 mg/mL solubilized in 25 mM NaH2PO4 with 1.2% w/v octyl β-D-glucopyranoside, pH 5.5) were then 
mixed into a homogeneous mesophase.  The resulting bolus of mesophase was then moved from the 
mixing chambers to the crystallization chamber by actuation of valves (Figure 4.9a).  Finally, the entire 
chip was sealed with Crystal Clear tape and stored in the dark at room temperature.  Plate-like purple 
hexagonal crystals appeared within a few days (Figure 4.9b) and grew to a diameter of 20-50 µm, 




Figure 4.9.  (a) Optical micrographs of a homogeneous mesophase of 13.5 mg/mL bacteriorhodopsin solution 
and monoolein being moved from the mixing chambers into the crystallization chamber in a punched-hole chip 
by actuation of the mixing chamber valves in a punched-hole chip.  Scale bar: 500 µm.  (b) Optical micrograph 
of the resulting bacteriorhodopsin crystals grown on-chip via the in meso method. 
4.4. Conclusions 
In conclusion, a microfluidic chip for the on-chip formation of lipidic mesophases for in meso 
crystallization at volumes sub-20 nL has been demonstrated.   This achievement is particularly significant 
due to the challenges of not only mixing fluids of different viscosities, but also driving fluid flow of highly 
viscous materials on the microfluidic scale.  The feasibility of in meso membrane protein crystallization 
was then validated using the membrane protein bacteriorhodopsin.  Compared to the present in meso 
crystallization screening approaches, the operational scale and amenability for high throughput 
processing of the microfluidic approach introduced here allows for a 1000-fold decrease in the preparative 
scale at which the mixing necessary for mesophase formulation can be performed.  This capability is 
particularly necessary to extend crystallization screening for the in meso technique to include multiple 
lipids and/or different lipid compositions.  In addition to crystallization screening, the ability to set up a 
large number of trials will allow detailed study of the interactions between artificial mesophases, 
membrane proteins, and precipitating agents.  Better understanding of these interactions will facilitate the 
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rational design of sparse matrix crystallization screens geared to determine suitable in meso 
crystallization conditions for membrane proteins of unknown structure.
1,108
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Design and Application of Microfluidic Platforms 




Recent efforts associated with the Protein Structure Initiative by the National Institutes of Health (NIH) 
have dramatically eased the bottlenecks associated with protein expression, purification, and 
crystallization for structural analysis.  While strategies exist for dealing with each of these challenges in a 
high throughput fashion, crystal harvesting and mounting for X-ray analysis is still largely a manual 
process.  During mounting there is significant potential for damaging fragile protein crystals, both from 
physical and environmental shock.  Microfluidic strategies for protein crystallization have been limited in 
their application for a variety of reasons including (i) difficulties in harvesting crystals from a chip and/or 
(ii) the need to translate results obtained on chip to a larger scale.  Here an X-ray transparent device 
architecture is described which allows for in situ X-ray analysis of protein crystals while maintaining the 
advanced fluid handling capabilities of multilayer microfluidics.  The design uses a traditional thin 
polydimethylsiloxane (PDMS) fluid layer to enable the actuation of pneumatic valves.  Thin films of cyclic 
olefin copolymer (COC) are used both for the device substrate and as a patterned control layer.  This 
structure takes advantage of the low X-ray scattering cross-section of organic polymers such as COC 
while minimizing the path-length of the more strongly scattering silicon-based PDMS.  These COC-based 
chips have also been shown to have significantly lower evaporative losses than traditional PDMS chips.  
This device architecture has been applied to microfluidic platforms for the microbatch crystallization of 
soluble proteins.  In situ crystal quality screening and full structure determination have been 
demonstrated, both at room temperature and under cryogenic conditions.  This approach was validated 
by crystallization and analysis of the soluble proteins lysozyme, thaumatin, and ribonuclease A and will be 
extended to microfluidic platforms for in meso membrane protein crystallization.   
  
                                                     
*
 Part of this work will be published:  S.L. Perry, S. Guha, A.S. Pawate, V. Argawal, S. Nair, and P.J.A. 
Kenis, X-ray Compatible Microfluidic Crystallization Platforms for In Situ Protein Crystallography, (in 
preparation). 
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5.1  Introduction 












 have helped to overcome these challenges.  
Automated methods also exist for the screening and collection of X-ray diffraction data from crystals.
42,87
  
Despite this level of automation, the harvesting and mounting of crystals for X-ray analysis remains the 
only fully manual step in the structural biology pipeline.
19,28,39,79,88
   
Harvesting and mounting can be particularly challenging for crystals that are very small and/or fragile.  
Historically the size of crystals which could be analyzed was well within the realm of mounting.  However, 
developments in synchrotron and beamline technologies continue to decrease the size of crystal which 
can be analyzed, opening up the potential for studying recalcitrant protein targets which only form tiny 
crystals.
26,29,87,89
  Also, protein crystals typically have a very large solvent content and are susceptible to 
dehydration and environmental shock, in addition to physical damage, during handling.
9,52,90-106
  The large 
surface area-to-volume ratio of small crystals has the potential to make dehydration and environmental 
effects an even more significant challenge.  The ability to grow crystals within the confines of a 
microfluidic chip and then perform in situ crystallographic analysis would side-step these challenges.  
Furthermore, removal of physical handling has the potential to enable structural biology studies of difficult 
proteins by facilitating the analysis of higher quality crystals by avoiding the potential for 
damage.
18,44,46,47,49,51,52,59,70,107,108
  In terms of microfluidic platforms for protein crystallization, in situ 
analysis would further enable the utility of these technologies by eliminating the challenge of harvesting 
crystals from a chip.   
This chapter discusses first some of the material considerations associated with in situ X-ray 
diffraction studies (Section 5.3.1), followed by strategies for adapting current microfluidic crystallization 
platforms to X-ray transparent materials (Sections 5.2.1 and 5.3.2).  The efficacy of these crystallization 
platforms for in situ analysis is then validated using first simple chips for the crystallization of the soluble 
proteins lysozyme, thaumatin, and ribonuclease A (Section 5.3.3).  This chip technology was then 
extended to array chips for the screening and optimization of crystallization conditions for lysozyme 
(Section 5.3.4).  Development efforts of this X-ray transparent device architecture are also extended to 
the microfluidic platforms for the in meso membrane protein crystallization
85
 from Chapter 4 and is 
discussed in Section 5.3.5. 
5.2  Materials and Methods 
5.2.1  Device Fabrication 
Microfluidic chips were fabricated out of a thin polydimethylsiloxane (PDMS, General Electric RTV 
650) fluid layer bonded to both a molded cyclic olefin copolymer (COC, 2-4 mil, 5013 and 6013, from 
TOPAS Advanced Polymers Inc.) control layer and a flat COC substrate.  Molding of the PDMS fluid layer 
was done using standard soft lithographic procedures reported previously.
82,109
  Briefly, the various control 
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and fluid layers were designed using Macromedia Freehand MX (Macromedia Inc.).  From the original 
design, the mask for the fluid layer was increased by 1.7% in order to ensure alignment of the layers.  
Based on this design, photolithography was used to fabricate replica masters for both the control and fluid 
layers as well as a separate master for inlet holes using high resolution transparencies (5080 dpi, 
University of Illinois at Urbana-Champaign Printing Services) as masks.  The masters for the control and 
inlet hole layers were fabricated using the negative-tone photoresist SU-8-25 (Microchem).  The masters 
for the fluid layers were fabricated using SU-8-25 or SU-8-2050 for 25 and 50 µm tall features, 
respectively.  The fabricated masters were then treated with (tridecafluoro-1,1,2,2-tetrahydrooctyl) 
trichlorosilane (Gelest, Inc.), a silanizing agent, to allow for easy release of PDMS replicas.  
Fluid, control, and inlet hole layers were fabricated via replica molding from these masters.  Spin-
coating was used to control the thickness of PDMS for the fluid layer.  The PDMS used for the fluid layer 
for simple well and array chip devices was prepared using a ratio of 15:1 (monomer to cross-linker) while 
the fluid layer for in meso crystallization devices used 20:1 PDMS.  Spin rates of 1750 and 1150 rpm 
were used to obtain a total PDMS film thickness of 45 and 70 µm respectively, resulting in a valve 
membrane thickness of ~20 µm.  A much thicker layer of 10:1 (monomer to cross-linker) PDMS (~5 mm) 
was fabricated to facilitate the integration of robust connections for fluid and valve lines.  All PDMS layers 
were cured at 75°C on a level hot plate.  Inlet connections through the thick PDMS layer were punched 
using a 27 AWG needle with a thin wire plunger.   
10:1 PDMS was also used to fabricate an inverse master of the control layer with the silicon master 
mounted on top of a stack of wafers in order to create a thick mold (Figure 5.1a).  High temperature 
epoxy resin (Conapoxy FR 1080, 83:100 hardener:epoxy, by mass) was mixed using a Thinky planetary 
centrifugal mixer (Thinky USA Inc.) for 15 min at 2000 rpm with rotation and then degassed for 12 min at 
2200 rpm.   The epoxy mixture was then poured into the PDMS master and cured on a level hot plate at 
120°C for 4 hours to yield a robust epoxy master for use in hot embossing COC.
78,110,111
  In the first 30 
min of curing occasionally bubbles needed to be removed from the surface of the PDMS master with a 
pipette tip. 
Control layers were replicated via hot embossing (Carver hot press, model 3851-0) of COC films 
against an epoxy master (Figure 5.1b).
78,110,111
  Two PDMS slabs were used to cushion and help provide 
firm contact between the epoxy master, the COC film, and a glass backing slide.  Hot pressing was done 
at 350°F, 50°F higher than the glass transition temperature (Tg) of the material, at a negligible applied 
pressure.  For best results the molded layers were removed from the epoxy master at 250°F, 50°F below 
Tg.  Flat substrates were also prepared by hot embossing between two glass slides in order to remove 
surface texture created during initial fabrication of the COC sheets.  Inlets for the COC control layer and 
PDMS fluid layer were drilled using a 750 µm drill bit.  The device was protected from dirt and damage 
during this process by a protective layer of Scotch Tape (3M).   
 101 
The COC control layer was chemically bonded to the thin PDMS fluid layer.  Simple well devices were 
bonded using an oxygen plasma treatment while subsequent devices utilized cross-linking between an 
epoxy-terminated silane on the surface of the control layer and an amine-terminated silane on the surface 
of the fluid layer.
112
  An 1 minute oxygen plasma treatment was used to activate the PDMS and COC 
surfaces for the formation of a silane bond.  The COC control layer was immersed in a 1% v/v solution of 
3-glycidoxypropyltrimethoxysilane (GPTMS, Sigma Aldrich) and the PDMS fluid layer was immersed in a 
1% v/v solution of 3-aminopropyltrimethoxysilane (APTMS, Sigma Aldrich) for 20 minutes. After rinsing 
with DI water and blowing dry with nitrogen the two layers were aligned and brought into contact (Figure 
5.1b).  A strong bond forms almost immediately and the structure was allowed to cure for 1 hour at room 
temperature.
112
  For simple array chips utilizing actuate-to-open valves
113,114
 it was not necessary to bond 
the device to the COC substrate or to the PDMS inlet layer.  However, for devices utilizing actuate-to-
close valves
109
 or positive pressure to drive in fluid, as in a gradient mixer, it was necessary to bond the 
PDMS fluid layer to the COC substrate and the PDMS layer defining the inlet holes to the COC control 
layer.   
 
Figure 5.1.  Schematic depiction of the procedure for fabricating a hybrid COC/PDMS/COC X-ray transparent 
microfluidic device.  (a) Replica molding is used to create first a PDMS inverse master from a silicon master.  A 
second replica molding step is then used to create a robust epoxy master from the inverse PDMS mold.  (b) Hot 
embossing using the epoxy replica as the master is then used to mold features into sheets of COC.  The 
molded COC sheet is then aligned and bonded to a traditional PDMS fluid layer.  The resultant device is then 
bonded to a thin COC substrate.   
5.2.2  Protein and Precipitant Solutions 
Hen egg white lysozyme (Sigma) was dissolved in 50 mM sodium acetate (Sigma-Aldrich) at pH 4.6 
with 20% (w/v) glycerol (Fisher Scientific) at a concentration of ~100 mg/mL.  Lysozyme concentrations 
were determined by UV absorbance measurements (Lambda 650 UV-Vis spectrophotometer, Perkin 
Elmer) at 280 nm using an extinction coefficient of 2.64 mL/(mg-cm).
115
  For proof-of-concept 
 102 
crystallography experiments precipitant solutions of 1M and 2M NaCl (Aldrich) in 50 mM sodium acetate, 
pH 4.6 with 20% (w/v) glycerol were prepared.  For screening experiments Crystal Screen chemicals 
were used directly (Hampton Research). 
Thaumatin from Thaumatococcus daniellii (Sigma) was dissolved in 100 mM NaH2PO4 (EMD 
Chemicals) at pH 6.5 at a concentration of 82 mg/mL.  The protein concentration was determined by UV 
absorbance measurements at 280 nm using an extinction coefficient of 1.25 mL/(mg-cm).
116
  A precipitant 




Ribonculease A (R-5500, Sigma) from bovine pancreas was dissolved in 100 mM sodium acetate at 
pH 4.5 at a concentration of 229 mg/mL.  The protein concentration was determined by UV absorbance 
measurements at 280 nm using an extinction coefficient of 0.70 mL/(mg-cm).
117
  A precipitant solution of 
saturated NaCl in 100 mM sodium acetate at pH 4.5 was used.
118
 
Prior to setting up a crystallization experiment, protein solutions were filtered through 0.1 µm 
(Ultrafree-MC, Millipore) filters.  Precipitant solutions were filtered through 0.22 µm (Steriflip, Millipore) 
filters.   
5.2.3  Crystallization Experiments 
Crystallization experiments were set up and visualized using either a stereomicroscope (Leica, 
MZ12.5) with an attached digital camera (Leica, DFC295) operated using Leica Application Suite software 
or a computer controlled imaging system comprised of an optical microscope (Leica Z16 APO) equipped 
with an auto-zoom lens (Leica 10447176), a digital camera (Leica DFC280), and a motorized x-y stage 
(Semprex KL66) controlled by Image Pro Plus (Media Cybernetics).  For visualization of protein crystals, 
images were occasionally taken with the use of cross-polarizers.   
For proof-of-concept large well and array chip crystallization experiments, actuate-to-open valving 
and fluid filling was achieved by the application of vacuum from a small vacuum pump (Gast) connected 
to the device through a plastic gas manifold (Cole-Parmer Instrument Co.) and 24 AWG PTFE tubing 
coupled with a thin metal tube to a small block of PDMS aligned over the inlets for the various control 
lines.  Fluids (protein and precipitant solutions) were supplied to the device by pipetting 1 – 2 µL of 
solution onto the inlet hole.  Vacuum within the chip due to actuation of valves and the air permeability of 
PDMS then served to pull fluid into the chambers.  Protein and precipitant solutions were mixed for large 
well experiments prior to loading into the microfluidic device.  For array chip experiments the protein and 
precipitant solutions were loaded separately and allowed to combine on-chip (Section 5.3.4).  
For testing of devices for in meso crystallization, the device was operated as described in Chapter 4.  
Fluids were supplied to the device using 30 AWG polytetrafluoroethylene (PTFE) tubing (Cole-Parmer 
Instrument Co.).  Pneumatic connections for valves were made using 24 AWG PTFE tubing coupled with 
a thin metal tube.  Pneumatic control for the various valve lines was accomplished using a computer-
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controlled bank of solenoid valves coupled to a nitrogen tank (Fluidigm Corp.).  The 32 individual control 
lines are separated into two banks of 16, enabling the use of two different pressures.  Typically, one bank 
is set at a lower pressure for driving fluid flow and the other is set to a higher pressure for actuation of 
isolation valves at a higher pressure.  
Traditional microbatch-under-oil crystallization trials were set up combining 2 µL each of protein and 
precipitant solutions in a Greiner wellplate (Hampton Research).   
Proof-of-concept crystallization trials of lysozyme in traditional wellplates as well as simple large well 
devices and array chips were incubated at 4°C.   Incubation of screening experiments for lysozyme as 
well as crystallization trials for thaumatin and ribonuclease A were performed in a dark box at room 
temperature.   
5.2.4  X-ray Diffraction Experiments 
The majority of experiments were carried out at the 21-ID beamlines at the Advanced Photon Source 
at Argonne National Laboratory with the assistance of the Life Sciences Collaborative Access Team (LS-
CAT).
119
  Beamlines 21-ID-F and 21-ID-G operate at a fixed wavelength (λ = 0.979 Å or 12.7 keV).  All 21-
ID stations utilize MD-2 diffractometers (EMBL, with LS-CAT developed extensions) with on-axis sample 
viewing and automatic sample alignment.  21-ID-F utilizes a MarMosaic 225 detector while 21-ID-G 
utilizes a MAR 200 CCD detector.  Samples were mounted on a standard magnetic goniometer mount 
(Hampton Research) with an attached metal tube into which a slit was cut and set-screw was used for 
securing samples (Figure 5.2b - inset).  Data collection was performed either at room temperature or 
under cryogenic conditions.  Flash-cooling of samples was achieved by direct immersion into liquid 
nitrogen.  Various sample-to-detector distances were used based on the quality of the crystal present.  
Typical data collection was done using a 1° oscillation with a 1 s exposure.     
 
Figure 5.2.  Photographs of (a) the macromolecular crystallography setup at 21-ID-F and (b) a single well 
microfluidic chip for protein crystallography mounted for in situ data collection.  The inset shows a 24-well array 
device attached to a magnetic goniometer mount. 
Bench-top diffraction experiments were performed at the George L. Clark X-ray Facility at the 
University of Illinois using a Bruker General Area Diffraction Detector System (GADDS) equipped with a 
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four circle diffractometer and HiStar multiwire area detector. A rotating anode generator (Bruker 
M18XHF22) operating at 40kV and 60mA was used with a graphite monochromator supplying a Cu Kα 
radiation beam (λ = 1.54 Å or 8.048 keV).  The sample to detector distance is ~18 cm.  Data collection 
was done in a coupled mode where 2ω =  2θ such that multiple frames could be collected over a wider 
range of 2θ.  Typically two such frames were collected, spanning the range of 2θ from 0° to 40° (up to 2.3 
Å resolution). 
5.2.5  Analysis of X-ray Diffraction Data 
Analysis of X-ray diffraction data collected at the synchrotron was performed using HKL2000 software 
for indexing, refinement, integration, and scaling.  (HKL Research Inc.).
120
  The resolution range of the 
data was established based on the resolution shell at which I/σ fell below 3.0 provided that Rsym was also 
less than 0.50.  Diffraction data collected at the University of Illinois was analyzed using the GADDS 
software (version 4.1.08, Bruker AXS) and Topas 3 (Bruker AXS).  Subsequent processing of 
crystallography datasets was done using the CCP4 suite of programs.
121-123
  MTZ files were generated 
using Scalepack2mtz.  Molecular replacement
124
 for lysozyme was done in Phaser using PDB structure 
193L as a model.
125
  Model refinement and solvent building were performed using Refmac5 and aRP-
Solvent, respectively.  Electron density maps were displayed using COOT.
126
   
5.3  Results and Discussion 
5.3.1  Characterization of Device Materials 
In designing an X-ray transparent microfluidic device for use in protein crystallography three main 
considerations with respect to the interaction between materials and X-rays must be taken into account: 
(i) attenuation and (ii) scattering of X-rays passing through device materials, and (iii) the strength of the 
diffraction resulting from a crystal.  Attenuation results from the absorption of photons into the material, 
thereby decreasing the intensity of both the incident X-ray beam and the resultant signal.  Scattering is an 
elastic redirection of photons based on the internal structure of the material and can affect the signal-to-
noise.  The strength of the diffraction signal from a crystal is related to not only the degree of order within 
the crystal, but also the packing density and size of the crystal.
12,127-130
 
Attenuation can be calculated for a particular energy based on the exponential decay in intensity of a 
narrow beam of monochromatic photons from an incident intensity I0 as it passes through a material of 
thickness x with a linear attenuation coefficient of the material μ.
131,132
   
 0 exp xI I            (5-1) 
Attenuation coefficients have been well studied and documented for elemental materials.
131
  For a 
compound containing multiple elements, a linear attenuation coefficient can be calculated based on the 
sum of the contribution to attenuation from each of the individual elements i, weighted based on their 
mass fraction wi.   
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i iw            (5-2) 
Table 5.1 lists the atomic mass fractional compositions of various materials commonly used in microfluidic 
device manufacture and Figure 5.3a shows calculated values for the linear attenuation coefficient for 
SiO2, PDMS, and COC as a function of photon energy.  As can be seen, the attenuation coefficient varies 
significantly as a function of photon energy.  Soft X-rays (lower energy) attenuate much more strongly 
than do harder X-rays (higher energy), thus the energy of X-rays used for an experiment can have a 
significant effect on the signal observed from a device.   
Table 5.1.  Atomic mass fraction, density, and a calculated value for the linear attenuation coefficient μ at 1Å 
(12.4 keV) for various materials used in microfluidic devices.  SiO2 = quartz,
133
 PDMS = polydimethylsiloxane 
(Si61O60C124H368),
132
 COC = cyclic olefin copolymer (C9H14),
111
 PMMA = polymethylmethacrylate (C5H8O),
132




Element SiO2 PDMS COC PMMA PI 
H -- 0.08100 0.11546 0.09586 0.02636 
C -- 0.32882 0.88454 0.71394 0.69118 
N -- -- -- -- 0.07328 
O 0.53257 0.21194 -- 0.19020 0.20918 
Si 0.46743 0.37824 -- -- -- 
Density (g/cm
3
) 2.65 0.92 1.02 0.94 1.42 
μ at 1Å (cm
-1
) 9.330 7.334 1.131 1.472 1.618 
 
Using values for the attenuation coefficient for X-rays with a wavelength of 1Å (12.4 keV), the 
transmission factor I/I0 can then be calculated as a function of material thickness.  A plot of I/I0 is shown 
in Figure 5.3b for PDMS and COC.  Because crystallography experiments commonly involve sample 
rotation, variations in path length as a function of the incident angle also need to be taken into account 
(Figure 5.3c).   
Several interesting observations can be made from the data presented in Table 5.1 and Figure 5.3.  
PDMS and PMMA have very similar densities; however the linear attenuation coefficient for PDMS is 
significantly higher.  This difference arises from the silicon content in PDMS.  Heavier atoms present a 
larger cross-section for interacting with photons and will thus cause a larger degree of attenuation.  The 
density of a material also plays a role in the degree of attenuation observed, with higher density materials 
increasing the number of atoms which can interact with a photon for a given path length, though this 
effect is less significant than elemental composition.   
Knowing the attenuation coefficient for various materials, an expression for the attenuation through a 
series of different films j can be calculated based on Eq. (5-1). 
 0 exp j jxI I           (5-3) 
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A typical device used here will have an X-ray path length of 145 µm of COC and 20 µm of PDMS (50 µm 
COC substrate, 20 µm PDMS membrane, 75 µm COC control layer).  Figure 5.3d shows a plot of 
transmission factor I/I0 as a function of photon energy for this device geometry. 
 
Figure 5.3.  (a) Linear attenuation coefficient for PDMS, COC, and SiO2 (quartz) as a function of photon energy.  
(b) Transmission factor I/I0 as a function of film thickness for PDMS and COC.  The transmission factor was 
calculated at a photon energy of 12.4 keV, or a wavelength of 1Å.  (c) The relative path length through a 
material as a function of incident angle.  Values for the path length have been normalized relative to the path 
length at 0° (normal incidence).  (d) Transmission factor I/I0 as a function of photon energy for a typical device 
architecture (50 µm COC substrate, 20 µm PDMS membrane, 175 µm COC control layer). 
In addition to attenuation, background scatter from the device materials can also increase.  Scattering 
is a result of the internal structure of a material.  Thus the characteristic length-scale of this internal 
geometry defines the location of a scatter ring.  An analysis of both PDMS and COC shows that these 
materials produce a characteristic scattering pattern (Figure 5.4).  Scatter from both PDMS and COC 
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occurs at relatively low angles of q-spacing or areas of low resolution diffraction; q  ≈ 0.161 Å
-1
 (7.5 Å) for 
PDMS and q  ≈ 0.232 Å
-1
 (5.2 Å) for COC.  A comparison of the scatter from different thicknesses of COC 
shows that a roughly linear relationship exists between scattering intensity and sample thickness.   
 
Figure 5.4.  Diffractograms showing the background scattering contribution of (a) varying thicknesses of COC 
sheets (6013, Topas) and (b) COC sheets with and without the presence of a thin PDMS membrane (< 30 µm).  
Scattering from COC occurs around q ≈ 0.232 Å
-1
 (5.2 Å).  Scattering from PDMS occurs around q ≈ 0.161 Å
-1
 
(7.5 Å).  (q = 4πsinθ/λ where 2θ is the scattering angle, λ is the X-ray wavelength).  (c) A compiled image from 
the two frames of taken of the scattering from a 100 µm COC device. 
5.3.2  Device Fabrication and Characterization 
While the use of hot embossing with COC has been reported previously for microfluidic devices, the 
majority of structures reported on have been relatively simple, single layer devices.
78,110
  Consequently, it 
was necessary to determine design and fabrication parameters for the assembly of a multilayer 
microfluidic device composed of both PDMS and COC and confirm the quality of pattern transfer and 
sealing between dense microfluidic structures.   
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Scanning electron microscopy (Hitachi S-4800 High Resolution SEM) was used to visualize the 
quality of pattern transfer between an SU-8-25 on silicon master, the resulting inverse PDMS master, the 
epoxy master for hot embossing, and the final COC structure (Figure 5.5).  As can be seen, the pattern 
transfer between replica molding steps is very good, as is the quality of the embossed COC film.  
Features with a minimum spacing of 50 µm were easily resolved.  Testing of the minimum resolution 
achievable by this method was beyond the scope of this work. 
 
Figure 5.5.  SEM images of the various stages of fabrication of the control layer for an array chip.  (a) The SU-
8-25 on silicon master.  (b) The PDMS inverse master, molded from the silicon master in (a).  (c) The epoxy 
master replicated from the PDMS master in (b), used for hot embossing.  (d) The final COC control layer 
formed via hot embossing from the epoxy master in (c). 
An additional design parameter necessary for the fabrication of multilayer microfluidic devices is the 
relative scaling factor to be used between device features on the various layers.  In traditional PDMS 
devices it is common to scale the uppermost device layer in order to account for relaxation of the features 
upon removal from the mold.
82
  In the case of aligning an embossed COC control layer over a PDMS fluid 
layer it proved necessary to increase the scale of the fluid layer by 1.7% to match the dimensions of the 
hot pressed COC layer.  Additionally, the epoxy masters were observed to expand slowly over time.  Thus 
masters were remade after 20 cycles through the hot press.   
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Adhesion between the various layers of the device is also a key requirement, not only for fabrication, 
but also for device operation.  In particular, the use of actuate-to-close valves requires the seal between 
layers to withstand significant pressures.  During initial testing the chemical bond resulting from a simple 
plasma treatment between PDMS and COC proved to be inadequate to withstand even mild pressures.  
However, the chemical bond resulting from an APTMS/GPTMS treatment (Section 5.2.1) was tested and 
able to withstand pressures of at least 30 psi.   
Evaporative losses and solvent absorption have been particularly challenging for PDMS-based 
microfluidic devices.  For crystallization trials which may need to incubate for days or weeks it is vital to 
minimize or control solvent evaporation from a device.  While a variety of strategies to overcome this 
limitation have been developed, including diffusion barriers and environmental control, it is desirable to 
avoid this issue.  The hybrid device structure used here to facilitate X-ray transparency is also 
advantageous for minimizing evaporative losses from a microfluidic device.  COC has very low water 
absorption and can serve as an effective barrier against evaporation.
111
  Additionally, minimizing the 
thickness of the PDMS fluid layer helps to limit water losses into this film.  Sealing of device inlets can be 
achieved using Crystal Clear tape.  The evaporation rate of water from these hybrid PDMS/COC devices 
was examined via automated data acquisition and image analysis using Image J (NIH).  Unsurprisingly, 
the rate of evaporation was found to correlate strongly with the quality of device fabrication.  In particular 
these experiments demonstrated the need to planarize the substrate COC sheets via hot pressing in 
order to avoid leakage.  For high quality devices a negligible rate of evaporation was observed over a 24 
hour period, and crystallization trials were observed to be stable over at least 5 days.   
A variety of device structures were fabricated and tested during the development of these hybrid 
COC/PDMS X-ray transparent microfluidic devices.  The simplest proof-of-concept structures were 
comprised of a single large well covered by a matching control layer (Section 5.3.3).  The control layer in 
this device was used only to supply vacuum pressure to the fluidic chamber for loading, no valve 
structures were present.  These devices were used to confirm that the device materials were amenable to 
both on-chip protein crystallization, and in situ X-ray analysis at both room temperature and cryogenic 
conditions.  The final device structures tested were highly integrated array chips for screening 
crystallization conditions of soluble or detergent solubilized proteins (Section 5.3.4), and microfluidic chips 
for in meso membrane protein crystallization
85
 from Chapter 4 (Section 5.3.5).  These two types of 
devices utilized actuate-to-open and actuate-to-close valves, respectively.  The use of both types of 
valves allowed for the testing of complex device integration separately from the requirement of a firmly 
bonded device.   
5.3.3  Validation of Device Architecture with Single Microfluidic Well Configuration: Crystallization 
of Soluble Proteins 
The simple device architecture shown in (Figure 5.6a) was utilized for proof-of-concept experiments.  
In developing fabrication procedures for PDMS/COC devices, the use of simple device structures allowed 
for validation of particular aspects of the fabrication procedure while avoiding complications related to 
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complex microfluidic valving.  The soluble proteins lysozyme, thaumatin, and ribonuclease A were 
crystallized in a batch fashion in these simple devices (Figure 5.6b-d).   
 
Figure 5.6.  (a) Schematic depiction of a simple large well device.  A large rectangular well with support posts is 
molded in PDMS (blue) and aligned with a matching COC control layer and substrate (green).  The entire 
assembly is then attached to a COC substrate.  Optical micrographs of (b) lysozyme, (c) thaumatin, and (d) 
ribonuclease A crystals grown on chip. 
A second advantage of this particular geometry is that the resultant device is small enough to be used 
for cryogenic data collection.  The two concerns for cryocooling are (i) the ability of the material to transfer 
heat at a fast enough rate to ensure vitrification of the sample, and (ii) the need to maintain the sample 
within a cryostream during data collection.  While a larger array of individual devices was fabricated as a 
single chip for ease in handling, the individual wells were cut out using a rotary cutting blade (Olfa), 
mounted onto a modified magnetic cap, and cryocooled in liquid nitrogen.  No difficulties in cryocooling 
were observed, though the planar geometry of a microfluidic chip is not ideal for use with the traditional 
cryostream used to maintain the sample temperature during data collection.  Figure 5.2 shows a 
photograph of a sample mounted for data collection at 21-ID-F at the Advanced Photon Source at 
Argonne National Laboratory.  
In situ cryogenic X-ray diffraction data was collected on various crystals of lysozyme, thaumatin, and 
ribonuclease A (Figure 5.7).  A diffuse scatter ring from the device materials was observed, as described 
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in Section 5.3.2, however, the presence of this increased background did not significantly interfere with 
data processing.  Unfortunately, optical alignment of crystals at oblique angles proved difficult.  As a 
result, the alignment of the crystal within the X-ray beam was often lost during the collection of data over 
large rotational angles, as is needed for a complete dataset.  In Section 5.3.4 potential strategies to 
overcome this challenge will be discussed. 
 
Figure 5.7.  Diffraction data collected under cryogenic conditions.  (a1) Diffraction data from a lysozyme crystal 
grown using the traditional microbatch method and mounted on a standard crystal mount.  (a2) Data from a 
lysozyme crystal grown in a large well device and analyzed in situ.  Sample to detector distance was 100 mm.  
In situ data from a crystal of (b) thaumatin and (c) ribonuclease A.  Sample to detector distance was 150 mm.  
Insets provide a closer view of spot quality. 
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The diffraction data in Figure 5.7 shows clearly defined diffractions spots.  Though the resolution to 
which crystals of each protein diffracted varied, individual spots are circular, indicating the high quality 
and low mosaicity of the crystals.  The data collected on the various crystals could be easily indexed for 
analysis despite background scatter from the device.   
The quality of the diffraction data obtained for lysozyme grown and mounted via traditional methods 
(Figure 5.7a1) can be compared with data collected from a microfluidic device (Figure 5.7a2).  Table 5.2 
provides a comparison of two such crystals.  Although the absolute value of the resolution obtained for 
the traditionally grown crystal is higher than for crystals grown in devices, the statistical measures of 
crystal quality such as Rsym, I/σ, and completeness are comparable.   
Linear R-factor (Rsym) provides a measure of the average discrepancy of a particular observation 
based on an average value of redundant observations.  Typical values for Rsym are 0.08 – 0.15 for all hkls 
and 0.25 – 0.50 for the highest resolution shell.
135
  For an excellent crystal Rsym for all hkls can be as low 
as 0.05, but if the value exceeds 0.2-0.3 the data is becoming too inaccurate to be useful.
136,137
  As can 
be seen, the values for Rsym for both of the crystals are well within this acceptable range. 
Table 5.2.  Crystallographic data statistics from the analysis of two lysozyme crystals under cryogenic 
conditions, one grown and mounted using traditional methods and the other grown and analyzed in situ in a 
microfluidic device.  Reported values are for all hkls.  Values shown in parenthesis represent the value for the 
highest resolution shell. 
Parameter Traditional Microfluidic 
Resolution 50 – 1.25 Å 50 – 1.5 Å 
Rsym 0.058 (0.338) 0.077 (0.410) 
Mosaicity 0.21° – 0.33° 0.33° – 0.61° 
Redundancy 7.4 (5.8) 8.4 (5.9) 
Completeness 99.1% (98.5%) 98.0% (92.3%) 
I/σ 33.8 (3.7) 25.4 (3.0) 
Frames of Data 100 112 
 
The completeness of a dataset to a particular resolution is defined as the number of unique 
reflections measured, compared to the total number of unique reflections.  It is desirable to have a 
completeness for all hkls >95%.  Experimentally, the completeness of the dataset is a function of the 
amount of data taken.  Depending upon the symmetry of the crystal and the diffraction experiment it can 
be necessary to take as much as 360° of data.  However, for a higher symmetry crystal such as 
tetragonal lysozyme, 90° is often sufficient.
137
   
Mosaic spread, or mosaicity is a measure of the disorder within a crystal.
138
  The mosaicity in good 
quality protein crystals can be expected to fall within the range of 0.2° – 0.5°, thus the mosaic spread of 
the crystals reported in Table 5.2 are reasonable.
139
  Although it would have been expected that crystals 
grown on-chip would have a lower mosaicity than ones harvested manually, it is possible that increases in 
mosaicity for the crystals grown on-chip are the result of delamination of the layers of the device during 
 113 
mounting due to inadequate bonding.  This challenge was overcome in subsequent generations of the 
PDMS/COC device through the use of APTMS/GPTMS bonding and additional data collected in more 
advanced devices will be discussed in Section 5.3.4. 
The term I/σ describes the signal-to-noise ratio of the observed diffraction spots.  This metric is 
particularly important when comparing data collected on-chip with data from a traditionally mounted 
crystal because it accounts for the potential effects of signal attenuation and background scatter from the 
device and is key in determining the resolution limit of a dataset.  A more detailed discussion of signal-to-
noise and attenuation effects will be presented in Section 5.3.4 and associated Figure 5.12.  
5.3.4  X-ray Transparent Microfluidic Array Chips for the Crystallization of Soluble Proteins 
Although the simple large wells described in Section 5.3.3 were adequate for initial proof-of-concept 
experiments, the ability of microfluidics to control and route very small volumes of liquid is a major 
strength.  To this end, the fabrication and testing of microfluidic valves using the PDMS/COC X-ray 
transparent device architecture was necessary.   
 
Figure 5.8.  Optical micrographs and schematic depictions of an actuate-to-open valve
113,114
 used in an array 
chip.  The valve is shown (a) closed, in the relaxed position, and (b) open.  Deflection of the PDMS valve 
membrane and subsequent filling of the device with fluid can be seen.  
The X-ray transparent device architecture used here was chosen specifically to allow for microfluidic 
valving.  The thin PDMS membrane present in the device results in significantly higher signal attenuation 
than would an equivalent thickness of COC.  However, the flexibility of PDMS is critical for the actuation 
of valves.  Two types of valve structures are common in microfluidics; (i) actuate-to-open
113,114




  Between these two, actuate-to-open valves are an easy next step to validate 
fabrication procedures because they can be tested without relying on a strong seal between the various 
layers of the device.  Actuate-to-close valves will be discussed in Section 5.3.5 with respect to the 
microfluidic platform for in meso crystallization. 
Actuate-to-open valves utilize vacuum pressure in order to deflect a thin PDMS membrane, thereby 
bridging a gap in a fluid line (Figure 5.8).  Because of their method of actuation it is common for the fluid 
layer of a device containing actuate-to-open valves to be only reversibly sealed to the substrate by means 
of van der Waals forces.  Additionally, the permeability of PDMS to air allows for the use of these vacuum 
actuated valves to not only permit fluid flow, but also to drive flow.  Because actuate-to-open valves can 
be located directly over fluidic lines and compartments they enable high density arrays and have been 
utilized previously for combinatorial screening applications.
113
  Testing demonstrated that the functionality 
of these valves was not affected by a transition to the PDMS/COC architecture used here.  They are fully 
capable, not only of actuating but also of drawing fluid into a device (Figure 5.8b).  Evaporation rate 
experiments, as discussed in Section 5.3.2 have shown that this valve structure is stable against 
evaporative losses over the course of days to weeks.  Here their use has been adapted for use in 
microfluidic array chips designed to screen for and optimize crystallization conditions.   
Microfluidic screening chips were designed for the screening of various protein/precipitant 
combinations for batch crystallization.  A 24-well chip allows for the testing of six different precipitant 
solutions in quadruplicate (Figure 5.9).  In this chip an individual crystallization trial is composed of two 
half-wells.  Fluid control is achieved by three separate actuate-to-open valve lines.  As shown in Figure 
5.9b, the actuation of one valve is used to fill in first protein solution into a half-well, while the actuation of 
a second valve loads various precipitant solutions into the other half-well (Figure 5.9c).  These two 
microfluidic compartments are then put into fluidic contact by the actuation of a third valve such that 
diffusion can take place (Figure 5.9d).  The volume of an individual half-well varies as a function of 
channel height, Table 5.3 summarizes these values.  The design of this chip was also expanded to a 96-
welI format (12 conditions replicated 8 times) and a 96-well format where the ratio of protein-to-precipitate 
is varied along each of the columns (Figure 5.10).   
Table 5.3.  Half-well volume for a standard microfluidic array chip with a 1:1 volume ratio of protein-to-
precipitant as a function of fluid layer channel height. 
Channel Height (µm)  Half-Well Volume (nL) 








Figure 5.9.  Schematic depiction of the design and operation of a 24-well microfluidic array chip for the 
crystallization of soluble or detergent solubilized proteins.  (a) The complete device.  Protein and precipitant 
inlets are indicated.  The fluid layer is shown in black while the various features of the control layer have been 
identified based on function.  Valves for the loading of protein are shown in blue, precipitant valves in green, 
and the valves to connect chambers and allow for diffusion between the protein and precipitant chambers are 
pink.  Yellow window structures are shown in yellow.  These structures are present in the control layer, but 
serve only to decrease the thickness of material present in the path of the X-ray beam.  (b-d) Depiction of 
device operation.  (b) Blue valves are actuated to fill in protein solution.  (c) Green valves actuate to fill in 
precipitant solutions.  (d) Pink valves actuate to connect the protein and precipitant chambers, allowing for 
diffusion over time. 
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Figure 5.10.  Schematic depiction of the design and operation of a 96-well microfluidic array chip with variable 
protein-to-precipitant ratios per screened condition for the crystallization of soluble or detergent solubilized 
proteins.  Protein and precipitant inlets are indicated and the volumetric ratio of protein to precipitant is indicated 
where blue corresponds to the volume of protein and green to the volume of precipitant.  The fluid layer is 
shown in black while the various features of the control layer have been identified based on function.  Valves for 
the loading of protein are shown in blue, precipitant valves in green, and the valves to connect chambers and 
allow for diffusion between the protein and precipitant chambers are pink.  Yellow window structures are shown 
in yellow.  These structures are present in the control layer, but serve only to decrease the thickness of material 
present in the path of the X-ray beam.   
The various microfluidic array chips were validated for crystallization screening experiments by 
testing a 100 mg/mL solution of lysozyme in 50 mM sodium acetate pH 4.6 with 20% glycerol against the 
50 condition Crystal Screen kit (Hampton Research) at room temperature.  After one week crystals were 
observed in 32 out of the 50 conditions in the array chips as compared to only 26 hits in the microbatch 
wellplate.  Of the various hits observed between the traditional wellplate and our microfluidic chips, 21 of 
the conditions produced crystals on both platforms while 5 conditions yielded crystals uniquely in the 
microbatch wellplates and 11 hits were observed uniquely in the microfluidic array chips.  The variability 
between these results can be explained both in terms of differences in the mixing of protein and 
precipitant solutions, slow concentration of solutions in the microfluidic chips over time, and the stochastic 
nature and variability of crystallization trials.
140
  However, the performance of the microfluidic array chips 
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appears to equal if not exceed that of traditional crystallization screening methods, while requiring 
significantly smaller total volumes of protein. 
Table 5.4.  Summary of the crystallization results of a microfluidic batch screen of 100 mg/mL lysozyme in 50 
mM sodium acetate pH 4.6 with 20% glycerol against the 50 condition Hampton Crystal Screen at room 
temperature.  Conditions #16 and 18 shaded in grey resulted in crystalline material that was not protein in 
nature.  Condition #25 shaded in pink could not be identified as either protein or salt because the crystal could 
not be located in the device during X-ray analysis.  Conditions #30, 33, 34, and 40 shaded in blue were 




6 0.2 M Magnesium chloride hexahydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4,000 
7 0.1 M Sodium cacodylate trihydrate pH 6.5, 1.4 M Sodium acetate trihydrate 
8 0.2 M Sodium citrate tribasic dihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% v/v 2-Propanol 
9 0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 30% w/v Polyethylene glycol 4,000 
10 0.2 M Ammonium acetate, 0.1 M Sodium acetate trihydrate pH 4.6, 30% w/v Polyethylene glycol 4,000 
11 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 1.0 M Ammonium phosphate monobasic 
12 0.2 M Magnesium chloride hexahydrate, 0.1 M HEPES sodium pH 7.5, 30% v/v 2-Propanol 
15 0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% w/v Polyethylene glycol 8,000 
16 0.1 M HEPES sodium pH 7.5, 1.5 M Lithium sulfate monohydrate 
17 0.2 M Lithium sulfate monohydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4,000 
18 0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 20% w/v Polyethylene glycol 8,000 
19 0.2 M Ammonium acetate, 0.1 M TRIS hydrochloride pH 8.5, 30% v/v 2-Propanol 
20 0.2 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate pH 4.6, 25% w/v Polyethylene glycol 4,000 
21 
0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% v/v (+/-)-2-Methyl-2,4-
pentanediol 
22 0.2 M Sodium acetate trihydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4,000 
23 0.2 M Magnesium chloride hexahydrate, 0.1 M HEPES sodium pH 7.5, 30% v/v Polyethylene glycol 400 
25 0.1 M Imidazole pH 6.5, 1.0 M Sodium acetate trihydrate 
27 0.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES sodium pH 7.5, 20% v/v 2-Propanol 
28 0.2 M Sodium acetate trihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% w/v Polyethylene glycol 8,000 
29 0.1 M HEPES sodium pH 7.5, 0.8 M Potassium sodium tartrate tetrahydrate 
30 0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8,000 
31 0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 4,000 
32 2.0 M Ammonium sulfate 
33 4.0 M Sodium formate 
34 0.1 M Sodium acetate trihydrate pH 4.6, 2.0 M Sodium formate 
35 
0.1 M HEPES sodium pH 7.5, 0.8 M Sodium phosphate monobasic monohydrate, 0.8 M Potassium phosphate 
monobasic 
36 0.1 M TRIS hydrochloride pH 8.5, 8% w/v Polyethylene glycol 8,000 
37 0.1 M Sodium acetate trihydrate pH 4.6, 8% w/v Polyethylene glycol 4,000 
38 0.1 M HEPES sodium pH 7.5, 1.4 M Sodium citrate tribasic dihydrate 
39 0.1 M HEPES sodium pH 7.5, 2% v/v Polyethylene glycol 400, 2.0 M Ammonium sulfate 
40 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 20% v/v 2-Propanol, 20% w/v Polyethylene glycol 4,000 
41 0.1 M HEPES sodium pH 7.5, 10% v/v 2-Propanol, 20% w/v Polyethylene glycol 4,000 
42 0.05 M Potassium phosphate monobasic, 20% w/v Polyethylene glycol 8,000 
43 30% w/v Polyethylene glycol 1,500 
44 0.2 M Magnesium formate dihydrate 
45 0.2 M Zinc acetate dihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 18% w/v Polyethylene glycol 8,000 
46 0.2 M Calcium acetate hydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5 , 18% w/v Polyethylene glycol 8,000 
47 0.1 M Sodium acetate trihydrate pH 4.6, 2.0 M Ammonium sulfate 
48 0.1 M TRIS hydrochloride pH 8.5, 2.0 M Ammonium phosphate monobasic 
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Subsequent in situ analysis of crystal quality at room temperature allowed for distinguishing between 
protein and salt crystals, and provided information on the quality of the initial crystal hits.  In addition to 
crystal quality screening, it was possible to collect complete or nearly complete high quality room 
temperature datasets for crystals grown in four.  Such information would have been significantly more 
difficult to obtain without in situ analysis capabilities.  Table 5.4 provides a summary of these crystal 
forming conditions while Table 5.5 summarizes the in situ crystallographic data obtained. 
Two distinctive features of the diffraction data obtained for several of the screened conditions were 
the high quality of the data as described by Rsym and the low levels of mosaicity.  As described previously, 
typical values for Rsym are 0.08 – 0.15 for all hkls and 0.25 – 0.50 for the highest resolution shell.
135
  As 
can be seen from the data in Table 5.5, the value of Rsym over all hkls for all four of the crystals screened 
indicates the excellent quality of the crystals.  In terms of mosaicity, while good quality protein crystals 
could be expected to have a mosaicity in the range of 0.2° – 0.5°,
139
 the mosaic spread of several the 
crystals reported in Table 5.5 is significantly lower than this range.   
Table 5.5.  Crystallographic data statistics from the analysis of lysozyme crystals obtained via crystallization 
screening using Hampton Crystal Screen.  Data was collected in situ at room temperature.  Reported values are 
for all hkls.  Values shown in parenthesis represent the value for the highest resolution shell.  All crystals 
indexed as P43212 tetragonal. 
Parameter 
Crystal Screen Reagent # 
30 33 34 40 
Resolution 50 – 1.75 Å 50 – 1.70 Å 50 – 1.60 Å 50 – 1.55 Å 
Rsym 0.075 (0.300) 0.050 (0.365) 0.044 (0.302) 0.041 (0.281) 
Mosaicity 0.08° – 0.27° 0.20° – 0.50° 0.15° – 0.20° 0.04° – 0.18° 
Redundancy 4.3 (2.7) 6.2 (5.3) 5.3 (4.4) 5.7 (3.5) 
Completeness 91.9% (77.3%) 97.5% (96.5%) 97.3% (93.4%) 99.4% (95.2%) 
I/σ 21.2 (3.2) 37.0 (4.0) 34.7 (4.5) 32.7 (4.2) 
Frames of Data 60 79 68 78 
 
While the size of the array chips used in these screening experiments was not conducive for 
complete rotation for data collection, the symmetry of the lysozyme crystals obtained (tetragonal P43212) 
was such that a complete dataset could be obtained within the limitations of the experimental setup (-60° 
to +60° from normal).
120,137
  However, it is unreasonable to only apply in situ crystallographic analysis to 
protein crystals of high symmetry which bypasses limitations associated with chip rotation.  An alternative 
strategy to enable data collection for any crystal is to collect a single shot, or a small wedge of diffraction 
data from a number of crystals and then merge the various datasets.  This strategy has been used 
repeatedly in the literature for very small and/or fragile crystals that suffer from excessive radiation 
damage,
104,141-143
 and is relatively common in Laue methods,
144-146
 as will be described in Chapter 6. 
To test the strategy of combining data taken from multiple crystals, a 24-well chip was used to grow 
lysozyme crystals at a single condition (120 mg/mL solution of lysozyme in 50 mM sodium acetate pH 4.6 
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with 20% glycerol combined with 1M NaCl (Aldrich) in 50 mM sodium acetate, pH 4.6 with 20% (w/v) 
glycerol).  The array chip was filled as shown in Figure 5.9 and allowed to incubate.  An optical 
micrograph of the resultant crystals is shown in Figure 5.11.  For each of the various crystals in this chip 
10° of data was collected (-5° to +5° from normal).  Data from various crystals was then merged to obtain 
a complete dataset.  Note that this data collection strategy requires that crystals be randomly oriented.  
Plate-like or other crystals with significant aspect ratios may tend to adopt a limited number of 
conformations due to the geometry of the microfluidic device.   
 
Figure 5.11.  Optical micrograph of lysozyme crystals grown in a 24-well X-ray transparent PDMS/COC 
microfluidic array device.  The inset shows a closer view of the crystals in a single well.  
To provide a direct comparison of the quality of data that could be obtained by merging data collected 
on-chip at room temperature as compared to on-chip cryogenic data, a small section of a 24-well device 
containing was also cut out and used for the collection of a single crystal cryogenic dataset.  This data 
was collected in addition to the data discussed in Section 5.3.3 in order to eliminate any variability 
associated with the difference in device design and crystallization kinetics.  Table 5.6 provides a summary 
of dataset statistics, including R-values from model building for (i) a single crystal using traditional 
cryogenic methods, (ii) a single crystal using cryogenic on-chip data collection from a 24-well chip, and 
(iii) data merged from multiple crystals taken at room temperature.   
As can be seen from the data in Table 5.6, high quality data was obtained in each case.  Although the 
room temperature data does not extend to as high a resolution as in the cryogenic trials, this limitation 
results more from the sample-to-detector distance than from the quality of the crystals themselves.  The 
data obtained for the room temperature crystals was analyzed to the edge of the detector and based on 
the value for I/σ in the highest resolution shell, the analysis could have been extended to higher resolution 
were the data present.   
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Table 5.6.  Crystallographic data statistics from the analysis of lysozyme crystals; (i) the "traditional" sample 
was grown and mounted using traditional methods utilizing cryogenic data collection,  (ii) cryogenic in situ 
analysis of a "single crystal" from a 24-well device, and (iii) the merging of small datasets from "multiple 
crystals" analyzed in situ at room temperature.  Reported values are for all hkls.  Values shown in parenthesis 
represent the value for the highest resolution shell except in the case of R (Rfree) statistics from model building 











Resolution 50 – 1.25 Å 50 – 1.35 Å 50 – 1.55 Å 
Rsym 0.058 (0.338) 0.078 (0.488) 0.064 (0.362) 
Mosaicity 0.21° – 0.33° 0.27° – 0.41° 0.03° – 0.08° 
Redundancy 7.4 (5.8) 7.6 (6.0) 22.9 (5.7) 
Completeness 99.1% (98.5%) 95.9% (98.8%) 98.1% (83.4%) 
I/σ 33.8 (3.7) 25.8 (3.4) 51.4 (3.9) 
Frames of Data 100 98 363 
Refinement 
R (Rfree) 0.187 (0.230) 0.169 (0.194) 0.164 (0.227) 
Ramachandran Plot 
Most Favored 95.28% (121) 97.64% (124) 96.06% (122) 
In Allowed Regions 4.72% (6) 2.36% (3) 3.94% (5) 
Disallowed 0.00% (0) 0.00% (0) 0.00% (0) 
 
The area where the room temperature data excelled far above that of either cryogenic dataset is in 
terms of crystal mosaicity.  The observed mosaic spread of the crystals was nearly an order of magnitude 
smaller than that of the cryogenic samples.  Additionally, this small range of mosaicity was consistent for 
nearly all of the crystals grown in the 24-well chip.  This consistency validates the reproducibility of well-
to-well crystallization, in particular, demonstrating fine control of fluid transport and thus crystallization 
kinetics.  While for the crystals analyzed here the range of mosaicity observed across all samples is 
acceptable, the potential for improving crystal quality could be particularly significant for crystals of 
membrane proteins which suffer from particularly weak crystal contacts.  
As described in Section 5.3.3, I/σ describes the signal-to-noise ratio of the observed diffraction spots.  
A comparison I/σ as a function of resolution allows for a determination of the impact of signal attenuation 
and background scatter resulting from device materials as compared to traditional crystal mounting 
methods.  As can be seen in Figure 5.12, a comparison of the two cryogenic datasets (square symbols) 
shows that in-situ analysis results in lower signal-to-noise than its traditionally mounted counterpart.  This 
trend could be due in part to differences in crystal size, however, scaling of the values of I/σ for the 
traditional cryogenic sample based on the signal attenuation expected from the device materials (dashed 
line) results in good agreement with the signal-to-noise levels obtained on-chip.  Interestingly, the data 
obtained on-chip at room temperature (triangles) shows values for I/σ at low resolution that are equivalent 
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to those obtained via traditional cryogenic methods.  This observation begs the question as to whether 
the diffraction signal from the crystals is adversely affected by cryocooling.  However, an in depth study of 
these effects is beyond the scope of the current investigation.   
 
Figure 5.12.  A plot comparing the signal-to-noise observed (I/σ) as a function of resolution for diffraction data 
collected using both traditional and on-chip methods.  Square symbols denote data obtained under cryogenic 
conditions, using either a traditional mount or on-chip.  The dashed line denotes the signal-to-noise for a 
traditionally mounted crystal as scaled by the attenuation factor expected for the material present in a 
microfludic device.   
An additional figure of merit included in this analysis are the values for R and Rfree.  These R-factors 
are a measure of how well the refined structure agrees with the observed electron density maps.  The 
free R-factor (Rfree) provides a metric for cross-validating the quality of the structural model by comparing 
it with a small test set of "free" reflections which were not used in the refinement of the model.
138,139
  
Generally speaking, for a structure determination made with data to 2.0 Å resolution, the final R-factor 
would be expected to be ~20%, with Rfree a few percent higher.
139
  As can be seen from the data 
presented in Table 5.6, for all of the data collection strategies, the data extended beyond 2.0 Å and 
resulted in R-factors < 20%.  It is interesting to note that both R and Rfree are lower for data collected on-
chip compared to data obtained via traditional cryogenic methods.  Additionally, a larger fraction of 
residues in the structures obtained from on-chip data collection fall within the most favored zones for 
structural conformations on a Ramachandran plot.   
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Figure 5.13.  Electron density maps displaying various aspects of the structure of hen egg white lysozyme for 
(a) 1.25 Å data obtained using traditional single crystal cryogenic data collection, (b) 1.35 Å data from a single 
crystal data collected under cryogenic conditions from a 24-well microfluidic chip, and (c) 1.55 Å data obtained 
by merging data from many crystals grown on-chip and analyzed at room temperature.  (1) The calculated 
structure for Trp111 at a sigma level of 2.0.  (2-3) Maps showing the difference between the calculated and 
observed structures for (2) Trp111 and (3) water molecules located near Glu35.  A "solvent" molecule visible at 
high sigma levels, suggesting the presence of a metal atom is highlighted.  The calculated map (blue) is 
displayed at a sigma level of 2.0, while the difference map (green) is displayed at a sigma level of 3.0. 
Examination of the resultant electron density maps provides a clear picture of the quality of structural 
data that can be obtained by these various data collection strategies (Figure 5.13).  The high resolution 
data obtained allows for clear visualization of the structure of amino acid side-chains.  As an example, the 
double-ring structure of the side-chain from tryptophan Trp111 can be clearly seen in all three cases 
(Figure 5.13a-c1), though the exact structure becomes clearer with the higher resolution data obtained 
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using the traditional cryogenic method (Figure 5.13a1).  The validity of this structure within the final map 
can be verified by examining a Fourier difference map with Trp111 missing (Figure 5.13a-c2).  A similar 
process can be performed to validate the location of water molecules within the structure (Figure 5.13a-
c3).  The agreement between the calculated (blue) and observed (green) maps clearly validates the 
location of these molecules within the structure.  Additionally, analysis of the solvent difference map at 
high sigma levels can be used to identify metal atoms present in the structure.  The "solvent" molecule 
highlighted in the lower right corner of Figure 5.13a-c3 is one such example of a heavier atom which 
could potentially be identified via this method, though the actual identity of the atom is beyond the scope 
of the analysis performed here.   
Table 5.7.  Crystallographic data statistics from the analysis of lysozyme crystals; (i) the "traditional" sample 
was grown and mounted using traditional methods utilizing cryogenic data collection,  (ii) cryogenic in situ 
analysis of a "single crystal" from a large well device, and (iii) the merging of small datasets from "multiple 
crystals" analyzed in situ at room temperature.  Reported values are for all hkls.  Values shown in parenthesis 
represent the value for the highest resolution shell except in the case of R (Rfree) statistics from model building 
and for the Ramachandran plot statistics where the number in parenthesis indicates the number of residues in a 
given region.  The data for the cryogenic samples is the same as in Table 5.6, but was re-analyzed over the 










Resolution 50 – 1.55 Å 50 – 1.55 Å 50 – 1.55 Å 
Rsym 0.052 (0.102) 0.072 (0.217) 0.064 (0.362) 
Mosaicity 0.21° – 0.34° 0.27° – 0.45° 0.03° – 0.08° 
Redundancy 7.7 (7.7) 7.9 (7.8) 22.9 (5.7) 
Completeness 99.7% (100%) 94.7% (98.1%) 98.1% (83.4%) 
I/σ 42.3 (19.4) 30.3 (10.0) 51.4 (3.9) 
Frames of Data 100 98 363 
Refinement 
R (Rfree) 0.173 (0.276) 0.162 (0.212) 0.164 (0.227) 
Ramachandran Plot 
Most Favored 96.06% (122) 96.06% (122) 96.06% (122) 
In Allowed Regions 3.94% (5) 3.94% (5) 3.94% (5) 
Disallowed 0.00% (0) 0.00% (0) 0.00% (0) 
 
In order to better compare equivalent statistics between the data collected by the various methods, 
the data originally presented in Table 5.6 was reanalyzed to a 1.55 Å cutoff in order to match the 
resolution obtained for the data merged from many crystals (Table 5.7).  By comparing the statistics 
resulting from an equivalent resolution range it can be easily seen that relatively complete, high quality 
datasets were obtained in all cases.  However, the mosaicity of the data resulting from the merging of 
data from multiple crystals is much lower than that for the cryogenically mounted samples.  This decrease 
in mosaicity was observed despite the potential for increased radiation damage and can be attributed to 
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both the lack of physical handling as well as the absence of cryocooling which is known to increase 
crystal mosaicity.
147,148
  A comparison of the resultant electron density maps is shown in Figure 5.14. 
 
Figure 5.14.  Electron density maps displaying various aspects of the structure of hen egg white lysozyme 
taken to 1.55 Å for (a) data obtained using traditional single crystal cryogenic data collection, (b) data from a 
single crystal data collected under cryogenic conditions from a 24-well microfluidic chip, and (c) data obtained 
by merging data from many crystals grown on-chip and analyzed at room temperature.  (1) The calculated 
structure for Trp111 at a sigma level of 2.0.  (2-3) Maps showing the difference between the calculated and 
observed structures for (2) Trp111 and (3) water molecules located near Glu35.  A "solvent" molecule visible at 
high sigma levels, suggesting the presence of a metal atom is highlighted.  The calculated map (blue) is 
displayed at a sigma level of 2.0, while the difference map (green) is displayed at a sigma level of 3.0. 
5.3.5  X-ray Transparent Devices for the In Meso Crystallization and Study of Membrane Proteins 
While the actuate-to-open valve configuration used in the array chips in Section 5.3.4 is amenable to 
use with soluble proteins and detergent solubilized membrane proteins, the microfluidic platform for in 
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meso membrane protein crystallization described in Chapter 4 relies on actuate-to-close valves to drive 
the flow of the highly viscous mesophase.
85,109
  In order to achieve this level of valving it was necessary to 
extend the fabrication procedures described previously to include a strong irreversible seal between the 
thin PDMS fluid layer and COC substrate as before, as well as the COC control layer and a larger block of 
PDMS for the creation of inlet connections. 
Previous attempts at using an oxygen plasma treatment to seal layers, as in traditional PDMS-based 
microfluidics resulted in an inadequate seal between layers.  However, the use of the APTMS/GPTMS 
bonding strategy produced a high quality seal.
112
  Initial testing demonstrated that APTMS/GPTMS 
treatment was not only able to seal densely packed features, but also was able to withstand applied 
pressures of at least 30 psi.  Figure 5.15 shows the actuation of a single isolation valve in an in meso 
crystallization device without cross-talk between valves spaced only 50 µm apart. 
 
Figure 5.15.  Optical micrographs and schematic depictions of an actuate-to-close,
109
 push down microfluidic 
isolation valve used in an in meso crystallization device comprised of a PDMS fluid layer sandwiched between a 
COC substrate and control layer with a larger PDMS inlet layer providing pneumatic connections.  The valve is 
shown in the (a) open, relaxed position, and in the (b) closed, actuated position.  Deflection of the PDMS valve 
membrane can be seen inside the channel.   
Validation of this PDMS/COC hybrid device architecture for in meso membrane protein crystallization 
is ongoing.  However, the functionality of the device has already been demonstrated.  Additionally, the 
decreased solvent loss from a PDMS/COC device as compared to a traditional PDMS device should be 
beneficial with respect to sample dehydration and incubation over extended periods of time.   
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5.4  Conclusions 
In summary, an X-ray transparent device architecture composed of a thin PDMS fluid layer coupled 
with a thin COC control layer and substrate has been validated for use in protein crystallization trials and 
for in situ crystallographic analysis.  This device architecture overcomes not only challenges associated 
with X-ray transparency, but also minimizes evaporative losses and allows for the incubation of 
crystallization trials for a longer period of time than would be possible with standard PDMS microfluidic 
devices. 
These PDMS/COC microfluidic devices have been demonstrated for X-ray data collection at both 
room temperature and under cryogenic conditions.  While the planar geometry of these chips may create 
rotational limitations in some experimental setups, strategies have been presented for not only the 
acquisition of a few frames of data for crystal quality screening, but also for the collection of complete 
datasets for protein structure determination.  The application of this kind of crystallization and analysis 
platform has tremendous potential to enable structural biology studies of recalcitrant proteins where 
crystal size and/or fragility might otherwise hamper crystallographic analysis. 
By coupling the advantages of microfluidic fluid handling with the ability to perform in situ diffraction 
analysis, the crystallization platforms demonstrated here circumvent difficulties associated with the 
manual harvesting of crystals, thus enabling reproducible analysis of high quality crystals.  Additionally, 
the fluid handling capabilities of microfluidics allow for consistent well-to-well crystallization kinetics, thus 
facilitating the growth of a large number of crystals with minimal crystal-to-crystal variations in quality.  
Overcoming these challenges is particularly important for the analysis of protein crystals which may only 
form tiny crystals or which may be highly susceptible to radiation damage, thus necessitating the analysis 
of a large number of crystals in order to obtain a complete dataset.  The platforms demonstrated here can 
be applied to not only soluble proteins, but also membrane proteins grown either in surfo or in meso.  The 
ability to efficiently perform room temperature diffraction studies over a large number of crystals has the 
potential to shift the paradigm of protein structure determination from cryocrystallographic analysis of a 
single crystal to data collection of a large number of crystals at biologically relevant temperatures.   
Having validated this approach for static protein structure determination, the fluid handling and in situ 
analysis capabilities of these microfluidic platforms could enable a wide range of truly exciting studies.  
For instance, real-time microfluidic fluid control could enable dynamic studies of the evolution of a protein 
structure as a function of various stimuli such as ligands, pH or environmental concentration changes as 
well as temperature changes.  These capabilities could be particularly powerful when coupled with the 
fast data collection methods using polychromatic X-rays as will be discussed in Chapter 6.   
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The X-ray transparent device architecture developed in Chapter 5 was applied to the polychromatic, 
or Laue diffraction method.  The microfluidic device structure used in this work is comprised of a thin 
polydimethylsiloxane (PDMS) fluid layer (middle) bonded to a thin cyclic olefin copolymer (COC) control 
layer (top) and a COC substrate (bottom) to form pneumatic valve structures.  The effects of sample and 
device geometry were investigated using the soluble protein lysozyme as a model system.  In 
collaboration with the BioCARS team at the Advanced Photon Source at Argonne National Laboratory, an 
automated "single-shot" method was developed for obtaining a complete dataset from many crystals 
grown on-chip to minimize the effects of radiation damage to the crystal on the resultant data.  Data from 
66 individual crystals was merged into a single dataset.  A comparison of similar datasets collected using 
monochromatic vs. polychromatic radiation demonstrated that this "single-shot" microfluidic method for 
data collection can be used to collect high quality data, overcoming many of the challenges typically 
associated with Laue data collection. 
  
                                                     
*
 Part of this work will be published:  S.L. Perry, S. Guha, Z. Ren, and P.J.A. Kenis, Automated Methods 
for In Situ Laue Crystallography Using Microfluidic Platforms for Protein Crystallization (in preparation). 
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6.1  Introduction 
While efforts in microfluidics for protein crystallization have advanced dramatically in the past ten 
years,
1-53
 the idea of coupling microfluidic technology with advanced crystallographic techniques for in situ 
analysis is an area where significant advances can still be made.  Thus far efforts have focused mainly on 
simple devices where monochromatic X-rays can be used to interrogate the sample.
2,4,5,13-15,17,19-
21,26,27,31,40,42-45,47,52
  In Chapter 5 a hybrid microfluidic device architecture was introduced which enabled in 
situ X-ray analysis of protein crystals grown on chip.  While monochromatic X-ray diffraction is used for a 
majority of structural biology studies, polychromatic X-ray diffraction, termed Laue diffraction,
54
 has 
various benefits over its more traditional counterpart.  The most significant benefit of Laue diffraction is 
the speed at which data collection can be performed.
54
  This faster rate of data collection is the result of 
using a range of X-ray wavelengths to interrogate the sample, resulting in an increased number of 
observed diffraction spots per image, thereby decreasing the number of frames of data which must be 
taken to form a complete dataset.  This increased rate of data acquisition has enabled the use of Laue 
crystallography for a variety of experiments where monochromatic diffraction has been limited, including 
(i) the analysis of crystals which are not amenable to flash-freezing, (ii) room temperature structural 
studies when the lifetime of the crystal is too short for traditional data collection, and (iii) time resolved 
kinetic studies of structural changes. 
Although performing data acquisition at room temperature is not an inherent requirement for Laue 
crystallography, it is not uncommon for experiments to be performed at ambient conditions either because 
the sample is not amenable to cryocooling, or because the experiment of interest involves determining 
the structure at near physiological conditions.
54
  Cryocooling is typically used for monochromatic 
experiments because it decreases molecular motion, thereby potentially improving the obtainable 
resolution, and also decreasing the extent of radiation damage.
54-57
  However, the stresses associated 
with cryocooling can also perturb the crystal structure,
56,57
 increasing the mosaicity which can have a 
detrimental effect on the quality of Laue data that can be collected. 
In terms of the speed of data collection at a synchrotron, in typical monochromatic experiments, 
frames of data are acquired using X-ray exposure times on the order of seconds.  However, for Laue 
methods the exposure time is three to four orders of magnitude shorter.
58
  The exposure time is 
measured in terms of the number of packets of radiation which the sample experiences.  In a synchrotron, 
packets of electrons circulate around the ring at high speed in different bunch conformations depending 
upon the operational mode of the synchrotron.  As each bunch passes the beamline a short dose of 
radiation is given off.  The radiation exposure of the sample is thus given in terms of the number of these 
bunches and, in total, is on the order of microseconds or less.
58
  
The use of such short exposure times and the increased density of data collection per frame have 
enabled time resolved structural studies at sub-nanosecond time resolution.
58
  In these studies it is 
necessary to synchronize and trigger a uniform structural change for a majority of the molecules in the 
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crystal and then match the X-ray exposure time to the timescale of the resultant structural changes.  
Photolysis is a common method for initiating such a structural change because the pulse of light can be 
easily timed with data collection and is able to penetrate the entire crystal.  However, chemical triggers 
can also be used.
54,58-60
  Thus Laue crystallography provides a very elegant platform for performing 
extremely meaningful kinetic experiments that directly probe changes that occur during protein function. 
While Laue crystallography possesses several advantages over monochromatic data collection, it 
also suffers from several significant limitations in terms of (i) radiation damage, (ii) sensitivity to crystal 
quality and background scatter, and (iii) the need for more intensive data analysis.  The use of 
polychromatic radiation results in a more intense X-ray beam than for monochromatic experiments.  
Therefore while there is a tradeoff in terms of exposure time, radiation damage from exposure to the 
polychromatic beam can be significant, particularly at room temperature.  Various data collection 
strategies have been developed to help overcome this limitation.  Also, combining data collected from 
multiple crystals is common.
54,59,61
 
The sensitivity of Laue crystallography to crystal quality, and in particular mosaicity is the result of 
spot elongation.  During data analysis it is necessary to identify the exact location of the various 
diffraction spots observed.  However, with an elongated or streaky spot identification of the spot location 
is much more difficult.  This problem can be further compounded by high levels of background scatter 
which decrease the signal-to-noise ratio for weak spots.  These limitations have typically restricted Laue 
data collection to crystals of relatively high quality and provided both a challenge and an opportunity for 
microfluidic crystallization platforms.   
In addition to the identification of diffraction spots, data analysis for polychromatic diffraction in 
general is more difficult than for monochromatic diffraction.  In indexing the various diffraction spots, both 
the indices of each spot as well as the wavelength of radiation responsible for its appearance must be 
determined.  The intensity of the various spots must then be normalized with respect to the intensity of 
the incident radiation spectrum.  Additionally, methods do not currently exist for ab initio structure 
determination using Laue diffraction, thus a Laue experiment must always be coupled with a 
monochromatic experiment in order to obtain phase information.   
In this chapter the X-ray transparent microfluidic platforms described in Chapter 5 will be used to 
perform Laue crystallography.  The efficacy of these platforms for in situ Laue analysis is first validated 
using a simple chip design (Section 6.3.1).  96-well crystallization array chips for the growth of a large 
number of crystals are then coupled with an automated process for collecting single-shot data which can 
be merged to generate a complete dataset (Section 6.3.2).  A comparison between merged datasets 
acquired using monochromatic and polychromatic diffraction is then presented.   
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6.2  Materials and Methods 
6.2.1  Device Fabrication and Operation 
The simple large well chips and 96-well array chips used here were fabricated and filled as described 
in Chapter 5.  Briefly, microfluidic chips were fabricated by bonding a thin polydimethylsiloxane (PDMS, 
General Electric RTV 650) fluid layer with either 25 µm or 50 µm features covered with a membrane 
thickness of ~20 µm.  This fluid layer was chemically bonded to a molded cyclic olefin copolymer (COC, 
2-4 mil, 5013 and 6013, from TOPAS Advanced Polymers Inc.) control layer and a flat COC substrate.   
6.2.2  Protein and Precipitant Solutions 
Hen egg white lysozyme (Sigma) was dissolved in 50 mM sodium acetate (Sigma-Aldrich) at pH 4.6 
with 20% (w/v) glycerol (Fisher Scientific) at a concentration of either 88 mg/mL for simple large well 
experiments or 120 mg/mL for 96-well array chip experiments.  Lysozyme concentrations were 
determined by UV absorbance measurements (Lambda 650 UV-Vis spectrophotometer, Perkin Elmer) at 
280 nm using an extinction coefficient of 2.64 mL/(mg-cm).
62
  For proof-of-concept Laue crystallography 
experiments precipitant solutions of 1M NaCl (Aldrich) in 50 mM sodium acetate, pH 4.6 with 20% (w/v) 
glycerol were prepared.  Prior to setting up a crystallization experiment, protein solutions were filtered 
through 0.1 µm (Ultrafree-MC, Millipore) filters.  Precipitant solutions were filtered through 0.22 µm 
(Steriflip, Millipore) filters.   
6.2.3  Crystallization Experiments 
Crystallization experiments were set up and visualized using either a stereomicroscope (Leica, 
MZ12.5) with an attached digital camera (Leica, DFC295) operated using Leica Application Suite software 
or a computer controlled imaging system comprised of an optical microscope (Leica Z16 APO) equipped 
with an auto-zoom lens (Leica 10447176), a digital camera (Leica DFC280), and a motorized x-y stage 
(Semprex KL66) controlled by Image Pro Plus (Media Cybernetics).  For visualization of protein crystals, 
images were occasionally taken with the use of cross-polarizers.   
For simple large well and array chip crystallization experiments, actuate-to-open valving and fluid 
filling was achieved by the application of vacuum from a small vacuum pump (Gast) connected to the 
device through a plastic gas manifold (Cole-Parmer Instrument Co.) and 24 AWG PTFE tubing coupled 
with a thin metal tube.  Fluids (protein and precipitant solutions) were supplied to the device by pipetting 1 
– 5 µL of solution onto the inlet hole.  Vacuum within the chip from actuation of valves then pulled fluid 
into the chambers.  After filling, the inlet holes for both the fluid and control layers were sealed with 
Crystal Clear tape (Hampton Research).  Incubation of crystallization experiments was performed at 4°C. 
6.2.4  X-ray Diffraction Experiments 
Diffraction experiments were carried out at beamline 14-ID-B (Figure 6.1a) at the Advanced Photon 
Source at Argonne National Laboratories with the assistance of the BioCARS team.
63
  Beamline 14-ID-B 
is an insertion device station with two in-line undulators (U27 and U23) that can operate over a wide 
energy range of 7 keV to 20 keV (1.77 Å to 0.62 Å) and can provide both a monochromatic and 
 137 
polychromatic X-ray beams.  Most data was collected with both undulators set to a peak energy of 12 keV 
(1.03 Å).  Experiments were also performed with the energies of the undulators offset by 2 keV (U27 at 
11.8 keV (1.05 Å), U23 at 13.8 keV (0.898 Å), thereby increasing the polychromatic range of the exposure 
and increasing the density of diffraction data obtained per image.  A MARCCD-165 detector was used, 
with optical visualization provided by off-axis cameras.   
Proof-of-concept large well devices were mounted on a standard magnetic goniometer mount with an 
attached metal tube into which a slit was cut and a set-screw was used for securing samples.  X-ray 
exposures of 1 or 10 pulses of 11 electron bunches each were used.  A sample-to-detector distance of 
100 mm, 120 mm, or 150 mm was used depending on the strength of the diffraction signal observed.  
Collection of a complete dataset from a single crystal was attempted.  90° of data was collected using 
either a single pass method in steps of 8°, or in a gap filling mode in steps of 6°.  All data collection was 
performed at room temperature. 
For experiments using the 96-well array, chips were mounted in a plastic frame attached to an 
automated x-y-z translational stage (Eastern Air Devices) (Figure 6.1b).  An automated python script 
coupled with two off-axis viewing cameras was used to identify and mark the location of individual crystals 
within the array chip (Figure 6.1c).  Once identified, single-shot data collection on each crystal occurred in 
an automated fashion.  X-ray exposures of 10 pulses of 11 electron bunches were used.  A sample-to-
detector distance of 110 mm was used.  All data collection was performed at room temperature. 
6.2.5  Analysis of X-ray Diffraction Data 
Analysis of Laue X-ray diffraction data was performed using Precognition analysis software for 
indexing, geometric refinement, integration, and scaling (Renz Research Inc.).
64
  Subsequent processing 
of crystallography datasets was done using the CCP4 suite of programs.
65-67
  MTZ files were generated 
using Scalepack2mtz.  Molecular replacement
68
 for lysozyme was done in Phaser using PDB structure 
193L as a model.
69
  Model refinement and solvent building were performed using Refmac5 and aRP-
Solvent, respectively.  Electron density maps were displayed using COOT.
70
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Figure 6.1.  Photographs of (a) the Laue crystallography experimental setup at the 14-ID-B beamline at the 
Advanced Photon Source at Argonne National Laboratory and (b) a 96-well microfluidic array chip mounted for 
in situ data collection.  The inset shows the device mounted in a plastic frame.  (c) The control computers used 
for sample alignment and data collection.  General sample position is shown on the top right.  A lower 
magnification camera is used for gross positioning of the chip (top left).  Finer control and crystal marking is 
performed using a split-screen view from two higher magnification cameras (lower left).  Detector readout is 
seen on the lower right. 
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6.3  Results and Discussion 
6.3.1  Proof-of-Concept On-Chip Laue Diffraction Experiments 
A simple microfluidic well structure was used for proof-of-concept experiments to demonstrate on-
chip Laue diffraction, as in Chapter 5, Section 5.3.3 (Figure 6.2a).  The size of lysozyme crystals grown in 
these devices (Figure 6.2b) was limited by the height of the microfluidic chamber, resulting in a maximum 
path length through the crystal of ~25 µm.  This path length is relatively small in comparison to the ~100 
µm path length of the beam through the device materials for devices fabricated from 2 mil 5013 COC or 
the ~200 µm path length for devices fabricated from 4 mil 6013 COC (total thickness includes ~ 20 µm of 
PDMS).  While the difference in these path lengths was not significant for monochromatic diffraction 
studies, it was important to validate this platform for use with Laue methods due to the increased 
sensitivity of this method to background scatter. 
 
Figure 6.2.  (a) Schematic depiction of a simple large well device.  A large rectangular well with support posts is 
molded in PDMS (blue) and aligned with a matching COC control layer and substrate (green).  The entire 
assembly is then attached to a COC substrate.  (b) Optical micrographs of lysozyme crystals grown on chip. 
In screening various crystals grown in these simple well structures, the significance of background 
scatter and crystal mosaicity were observed.  In Figure 6.3a the effect of high crystal mosaicity can be 
clearly seen by the radial streaking of diffraction spots.  Figure 6.3b-c show the diffraction patterns 
resulting from crystals with a much lower mosaicity.  Similarly, the increased background scatter resulting 
from data collection through a thicker device limited the resolution to which spots could be clearly 
observed.   
The effects of radiation damage from exposure to the polychromatic X-ray beam were observed 
during the course of data collection, both in terms of the quality of the diffraction image, and on the crystal 
itself.  In Figure 6.3d optical micrographs clearly show damage to the crystal as a result of exposure to 
the beam.  Radiation damage resulted in an increase in mosaicity as a function of exposure.  Thus during 
the course of data collection on a single crystal the observed spots in the diffraction image changed from 
nearly circular to elongated streaks.   
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Figure 6.3.  Polychromatic diffraction data collected in situ from lysozyme crystals grown in a simple large well 
device.  (a) Laue diffraction from a highly mosaic crystal, as indicated by the streaking and elongation of the 
spots.  (b) High quality in situ Laue diffraction with the beam energy peaked at 12 keV (1.033 Å).  (c) High 
quality in situ Laue diffraction with the energy of the undulators offset by 2 keV (11.8 keV (1.05 Å) and 13.8 keV 
(0.898 Å)).  A higher density of diffraction spots is observed here compared to (b) due to the increased range of 
X-ray energy present.  Insets provide a closer view of spot quality.  (d) Optical micrographs of crystals mounted 
for in situ analysis.  Damage to the crystal due to X-ray exposure can be seen, as highlighted in the dashed 
rectangle.   
Because of the sensitivity of the Laue method to radiation damage, a variety of data collection 
strategies have been developed to try and optimize the workable lifetime of a crystal.  Gap-filling 
strategies where one pass through rotational space at large intervals followed by filling in with additional 
frames to sample between these intervals can be used to maximize the completeness of a dataset before 
radiation damage becomes too severe.  In addition to gap-filling, a wider range of X-ray radiation can be 
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achieved by offsetting the peak of the beamline undulators to further increase the density of spots per 
frame, although there is a balance to be struck between an increase in data density and the ability to 
resolve individual spots.   
Both the gap filling and increased spectrum of radiation were used to collect complete datasets from 
single crystals of lysozyme.  A summary of the data collection statistics is given in Table 6.1.  Whereas in 
monochromatic diffraction analysis the high resolution limit is determined typically based off of the level at 
which the signal-to-noise (I/σ) level falls below 3, for Laue crystallography a criterion of completeness in 
the highest resolution shell greater than 25% was used.  However, as can be seen from the statistics in 
Table 6.1, the overall completeness of both datasets is very poor.  Additionally, Rsym for the case of 
increased spot density per frame is very poor.  A strategy to overcome the limitation of radiation damage 
during room temperature Laue data collection is discussed in Section 6.3.2. 
Table 6.1.  Crystallographic data statistics from the diffraction analysis of lysozyme crystals grown on chip using 
in situ Laue analysis of single crystals taken at different undulator settings.  A gap filling method with 6° spacing 
was used with a narrower band of X-ray radiation achieved by peaked undulators.  Simple data acquisition was 
used in 8° increments with the higher data density achieved by using offset undulators.  All data collection was 
performed at room temperature.  Reported values are for all hkls.  Values shown in parenthesis represent the 
value for the highest resolution shell. 
Parameter 
Peaked Undulators 
6° Gap Filling 
Offset Undulators 
8° Intervals 
Resolution 100 – 2.20 Å 100 – 2.00 Å 
Rsym 0.046 0.426 
Mosaicity 0.028° – 0.116° 0.010° – 0.111° 
Completeness 56.5% (26.6%) 70.2% (26.4%) 
Frames of Data 7 9 
 
6.3.2  In Situ Single-Shot Laue Structure Determination of Crystals Grown in a Microfluidic Chip 
Due to the significant adverse effects of radiation damage on the crystals grown on chip, the 
collection of a high quality dataset from a single crystal grown on-chip proved to be difficult to achieve, as 
expected, despite the use of various data acquisition strategies.  This observation is particularly striking 
given that the model system used, lysozyme, forms particularly robust high quality crystals such that 
radiation damage and mosaicity would be much more significant for crystals of most other proteins.  
However, microfluidic methods have the advantage of being able to prepare a large number of samples in 
parallel.  Therefore a large array chip with 96 wells (Figure 6.4) was used to generate a large number of 
lysozyme crystals (Figure 6.5), enabling "single-shot" structure determination.  Additionally, the path 
length through the crystal in these devices was increased relative to the total thickness of the device.  In 
these devices the crystals were able to grow to ~50 µm in size and did not appear to have been 
significantly limited in their growth by the height of the chamber.  This increase in the crystal size enabled 
the use of thicker device layers (a total path length of ~100 µm, including ~20 µm of PDMS) to yield more 
robust devices.   
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Figure 6.4.  Schematic depiction of the design of a 96-well microfluidic array chip for the crystallization of 
soluble or detergent solubilized proteins.  Protein and precipitant inlets are indicated.  The fluid layer is shown in 
black while the various features of the control layer have been identified based on function.  Valves for the 
loading of protein are shown in blue, precipitant valves in green, and the valves to connect chambers and allow 
for diffusion between the protein and precipitant chambers are pink.  Window structures are shown in yellow.  
These structures are present in the control layer, but serve only to decrease the thickness of material present in 
the path of the X-ray beam.   
Data collection by taking a single diffraction image of a large number of crystals is particularly 
attractive for microfluidic applications, provided that crystals can be grown without an orientational bias 
on-chip.  One of the significant challenges for data collection in a planar microfluidic device is the need to 
maintain alignment of the crystal during rotation, coupled with geometric limitations for rotation of the 
device.  For single-shot analysis the microfluidic chip can be mounted perpendicular to the X-ray beam 
and simply translated from well-to-well.  The random orientation of crystals within the chip would then 
allow for a full survey of rotational space without having to rotate the sample itself.  This type of a setup 
avoids difficulties with rotational and geometric limitations and eases difficulties with optically aligning a 
rotating crystal in the beam.  This method was further enabled by the development of an automated 
method for marking the location of crystals within a microfluidic chip such that data collection could be 
performed automatically once all crystals have been located.   
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Figure 6.5.  Composite optical micrograph of lysozyme crystals grown in a 96-well microfluidic array chip used 
for Laue X-ray diffraction experiments.  Insets provide a magnified view of crystals in individual wells.   
Diffraction analysis of crystals grown on a single chip resulted in 169 frames of data, of which 122 
represented high quality data.  Of the 34 frames taken where no diffraction was observed, the majority of 
these lost frames can be attributed to errors in controlling sample translation, the scripting for which was 
corrected during the course of data collection.  Also, the accuracy of crystal marking coupled with fine 
control of sample translation over the entire dimensions of the chip (20 mm x 10 mm) were validated in 
that only a single frame of data was collected which showed overlapping diffraction patterns from multiple 
crystals, despite the close proximity of many crystals within wells.   
Of the 122 frames of data obtained, 66 were merged to form a single dataset.  While is possible that 
the quality and completeness of the final result could have been improved by including additional frames 
of data, scripting was used to analyze the entire dataset in an automated fashion so as to maintain the 
high throughput nature of this method.  More careful analysis for inclusion of the excluded frames is 
beyond the scope of the current study.   
The data obtained by "single-shot" Laue methods was then compared to an analogous dataset 
obtained by collecting small wedges of data from a large number of crystals using monochromatic 
diffraction, as presented in Chapter 5.  Statistics associated with the data collection and model refinement 
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of the two datasets are given in Table 6.2.  As can be seen in Table 6.2, the two datasets extend over 
similar resolution ranges and have comparable values for the linear R-factor (Rsym).  One particularly 
observation is that significantly lower levels of mosaicity were seen for crystals analyzed by "single-shot" 
Laue methods as compared to an equivalent monochromatic method.  However, despite the collection of 
high quality, low mosaicity data, the completeness of the Laue dataset is significantly lower than that of 
the monochromatic dataset.  Although part of this difference could stem from the criteria used to establish 
resolution limits, this difference in completeness could account for differences seen in the resultant 
electron density maps (Figure 6.6) and the higher levels of R and Rfree obtained during model refinement.   
Table 6.2.  Crystallographic data statistics from the room temperature diffraction analysis of lysozyme crystals 
grown on chip and analyzed in situ using (i) "single-shot" Laue methods (polychromatic) and (ii) "small wedge" 
monochromatic diffraction.  Data was collected from a large number of crystals and merged to form a complete 
datasets.  Reported values are for all hkls.  Values shown in parenthesis represent the value for the highest 
resolution shell except in the case of R (Rfree) statistics from model building and for the Ramachandran plot 
statistics where the number in parenthesis indicates the number of residues in a given region.   
Parameter Polychromatic  Monochromatic 
Data Collection 
Resolution 50 – 1.62 Å 50 – 1.55 Å 
Rsym 0.074 0.064 (0.362) 
Mosaicity 0.006° – 0.062° 0.03° – 0.08° 
Completeness 90.1% (39.1%) 98.1% (83.4%) 
Frames of Data 66 363 
Refinement 
R (Rfree) 0.281 (0.346) 0.164 (0.227) 
Ramachandran Plot 
Most Favored 94.49% (120) 96.06% (122) 
In Allowed Regions 5.51% (7) 3.94% (5) 
Disallowed 0.00% (0) 0.00% (0) 
 
As can be seen in Figure 6.6a-b1, the electron density maps generated from the "single-shot" Laue 
data are not capable of generating as clear a picture of amino acid side-chain conformations as was the 
more complete monochromatic dataset.  The difference in quality of these two maps becomes even more 
apparent when a difference map comparing of the observed and calculated electron density of a single 
sidechain, tryptophan Trp 111 are made (Figure 6.6a-b2).  The electron density map generated from 
Laue data shows discontinuous regions of electron density suggesting a difference in quality of the two 
maps.  A comparison of the observed solvent molecules showed areas of both agreement and 
disagreement between the two datasets (Figure 6.6a-b3).  Despite the differences of the two datasets, 
these results clearly demonstrate the capability of single-shot in situ data collection for structure 
determination using Laue methods.   
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Figure 6.6.  Electron density maps displaying various aspects of the structure of hen egg white lysozyme 
obtained by merging data from many crystals grown on-chip and analyzed at room temperature to (a) 1.62 Å 
using single-shot Laue diffraction, and (b) 1.55 Å obtained using monochromatic diffraction methods.  (1) The 
calculated structure for Trp111 at a sigma level of 2.0.  (2-3) Maps showing the difference between the 
calculated and observed structures for (2) Trp111 and (3) water molecules located near Lys1.  The calculated 
map (blue) is displayed at a sigma level of 2.0, while the difference map (green) is displayed at a sigma level of 
3.0. 
6.4  Conclusions 
In summary, the utility of the X-ray transparent device architecture developed in Chapter 5 has been 
extended to polychromatic Laue diffraction methods.  The effects of sample and device geometry have 
been investigated and the relative path length through the crystal as compared to the device materials 
was shown to be significant.  Taking advantage of the lack of sample manipulation during Laue data 
collection, an automated method for collecting "single-shot" diffraction data from a large number of 
crystals grown on chip has been developed in collaboration with the BioCARS team at the Advanced 
Photon Source at Argonne National Laboratory.  Automated strategies for data processing are also in 
place to facilitate the high throughput analysis of the large number of frames of data which could result 
from this data collection strategy. 
As in the case of monochromatic diffraction analysis, these X-ray transparent microfluidic platforms 
circumvent challenges associated with the growth and mounting fragile protein crystals.  Fine control over 
the fluid transport on-chip enables reproducible crystallization of a large number of crystals with limited 
well-to-well variability.  The ability to perform in situ X-ray analysis further decreases the potential for 
crystal-to-crystal variability that could occur as a result of physical handling and/or environmental shock.  
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While these strategies have been demonstrated with lysozyme as a model system, further validation of 
this approach with more challenging systems such as less strongly diffracting soluble protein targets, 
and/or membrane proteins crystallized both in surfo and in meso would be a truly powerful demonstration 
of the efficacy of this approach.  The ability to efficiently perform Laue diffraction studies using a large 
number of crystals has the potential to enable the time resolved study of a large number of protein targets 
which have otherwise resisted analysis by Laue methods.   
In addition to the static structural studies presented here, there is tremendous potential for developing 
microfluidic crystallization platforms for use in time resolved structural studies.  In these more advanced 
studies the fluid handling capabilities of microfluidics and the fine control over transport phenomena could 
be utilized not only to grow a large array of crystals, but also to supply ligands or substrates to study 
structural changes associated with protein function, or more subtle changes associated with variations in 
pH, ionic strength, temperature, or other biologically relevant parameters.  The majority of time resolved 
studies reported thus far have been limited to systems for which robust protein crystals can be grown.  
Eliminating the need for manual handling of crystals not only avoids the potential for physically damaging 
fragile crystals, it also enables the analysis of a significantly larger number of crystals.  The development 
and validation of this technology for time resolved and dynamic crystallography studies would be 
extremely powerful and would provide a new niche area where microfluidic technologies can truly excel.   
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Chapter 7  
Microfluidic Platforms for In Situ Analysis of 
Lipid Phase Behavior 
Abstract 
The X-ray transparent microfluidic device architecture developed in Chapters 5 and 6 for protein 
crystallography has been applied to the challenge of in situ small angle X-ray diffraction studies for the 
determination of the phase behavior of aqueous/lipid systems.  The feasibility of analyzing very thin 
microfluidic samples was tested by examining the effect of sample thickness on the observed signal 
intensity and the effects X-ray irradiation on microfluidic samples.  The use of these platforms for the 




7.1  Introduction 
As was discussed in Chapter 2, the in meso crystallization method relies on the self-assembly of 
liquid crystalline mesophase structures above a limiting concentration of certain lipids in water.  
Understanding the phase behavior of these self assembling aqueous/lipid systems is critical for the 
advancement of the in meso crystallization method.  However, the preparation of highly viscous 
mesophase samples is non-trivial and mapping out the phase behavior of even a binary water/lipid 
mixture is both time and sample intensive.  To understand crystallization systems it is necessary to not 
only understand the phase behavior of the simple lipid water system, but also to understand the effect 
that a wide variety of additives can have on phase behavior.   
The preparation of aqueous/lipid mesophases, particularly at small volumes is challenging because of 
the high viscosity of the lipid solution (~30 times higher than the viscoity of water) and the non-Newtonian 
behavior and the extremely high viscosity (~10
5
 times higher than the viscosity of water at the shear rates 
employed) of the resulting mixture.
1-4
   Sample preparation in the literature has typically been done either 
by repeated centrifugation in a small tube along with extended periods of equilibration,
5-22
  or through the 
use of two microsyringes that are coupled through a small bore connector.
3,22-32
   
 
Figure 7.1.  Equilibrium temperature/composition phase diagram for the binary monoolein/water system.  
Legend:  Lc and La are lamellar phases, Ia3d and Pn3m are bicontinuous cubic phases, HII is an inverted 
hexagonal phase and FI is a fluid isotropic phase.  471 individual data points were needed for the construction 
of this phase diagram.  (Figure adapted from Briggs and Caffrey, 1994).
33
 
Determination of the phase diagram for an aqueous/lipid system is highly labor intensive, involving 
preparation of all individual compositions, followed by transfer into X-ray capillaries and analysis.  For 
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example, determination of the equilibrium temperature/composition phase diagram for monoolein and 
water required nearly 500 separate measurements (Figure 7.1).
33
  To determine a phase diagram, 
mesophase samples of specific concentrations are prepared.  The phase identity of each sample is then 
analyzed by a variety of techniques including small angle X-ray diffraction.
32-36
  X-ray analysis provides 
direct insight into the dimensions of the mesophases: for example, a fully hydrated cubic Pn3m phase of 
monoolein and water has a bilayer thickness of 32Å and water channels with a diameter of 40Å.
37
  The 
metastable character of the various mesophases requires long incubation times in excess of 3 hours at 
each temperature increment to minimize these effects.
7,22,32,33,35-37
  Temperature-controlled sample 
holders are also limited in the number of samples which can be mounted at one time.  Actual diffraction 
data collection takes between 15 minutes to 24 hours using a „bench-top‟ X-ray source
20,32,35
 or on the 
order of seconds when a synchrotron source is used.
22,34
   
In meso crystallization has thus far utilized the wealth of self-assembling phase behavior observed in 
aqueous/monoacylglycerol (MAG) systems, most commonly with the lipid monoolein (1-monooleoyl-rac-
glycerol).  While these aqueous/MAG systems form a variety of phases including lamellar phases, 
bicontinuous cubic and inverted hexagonal phases,
3,10,28,30,38-40
 the lamellar and cubic phases are thought 
to be the most important for in meso crystallization.
3,8,31,41-46
  Lamellar phases are locally planar lipid 
bilayer structures with varying degrees of inter-bilayer hydration.  Cubic phases can be described as 
networks of interconnected aqueous channels surrounded by lipid bilayers with negative curvature.  
These phases are bicontinuous, allowing for diffusion in both the aqueous channels and the curved lipid 
bilayers.   
Additives such as salts, detergents, lipids, other components of crystallization screens, biologically 
relevant molecules and cofactors, and the membrane proteins themselves have been shown to have a 
significant effect on not only the phase behavior of these aqueous/MAG systems, but also potentially on 
the related in meso crystallization trial.
3,8-13,15-17,19-22,26-31,41,45,47-53
  Understanding the effect of these various 
additives, not only on the identity of a particular mesophase, but also on the lattice parameter and 
curvature of the phase is critical for developing a rational understanding of in meso crystallization.  
However, performing such a survey of the effects of even a small set of the additives typical in 
crystallization experiments would be an immense undertaking, particularly given current methods.   
In Chapters 4 and 5 a microfluidic platform for the preparation of in meso crystallization samples with 
in situ analysis capabilities was introduced.  This microfluidic platform decreased the preparative scale at 
which mesophase samples could be prepared by 1000x from traditional syringe-based methods and has 
the potential to be scaled out for high throughput screening.  In this chapter the development and 
characterization of a microfluidic platform for the preparation and in situ X-ray analysis of mesophase 
samples for phase behavior studies is described.  This work was truly enabled by the development of a 
small angle X-ray diffraction setup with advanced sample visualization capabilities by the Life Sciences 
Collaborative Access Team (LS-CAT) at the Advanced Photon Source at Argonne National Laboratory 
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(Section 7.3.1).  The visualization capabilities of this setup were necessary to enable targeting of 
individual samples in an integrated microfluidic chip.  Using this setup, an investigation into the effects of 
signal as a function of sample thickness for very thin microfluidic samples was done (Section 7.3.2).  
Several integrated microfluidic chips were developed to study various aspects of phase behavior, 
including the effects of additives (Section 7.3.3), and initial testing of in situ small angle X-ray diffraction 
analysis of mesophase samples in a microfluidic device validated the efficacy of this approach (Section 
7.3.4). 
7.2  Materials and Methods 
7.2.1  Device Fabrication and Operation 
The microfluidic chips used here were fabricated as described in Chapter 5.  Briefly, microfluidic chips 
were fabricated by bonding a thin polydimethylsiloxane (PDMS, General Electric RTV 650) fluid layer with 
10 µm features covered with a membrane thickness of ~20 µm.  This fluid layer was chemically bonded to 
a molded cyclic olefin copolymer (COC, 4 mil 6013, from TOPAS Advanced Polymers Inc.) control layer 
and a flat COC substrate (2 mil 5013, TOPAS Advanced Polymers Inc.).  A thick layer of PDMS with 
punched holes for the fluid and control lines was then bonded to the control layer.  This layer of PDMS did 
not cover the areas of interest for analysis on the chip. 
7.2.2  Chemicals and Solutions 
Monoolein (1-monooleoyl-rac-glycerol, Fluka) was purchased and stored at -12°C.  Mixtures of 
monoolein and β-octylglucoside (anagrade, Anatrace) were prepared by dissolution in chloroform 
followed by evaporation of the solvent first under a nitrogen stream and then by drying under vacuum at 
room temperature overnight.  Mixtures with a ratio of 0.033 (w/w), 0.066 (w/w), and 0.099 (w/w) β-
octylglucoside/monoolein were prepared.  1.3M KH2PO4 (Sigma), pH 5.5 was prepared gravimetrically, 
taking careful note not only of the mass of salt present, but also the mass of water added.  Prior to use, 
solutions were filtered through 0.22 µm (Steriflip, Millipore) filters.   
Mesophase preparation was done using a coupled syringe mixer.
3,22-32
  The dry lipid or lipid/detergent 
mixture was carefully loaded into a 250 µL gastight syringe (Hamilton Co.) and weighed using a 
microbalance (Ohaus Discovery DV215CD).  The aqueous solution was pipetted into a 100 µL gastight 
syringe and similarly weighed.  The syringe mixer was then assembled, taking care to avoid trapping air 
in the syringes.  Mixing was then achieved by driving the contents of the syringes back and forth until a 
uniform mixture was obtained.  The resultant mesophase was inspected both visually and under 
crosspolarized light.  Cubic phases are optically transparent and nonbirefringent while lamellar phases 
tend to be opaque and are birefringent.
3-6,8,20,24,26,35,39,40,42-45,54-65
 
For sample thickness experiments a 50/50 (w/w) mixture of monoolein and water was prepared.  This 
composition of monoolein and water forms a hydrated cubic phase at 25°C.  A second mixture with lower 
water content was also prepared.  The composition of this phase was unknown due to losses during 
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sample preparation.  For in situ analysis of mesophases in microfluidic chips a mixture of 90/10 (w/w) 
mixture of monoolein and β-octylglucoside with 1.3M KH2PO4 pH 5.5 were prepared using different (w/w) 
ratios of monoolein and β-octylglucoside.   
7.2.3  Sample Thickness Experiments 
Testing of the signal intensity as a function of sample thickness was performed using both traditional 
capillary mounted samples, and also proof-of-concept structures to mimic the architecture of a microfluidic 
device.  Cubic mesophase samples were prepared as in Section 7.2.2 and dispensed into thin-walled 
glass capillaries (Charles Supper) with a nominal wall thickness of 10 µm and nominal diameters of 200 
µm, 300 µm, 500 µm, and 800 µm.   The ends of the capillaries were sealed with Critoseal (Leica) and 
epoxy (Loctite Quick Set Epoxy, Henkel Consumer Adhesives) and stored at -12°C after preparation.  
Samples were allowed to equilibrate to room temperature (~25°C) for at least 4 hours prior to data 
collection. 
For proof-of-concept experiments a mesophase sample was prepared and dispensed into both 900 
µm glass capillaries (nominal thickness) as a control and test device structures ranging in thickness from 
25 to 100 µm (nominal).  Test structures were made from 2 mil (~50 µm) 5013 COC windows attached to 
double-sided adhesive films (3M) of varying nominal thicknesses (Table 7.1) with a small hole punched to 
form the sample compartment.  The mesophase sample was dispensed directly into these devices and 
they were sealed immediately. 
Table 7.1.  Summary of 3M adhesive film spacers used to fabricate the test structures.  Single sheets were 
used unless otherwise specified.  
3M Adhesive Film Nominal Film Thickness 
9019 1 mil (~25 µm) 
9628B 2 mil (~50 µm) 
666 3 mil (~75 µm) 
2 sheets of 9628B 2 x 2 mil (~100 µm) 
 
7.2.4  In Situ Analysis of Phase Behavior on a Microfluidic Chip 
Experiments were set up and visualized using a stereomicroscope (Leica, MZ12.5) with an attached 
digital camera (Leica, DFC295) operated using Leica Application Suite software.  For visualization of 
mesophases, images were taken with the use of cross-polarizers.   
For proof-of-concept experiments a mesophase sample was prepared as in Section 7.2.2 and flowed 
into a microfluidic device through 24 AWG polytetrafluoroethylene (PTFE) tubing (Cole-Parmer Instrument 
Co.) coupled with a thin metal tube connected to a syringe. 
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After filling, the inlet holes for both the fluid and control layers were sealed with Crystal Clear tape 
(Hampton Research).  Samples were stored at -12°C after preparation and were allowed to equilibrate to 
room temperature (~25°C)  for at least 4 hours prior to data collection. 
7.2.5  Small Angle X-ray Diffraction Experiments 
Synchrotron experiments were performed at the 21-ID-D beamline in collaboration with the Life 
Sciences Collaborative Access Team (LS-CAT) at the Advanced Photon Source at Argonne National 
Laboratory.
66
  21-ID-D operates over a wide energy range of 6.5 keV to 20 keV (1.91 Å to 0.62 Å).  
Thickness experiments were performed using an energy of 8.048 keV (1.54 Å, Cu-α edge).  Experiments 
examining mesophases within microfluidic devices were performed using 8 keV radiation (1.55 Å).  All 21-
ID stations utilize MD-2 diffractometers (EMBL, with LS-CAT developed extensions) with on-axis sample 
viewing and automatic sample alignment.  A MAR 300 CCD detector was used at a sample-to-detector 
distance of ~890 mm.  Precise calibration of the sample-to-detector distance was performed using a silver 
behenate standard.
67
  The X-ray beam was focused either in horizontal direction (singly-focused beam) or 
in both vertical and  horizontal directions (doubly-focused beam) using a set of Kirkpatrick-Baez bimorph 
mirrors (ACCEL, Germany).  The doubly-focused beam as used in the setup was about an order of 
magnitude more intense than a singly-focused beam.  The beam was collimated with a set of slits and 
finally with a 20 µm or 50 µm pinhole aperture followed by a cleanup capillary with a pinhole (Figure 7.2).  
All experiments were performed using a vacuum flight tube with a mica window on the end closest to the 
sample and a Kapton window with an attached beamstop on the end closest to the detector.  A base 




 Torr was used to minimize air scatter from the X-ray beam (Figure 
7.3a). 
 
Figure 7.2.  Diagram of the experimental configuration for small angle X-ray data collection on 21-ID-D.  Figure 
was provided by Dr. Elena Kondrashkina from the Life Sciences Collaborative Access Team (LS-CAT) at the 
Advanced Photon Source at Argonne National Laboratory. 
Capillary and samples for thickness measurements were mounted using a standard magnetic 
goniometer mount with an attached metal tube as a sample holder.  Capillary samples were mounted into 
this holder using beeswax while a modified design with a slit and set-screw were used to mount samples 
for thickness measurements (Figure 7.3b – inset 1).  Microfluidic chips were mounted in a plastic frame 
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Sample visualization and alignment was achieved through the use of an on-axis video microscope.  Data 
collection was performed at ambient conditions (~25°C). 
 
Figure 7.3.  Photographs of (a) the small angle X-ray experimental setup at 21-ID-D and (b) a microfluidic chip 
for phase diagram determination mounted for in situ data collection.  Inset (1) shows a thickness sample 
mounted on a magnetic cap.  Inset (2) shows a microfluidic chip for phase diagram determination mounted in a 
plastic frame. 
For thickness experiments, performed using a singly focused X-ray beam, exposure times ranging 
from 1s to 30s were used for the test structures, all taken at the same location within a sample.  Exposure 
times for capillary samples were typically 10s.  Two shots were taken sequentially at the same location in 
each capillary in order to investigate the effect of the X-ray beam on the sample.  All samples were 
rotated 360° during the course of data collection to average out the effects of oriented grains.  Images 
were captured for each sample as it was mounted on the beamline in order to facilitate determination of 
sample thicknesses. 
For experiments on mesophases in microfluidic device structures exposure times of 1s to 5s were 
used without rotation.  The corresponding capillary data was collected using a 1s exposure with a 180° 
rotation.  The X-ray beam for these experiments was doubly focused, and thus more intense than in 
previous experiments.   
7.2.6  Analysis of Small Angle X-ray Diffraction Data  





  Briefly, an automated script was used to integrate each diffraction image and 
identify peak locations and phase identities.  These assignments were confirmed by manual inspection.   
One of the difficulties in comparing samples of both different thickness and also different material 
properties is the variation in background.  In an attempt to overcome this, a baselining procedure was 
used where the average signal value from values of q-spacing between 0.054 Å
-1
 and 0.068 Å
-1
 where no 
peaks were observed was calculated and subtracted from the entire spectrum. 
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In order to consider the signal intensity, the height of the main peak for the various phases present in 
a sample was determined using the MAX function in Excel over the appropriate range of data points.  
Most samples only had a single phase present, and while the information was collected for the second 
phase in the few cases were multiple phases were present, it was not included in the analysis. 
Sample thickness was determined using image analysis in ImageJ software of the digital images 
taken of the various mounted samples.  A scale of 0.377 pixels = 1 µm was determined from the 
embedded scalebar.  The sample thickness was taken to be the vertical distance from the edges of the 
capillary at the point where the X-ray beam passed through the sample, as indicated by the crosshairs in 
the photograph (Figure 7.4) minus an assumed nominal value for the wall thickness of the capillary (2 x 
10µm).  This value does not correspond to the actual diameter of the capillary in some cases when the 
sample was not perfectly horizontal.  The diameter of the capillaries was found to be significantly different 
from the nominal value and varied along the length of the capillary.  These nonuniformities were also 
evident upon visual inspection of the capillaries. Similar measurements were attempted on the test-
structures, but difficulties in imaging the edge of a planar device made this an ineffective method. 
 
Figure 7.4.  Photograph of a 200 µm (nominal) capillary containing a mesophase sample mounted on LS-CAT 
beamline 21-ID-D at the Advanced Photon Source at Argonne National Laboratory.   
7.3  Results and Discussion 
7.3.1  Development of Small Angle X-ray Analysis Capabilities at LS-CAT with High Resolution 
Sample Visualization Capabilities 
While small angle X-ray analysis setups are common at synchrotron sources, they typically lack the 
ability to clearly visualize the sample.  In developing microfluidic platforms to study the phase behavior of 
mesophase systems it is critical to be able to target specific microfluidic wells for analysis.  The 
experimental setup at LS-CAT at the Advanced Photon Source is designed for high quality 
macromolecular crystallography.
66
  To this end it employs high resolution sample visualization along the 
same axis as the X-ray beam coupled with precise sample targeting strategies.  A collaboration with LS-
CAT, headed by Dr. Elena Kondrashkina was established to enable the development and testing of 
microfluidic devices to study phase behavior and to establish and expand the capabilities of the LS-CAT 
setup for potentially new and exciting areas of research.    
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Examples of the visualization capabilities of the experimental setup at LS-CAT are shown in Figure 
7.5.  These optical micrographs clearly visualize not only the location of the microfluidic chip, but also the 
targeting area of the 20 µm X-ray beam used in these experiments (Figure 7.5a), and changes in the 
sample as a result of exposure to the X-ray beam (Figure 7.5b).  This level of visualization is critical for 
the use of in situ analysis in highly integrated microfluidic devices in order to clearly identify the target 
area of interest. 
 
Figure 7.5.  Optical micrographs demonstrating the visualization capabilities of the on-axis camera at the LS-
CAT beamline 21-ID-D.  (a) A microfluidic chip for phase diagram determination.  Targeting for the X-ray beam 
can be seen by the red cross-hairs indicating that a sample in the side chamber of a mixer is to be sampled.  (b) 
A series of small circles within a microfluidic mesophase sample resulting from multiple exposures to the beam 
are highlighted, providing visual evidence for radiation damage.   
7.3.2  Proof-of-Concept Experiments: Signal Intensity as a Function of Sample Thickness 
7.3.2.1  Phase Identification and Lattice Parameter Determination 
Small angle X-ray diffraction analysis of the 50/50 (w/w) monoolein/water samples prepared in 
capillaries confirmed the presence of a Pn3m cubic phase.  Analysis of capillary samples prepared with a 
monoolein/water mixture of unknown composition resulted in the formation of either an Ia3d cubic phase 
or a Lα lamellar phase.  Identification of the various phases was done based on the location of the 
observed diffraction rings.  Lamellar phases are characterized by a single strong diffraction signal while 
cubic phases display two main diffraction peaks as well as other smaller peaks at higher values of q-
spacing (Figure 7.6).   
The location of the various peaks is defined by Bragg's Law where λ is the wavelength of the incident 
and diffracted radiation, θ corresponds to the diffraction angle, and d is the interplanar spacing for a family 
of parallel planes in the crystal lattice. 
2 sind            (7-1) 
In crystallography the orientation of a particular set of planes is described via Miller indices (hkl) and the 
interplanar spacing is related to the unit cell dimensions (lattice parameter): The d-spacing of a particular 
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phase corresponds to the lattice parameter a based on the indices (hkl) of the observed peaks.  For a 
lamellar phase d = a, while for a cubic phase: 
      
      
      
Figure 7.6.  Small angle diffraction images collected in 200 µm (nominal thickness) glass capillaries.  The 
diffraction image and the resultant diffractograms are shown for a (a) Pn3m cubic phase, (b) an Ia3d cubic 
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           (7-5) 
For small angle diffraction the approximation θ = sin(θ) can be made.  Using this approximation in 





             (7-6) 
For a Pn3m cubic phase the two main peaks in the diffraction pattern correspond to the (011) and (111) 
planes.  For an Ia3d cubic phase the main peaks correspond to the (211) and (220) planes.
70,71
  Thus 
knowing the indices of these peaks, a comparison of the relative spacing between the two main peak 
locations can be used to identify the two phases.   
2 2 2
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For the Pn3m phase, this ratio corresponds to 3 1.224
2




However, the values of 2θ corresponding to the location of the observed diffraction rings varies as a 
function of wavelength.  Therefore it is more common to report diffractograms in terms of q-spacing, 







           (7-8) 
7.3.2.2 The Effects of Signal vs. Sample Thickness in Capillaries 
To first examine the feasibility of analyzing thin microfluidic samples, an analysis of the observed 
signal intensity from the main diffraction peak of various mesophases as a function of sample thickness 
was performed using traditional capillary mounted samples.  Signal was clearly observable over the range 
of sample thicknesses considered, and trends in both the signal intensity as a function of thickness and 
as a function of phase identity were observed.  The lamellar Lα and the cubic Ia3d phases showed 
significantly higher intensity for the same sample thickness than did samples containing the cubic Pn3m 
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phase (Figure 7.7a).  It is possible that this difference could be negated by considering the total area of all 
peaks in the spectrum, though this analysis was not performed.   
 
Figure 7.7.  Plots of normalized intensity as a function of sample thickness for the diffraction of various 
mesophases prepared in capillaries.  Two exposures of the mesophase were taken of the same location for 
each sample to investigate the effects of the X-ray beam on the sample, designated "1
st
 shot" and "2
nd
 shot."  
(a) A comparison of data for all three phases.  (b) Pn3m cubic phase only.  (c) Ia3d cubic phase only.  (d) Lα 
lamellar phase only.  Linear curve fits are shown in plots (b-d) for the individual phases for each shot.   
7.3.2.3 The Impact of Radiation on Mesophase Samples in Capillaries 
To investigate the effect of radiation on the samples, a comparison was made between the observed 
peaks resulting from two frames taken at the same location in quick succession.  Both a slight decrease 
in intensity and a shift in the peak location were observed.  The decrease in peak intensity can be clearly 
seen in Figure 7.7, both from the raw data and from the plotted trendlines.  However, the total area under 
 161 
the peak was estimated to remain the same by summing the intensities over a given range.  These 
observations correspond to broadening of the observed diffraction peaks and could be evidence of 
radiation damage.
72
  The shift in peak location translates to a slight decrease in the lattice parameter of 
the various phases (0.1 Å – 0.3 Å).  These observations suggest that sample heating occurs as a result of 
X-ray exposure as the lattice parameter is known to decrease upon heating.
33
  
7.3.2.4 The Effects of Signal vs. Sample Thickness in Test Structures 
While experiments in traditional glass capillaries provided a useful baseline with which measurements 
could be compared, the length scale of microfluidics is an order of magnitude smaller than typical X-ray 
capillaries.  Additionally, the high silicon content in the walls of glass capillaries might be expected to 
contribute significantly to signal attenuation for very thin samples.  In order to circumvent these 
challenges, a test structure was fabricated using thin sheets of COC similar to what would be present in 
an actual microfluidic device.  Adhesive spacers of varying thicknesses were then used to define wells in 
the range of 25 µm to 100 µm (Figure 7.3b – inset 1).   
 
Figure 7.8.  Plot of (a) baseline-normalized intensity and (b) exposure time-normalized intensity as a function of 
sample thickness and different exposure times for the diffraction of a Pn3m cubic phase in proof-of-concept test 
structures.  
For these test-structures, reasonable signal was observed over the range of sample thicknesses and 
exposure times considered (Figure 7.8a).  However, there was not an easily distinguishable trend in the 
data.  Excepting the data points at 100 µm, the data could be fit reasonably well with an exponential 
curve.  However, all of the data taken at 100 µm clearly shows a deviation from the trend.  It is possible 
that this deviation comes from variations in the physical dimensions (other than thickness) of the device.  
Because the samples were rotated 360° during the course of data collection, a larger device could 
attenuate the signal more and artificially lower the observed signal.   
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Another observation from the data is that the signal intensity varies linearly with exposure time 
(Figure 7.8b).  Thus it is possible to normalize the observed signal intensity by the exposure time.  
However, the effects of exposure to the X-ray beam as a function of sample thickness are not known.  
While it is not clear at this point where or how experimental variation has affected these results, these 
experiments have validated the potential for collecting small angle X-ray diffraction data on mesophases 
at microfluidic path lengths.  At the shortest path length of 25 µm, the observed signal was significantly 
above the baseline over a range of exposure times. 
7.3.3  Design of Microfluidic Chips for Phase Diagram Determination 
In designing microfluidic chips to explore aqueous/lipid phase behavior, the simplest system to 
consider would be that of a binary mixture.  To map out a phase diagram for a two component system it is 
merely necessary to vary the concentration of the two species across an integrated microfluidic chip 
based on the volume of the various microfluidic compartments (Figure 7.9).  The arrangement of 
compartments on this chip was designed around the lipid mixing unit described in Chapter 4.  The 
preparation of a large number of compositional samples in parallel would enhance the rate at which these 
experiments could be performed.  In order to map out both the effects of concentration and temperature it 
would be necessary to either use a temperature-controlled sample holder, or to integrate heating/cooling 
elements onto the chip itself.   
 
Figure 7.9.  Schematic depiction of the fluid layer for a microfluidic array chip for the screening of a binary 
lipid/water mixture.  Lipid and water are filled into the device through the specified lines.  For systems with either 
a low water or lipid content and injection of the contents of the small outer chamber would precede mixing within 
the three main chambers.    
Exploring the effect of a particular contaminant would most likely be performed at a particular lipid 
content or hydration level.  For instance, the chip shown in Figure 7.10 was designed to test the effect of 
a particular contaminant in a mesophase that is 50/50 (v/v) aqueous phase/lipid.  This chip takes 
advantage of not only the parallel processing capabilities of microfluidics, but also the ability to generate 
solutions of known concentration on-chip.  During filling, this chip is designed first to flow lipid into the 
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center chambers of each mixing unit.  A diluent solution such as water or buffer is then metered into the 
circular blue wells.  A valve located over each of these diluent chambers is then used to meter this 
volumetrically defined quantity of liquid into the side chamber of the mixer.  Following a rinsing step, the 
side chambers are then filled the rest of the way with a solution of concentrated additive.  The previously 
metered diluent thus creates a variation in the concentration of the additive from the stock solution 
(100%), to one half of this concentration.  The design could be altered or expanded to change this range.   
 
Figure 7.10.  Schematic depiction of the fluid layer for a microfluidic array chip for the screening of contaminant 
effects on a 50/50 (v/v) mixture of lipid and aqueous phase.  Lipid is metered into the center chambers.  The 
aqueous phase is metered first by the filling of the blue line with water or buffer.  Actuation of valves over the 
circular chambers depicted meters a specified volume of water or buffer into the side chamber.  After rinsing of 
this line, the side chambers are filled with a concentrated solution of the additive of interest.  The buffer metered 
into the side chamber previously serves to dilute the concentrated solution by the amount indicated.   
7.3.4  Validation of Platform by In Situ Analysis of Phase Behavior 
While proof-of-concept experiments with test structures were able to demonstrate the potential for 
data collection in a microfluidic device, it was important to extend this work to an actual device.  For 
simplicity, and to allow for direct comparison with a known sample, various mesophases were prepared 
using a traditional syringe mixer.  The mesophases were loaded into both traditional capillaries and a 
series of X-ray transparent PDMS/COC microfluidic devices (Figure 7.5).  Both of these samples were 
stored at -12°C, both to eliminate metastable phase behavior, and for improved stability during storage.   
One of the concerns related to preparing and analyzing mesophase samples on-chip is the potential 
for evaporation and solvent loss.  As was discussed in Chapter 5, the PDMS/COC hybrid device 
architecture provides significantly lower evaporative losses than traditional PDMS devices.  However, the 
loss of even small amounts of water could produce a significant change in the observed phase behavior 
of a sample, particularly for water poor samples.  To test this, a sample containing a 0.033 (w/w) mixture 
of monoolein and β-octylglucoside combined in a 90/10 (w/w) ratio with 1.3M KH2PO4 pH 5.5 was 
prepared.  Because of the low water content, this mixture was expected to form a Lα lamellar phase.  
Analysis of small angle diffraction from both traditional capillaries and samples loaded into PDMS/COC 
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microfluidic devices confirms the lamellar nature of this phase (Figure 7.11).  The average lattice 
parameter calculated for both the capillary samples and measurements taken on-chip was 37.5 Å.  
Although the lattice parameter of lamellar phases can be moderately insensitive to changes in hydration, 
these values validate the capability of this PDMS/COC X-ray transparent device architecture to deal with 
mesophase samples with a very low water content.   
      
      
Figure 7.11.  Small angle diffraction images and diffractograms of a sample containing a 0.033 (w/w) mixture of 
monoolein and β-octylglucoside combined in a 90/10 (w/w) ratio with 1.3M KH2PO4 pH 5.5 collected in (a) a 
glass X-ray capillary and (b) a PDMS/COC X-ray transparent microfluidic device. 
While the use of a lamellar phase allowed for compatibility testing of the PDMS/COC device with low 
water content samples, the diffraction from lamellar phases is relatively strong and it would be interesting 
to also observe a cubic phase on chip.  To accomplish this, a hydrating solution of 1.3M KH2PO4 pH 5.5 
was injected into a chip that was originally loaded with a lamellar phase and allowed to equilibrate.  As 
discussed in Chapter 2, the use of a concentrated salt solution helps to stabilize the formation of a cubic 
phase, and the injection of this solution enabled the recovery of a cubic phase from the initially lamellar 
sample.   
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Figure 7.12.  (a-b) Small angle diffraction images from different points in a hydrated crystalline cubic phase in a 
PDMS/COC X-ray transparent microfluidic device.  Images correspond to traces (4) and (7).  (c) Diffractograms 
from various different points in the hydrated crystalline cubic phase.  Depending on location, different diffraction 
planes (hkl) for the same cubic phase are observed.  Vertical lines serve as a guide for the eye, defining the 
various peaks and their corresponding (hkl) values.  Traces (1 – 6) were taken with a 5s exposure, (7 – 9) with 
a 1s exposure. 
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One particularly interesting aspect of the observed cubic phase was that instead of obtaining a 
powder diffraction ring, single crystal diffraction spots were seen (Figure 7.12a-b).  An analysis of 
diffraction data collected at different points throughout the device displayed both a peak corresponding to 
an unknown phase at low values of 2θ, but also different (hkl) reflections corresponding the same Pn3m 
cubic phase (Figure 7.12c).  In this sense, collecting data at multiple points in a crystalline mesophase 
could be treated similarly to collecting "single-shot" data on multiple crystals as in Chapters 5 and 6.  
However, rotation of the sample during data collection would help to restore the observed powder 
diffraction patterns and could assist in unambiguously identifying phases. 
7.3.4.1 The Effect of the X-ray Beam on Microfluidic Mesophase Samples 
In Section 7.3.2.1 the X-ray beam was shown to have a significant effect on capillary-mounted 
samples.  Another aspect of in situ X-ray analysis of mesophase behavior in microfluidic chips is the 
potential for radiation damage and/or local heating to have an adverse effect on the very thin sample.  As 
seen in Figure 7.5b, the X-ray beam produced a visual change in the sample, however it was unclear 
from these observations how the visual change in the sample corresponded to the actual identity and 
lattice parameter of the mesophase.   
 
Figure 7.13.  Plot (offset) of diffractograms for multiple exposures of the same location on a microfluidic device, 
labeled (1) to (7).  From the initial diffractogram (1), continued exposure to the X-ray beam results in both the 
broadening of the diffraction signal and also a shift to higher values of q.  However, if the sample is allowed to 
cool, the location of the peak upon subsequent testing shifts back to lower values of q (curve 7).  A vertical line 
is drawn as a guide to the eye for the locations of the various peaks in comparison to the initial diffractogram. 
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To investigate the effects of prolonged exposure to the X-ray beam on the sample a series of frames 
were taken in the same location (Figure 7.13) with approximately 30 s intervals except frames #6 and #7 
that were taken with a 7 minute interval..  Starting from the initial image (1), continued exposure to the X-
ray beam produces two effects: (i) a broadening of the diffraction peak and (ii) a shift in the peak location 
to higher values of q.  As discussed in Section 7.3.2.1, peak broadening has been reported in the 
literature as evidence for radiation damage in mesophase samples,
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 although these effects appear to be 
somewhat reversible.  The shift in the peak location  indicates a decrease in the lattice parameter of the 
phase, and could easily be the result of heating due to the X-ray beam.  The idea of local heating is 
supported by the reversibility of this peak shift if the sample is allowed to cool for a time between 
exposures (6) and (7). 
  The sensitivity of these very thin microfluidic mesophase samples is a potential challenge for in situ 
analysis, particularly because without a standard for comparison, there is no way of knowing if the first 
observation is actually an accurate representation of the original phase.  However, a straightforward 
method for decreasing the sensitivity of these samples would be to simply increase the height of the 
device features.   
7.4  Conclusions 
In summary, the X-ray transparent microfluidic device architecture applied in Chapters 5 and 6 for 
protein crystallography has been validated for use in small angle X-ray diffraction studies for the 
determination of the phase behavior of aqueous/lipid systems.  Studies of the observed signal intensity 
from samples of varying thickness validated the possibility of in situ data collection from microfluidic 
chambers as thin as 10 µm, though several issues related to X-ray irradiation were identified and should 
be studied further. 
Understanding these mesophase systems is critical for the development of a rational understanding 
of the in meso crystallization method, however studies of phase behavior are tremendously sample 
intensive.  The integrated microfluidic platforms discussed here have the potential to streamline the 
preparation and analysis of samples by utilizing nanoliter-scale preparation of multiple samples in parallel 
followed by in situ analysis of the resultant phase behavior.   
7.5  Acknowledgements 
This work was funded by NIH (R01 GM086727) and a NIH Kirschstein Predoctoral Fellowship from 
the National Institute of Biomedical Imaging and Bioengineering (F31 EB008330).  Use of the Advanced 
Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic 
Energy Sciences, under Contract No. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was 
supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-
Corridor for the support of this research program (Grant 085P1000817). 
 168 
The collaborative efforts of the Life Sciences Collaborative Access Team (LS-CAT) at the Advanced 
Photon Source at Argonne National Laboratory, and in particular Dr. Elena Kondrashkina helped to make 
this work possible.  Also, Daria Khvostichenko was invaluable in her assistance in the study of lipidic 
phase behavior and Sudipto Guha was invaluable in his assistance with the development and testing of 
X-ray transparent microfluidic chips. 
7.6  References 
(1) Bonacucina, G.; Palmieri, G. F.; Craig, D. Q. M. J Pharm Sci-Us 2005, 94, 2452. 
(2) Mezzenga, R.; Meyer, C.; Servais, C.; Romoscanu, A. I.; Sagalowicz, L.; Hayward, R. C. 
Langmuir 2005, 21, 3322. 
(3) Caffrey, M. Ann Rev Biophys 2009, 38, 29. 
(4) Perry, S. L.; Roberts, G. W.; Tice, J. D.; Gennis, R. B.; Kenis, P. J. A. Cryst Growth Des 2009, 9, 
2566. 
(5) Nollert, P. Methods 2004, 34, 348. 
(6) Persson, G.; Edlund, H.; Amenitsch, H.; Laggner, P.; Lindblom, G. Langmuir 2003, 19, 5813. 
(7) Persson, G.; Edlund, H.; Lindblom, G. European Journal of Biochemistry 2003, 270, 56. 
(8) Sparr, E.; Wadsten, P.; Kocherbitov, V.; Engstrom, S. Bba-Biomembranes 2004, 1665, 156. 
(9) Vargas, R.; Mateu, L.; Romero, A. Chem Phys Lipids 2004, 127, 103. 
(10) Takahashi, H.; Matsuo, A.; Hatta, I. Phys Chem Chem Phys 2002, 4, 2365. 
(11) Takahashi, H.; Matsuo, A.; Hatta, I. Mol Cryst Liq Cryst 2000, 347, 475. 
(12) Awad, T. S.; Okamoto, Y.; Masum, S. M.; Yamazaki, M. Langmuir 2005, 21, 11556. 
(13) Caboi, F.; Nylander, T.; Razumas, V.; Talaikyte, Z.; Monduzzi, M.; Larsson, K. Langmuir 1997, 
13, 5476. 
(14) Engblom, J.; Miezis, Y.; Nylander, T.; Razumas, V.; Larsson, K. In Surface and Colloid Science; 
Springer: Berlin / Heidelberg, 2000; Vol. 116, p 9. 
(15) Engström, S.; Alfons, K.; Rasmusson, M.; Ljusberg-Wahren, H. Progress in Colloid and Polymer 
Science 1998, 108, 93. 
(16) Li, S. J.; Yamashita, Y.; Yamazaki, M. Biophys J 2001, 81, 983. 
(17) Masum, S. M.; Li, S. J.; Awad, T. S.; Yamazaki, M. Langmuir 2005, 21, 5290. 
(18) Murgia, S.; Lampis, S.; Angius, R.; Berti, D.; Monduzzi, M. The Journal of Physical Chemistry B 
2009, 113, 9205. 
(19) Okamoto, Y.; Masum, S. M.; Miyazawa, H.; Yamazaki, M. Langmuir 2008, 24, 3400. 
(20) Razumas, V.; Larsson, K.; Miezis, Y.; Nylander, T. J Phys Chem-Us 1996, 100, 11766. 
(21) Razumas, V.; Talaikyte, Z.; Barauskas, J.; Larsson, K.; Miezis, Y.; Nylander, T. Chem Phys Lipids 
1996, 84, 123. 
(22) Caffrey, M. Biochemistry-Us 1987, 26, 6349. 
(23) Cherezov, V.; Caffrey, M. J Appl Crystallogr 2005, 38, 398. 
(24) Caffrey, M.; Cherezov, V. 2009, 4, 706. 
(25) Cheng, A. H.; Hummel, B.; Qiu, H.; Caffrey, M. Chem Phys Lipids 1998, 95, 11. 
(26) Misquitta, Y.; Caffrey, M. Biophys J 2003, 85, 3084. 
(27) Ai, X.; Caffrey, M. Biophys J 2000, 79, 394. 
(28) Cherezov, V.; Fersi, H.; Caffrey, M. Biophys J 2001, 81, 225. 
(29) Boyle-Roden, E.; Hoefer, N.; Dey, K. K.; Grandinetti, P. J.; Caffrey, M. J Magn Reson 2007, 189, 
13. 
 169 
(30) Cherezov, V.; Clogston, J.; Misquitta, Y.; Abdel-Gawad, W.; Caffrey, M. Biophys J 2002, 83, 
3393. 
(31) Liu, W.; Caffrey, M. Journal of Structural Biology 2005, 150, 23. 
(32) Qiu, H.; Caffrey, M. Biomaterials 2000, 21, 223. 
(33) Briggs, J.; Chung, H.; Caffrey, M. J Phys Ii 1996, 6, 723. 
(34) Briggs, J.; Caffrey, M. Biophys J 1994, 66, 573. 
(35) Misquitta, Y.; Caffrey, M. Biophys J 2001, 81, 1047. 
(36) Misquitta, Y.; Cherezov, V.; Havas, F.; Patterson, S.; Mohan, J. M.; Wells, A. J.; Hart, D. J.; 
Caffrey, M. Journal of Structural Biology 2004, 148, 169. 
(37) Misquitta, L. V.; Misquitta, Y.; Cherezov, V.; Slattery, O.; Mohan, J. M.; Hart, D.; Zhalnina, M.; 
Cramer, W. A.; Caffrey, M. Structure 2004, 12, 2113. 
(38) Caffrey, M.; Cheng, A. Current Opinion in Structural Biology 1995, 5, 548. 
(39) Caffrey, M. Current Opinion in Structural Biology 2000, 10, 486. 
(40) Caffrey, M. Journal of Structural Biology 2003, 142, 108. 
(41) Caffrey, M. Cryst Growth Des 2008, 8, 4244. 
(42) Grabe, M.; Neu, J.; Oster, G.; Nollert, P. Biophys J 2003, 84, 854. 
(43) Cherezov, V.; Caffrey, M. Faraday Discussions 2007, 136, 195. 
(44) Nollert, P.; Qiu, H.; Caffrey, M.; Rosenbusch, J. P.; Landau, E. M. Febs Lett 2001, 504, 179. 
(45) Sennoga, C.; Heron, A.; Seddon, J. M.; Templer, R. H.; Hankamer, B. Acta Crystallogr D 2003, 
59, 239. 
(46) Qutub, Y.; Reviakine, I.; Maxwell, C.; Navarro, J.; Landau, E. M.; Vekilov, P. G. J Mol Biol 2004, 
343, 1243. 
(47) Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. 
S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. Science 2007, 318, 1258. 
(48) Kors, C. A.; Wallace, E.; Davies, D. R.; Li, L.; Laible, P. D.; Nollert, P. Acta Crystallographica 
Section D 2009, 65, 1062. 
(49) Saturni, L.; Rustichelli, F.; Di Gregorio, G. M.; Cordone, L.; Mariani, P. Phys Rev E 2001, 6404. 
(50) Bitan-Cherbakovsky, L.; Yuli-Amar, I.; Aserin, A.; Garti, N. Langmuir 2009. 
(51) Clogston, J.; Caffrey, M. J Control Release 2005, 107, 97. 
(52) Yaghmur, A.; Kriechbaum, M.; Amenitsch, H.; Steinhart, M.; Laggner, P.; Rappolt, M. Langmuir 
2010, 26, 1177. 
(53) Hunte, C.; Richers, S. Current Opinion in Structural Biology 2008, 18, 406. 
(54) Chiu, M. L.; Nollert, P.; Loewen, M. C.; Belrhali, H.; Pebay-Peyroula, E.; Rosenbusch, J. P.; 
Landau, E. M. Acta Crystallogr D 2000, 56, 781. 
(55) Johansson, L. C.; Wöhri, A. B.; Katona, G.; Engström, S.; Neutze, R. Current Opinion in 
Structural Biology 2009, 19, 372. 
(56) Liu, W.; Hanson, M. A.; Stevens, R. C.; Cherezov, V. Biophys J 2010, 98, 1539. 
(57) Nollert, P.; Royant, A.; Pebay-Peyroula, E.; Landau, E. M. Febs Lett 1999, 457, 205. 
(58) Nollert, P.; Navarro, J.; Landau, E. M. Method Enzymol 2002, 343, 183. 
(59) Rouhani, S.; Facciotti, M. T.; Woodcock, G.; Cheung, V.; Cunningham, C.; Nguyen, D.; Rad, B.; 
Lunde, C. S.; Glaeser, R. M. Biopolymers 2002, 66, 300. 
(60) Rummel, G.; Hardmeyer, A.; Widmer, C.; Chiu, M. L.; Nollert, P.; Locher, K. P.; Pedruzzi, I.; 
Landau, E. M.; Rosenbusch, J. P. Journal of Structural Biology 1998, 121, 82. 
(61) Wadsten, P.; Wo?hri, A. B.; Snijder, A.; Katona, G.; Gardiner, A. T.; Cogdell, R. J.; Neutze, R.; 
Engström, S. J Mol Biol 2006, 364, 44. 
(62) Wöhri, A. B.; Johansson, L. C.; Wadsten-Hindrichsen, P.; Wahlgren, W. Y.; Fischer, G.; 
Horsefield, R.; Katona, G.; Nyblom, M.; Öberg, F.; Young, G.; Cogdell, R. J.; Fraser, N. J.; 
Engström, S.; Neutze, R. Structure 2008, 16, 1003. 
 170 
(63) Kissick, D. J.; Gualtieri, E. J.; Simpson, G. J.; Cherezov, V. Anal Chem 2009, 82, 491. 
(64) Katona, G.; Andreasson, U.; Landau, E. M.; Andreasson, L.-E.; Neutze, R. J Mol Biol 2003, 331, 
681. 
(65) Porcar, L.; Hamilton, W. A.; Butler, P. D. Langmuir 2003, 19, 10779. 
(66) Life Sciences Collaborative Access Team (LS-CAT). http://ls-cat.org/  
(67) Huang, T. C.; Toraya, H.; Blanton, T. N.; Wu, Y. J Appl Crystallogr 1993, 26, 180. 
(68) Hammersley, A. P. FIT2D: An Introduction and Overview, 1997. 
(69) 7.6.0.234 ed.; Mathworks Inc.: Natick, MA, 2008. 
(70) Larsson, K. Nature 1983, 304, 664. 
(71) International Tables for Crystallography. http://it.iucr.org/ (August 4, 2010). 




Chapter 8  
Summary of Accomplishments and Future 
Directions 
8.1  Introduction 
The development of microfluidic platforms for a variety of applications including protein crystallization 
has increased dramatically in the last decade.  These platforms take advantage of not only decreases in 
volume at the microscale, but also enhancements in the level of control over fluid handling, 
concentrations, and local gradients.  However, the efficacy of these platforms is limited without the 
potential for performing analysis on-chip.  The work presented in the previous chapters represents 
significant advancements in the field of microfluidics for protein crystallization and in situ X-ray analysis.  
Challenges associated with the mixing of highly viscous and non-Newtonian fluids were overcome, and 
an X-ray transparent device architecture was developed which enabled both protein crystallography and 
small angle X-ray studies of lipidic mesophases. 
8.2  Microfluidic Platforms for Protein Crystallization 
8.2.1  Microfluidic Platforms for the Crystallization of Solubilized Proteins 
During the course of developing an X-ray transparent device architecture for protein crystallography, 
a series of array chips utilizing actuate-to-open valves were designed.  These chips have tremendous 
potential for the screening and optimization of crystallization conditions for both soluble proteins and 
detergent solubilized membrane proteins, and should be applied in structural biology efforts on novel 
protein targets.  Collaborative efforts with the Gennis and Nair labs at the University of Illinois for the 
crystallization of various heme-copper oxidases and other novel proteins using these X-ray transparent 
chips are ongoing at this time (Nov 2010). 
The various 24- and 96-well array chips reported in Chapters 5 and 6 were fabricated for various 
different applications and the total number of wells per chip in these designs did not necessarily reflect 
the actual number of crystallization conditions which were screened per device.  For crystallography 
experiments where the goal is to analyze a large number of crystals on chip a large array of identical 
wells is desirable.  However, for crystallization screening efforts a chip design such as the one reported in 
Chapter 5 in which the volumetric ratios of protein and precipitant solution are varied for a given condition 
are more useful.  A powerful aspect of microfluidics is the ease whereby modifications can be made to an 
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existing design to enhance its efficacy or tailor it to a specific application. For instance, using microfluidics 
one has the ability to generate solutions of a desired composition on chip.  For the optimization of 
screening conditions, the automated generation of a concentration grid would improve the efficiency 
associated with the use of a microfluidic platform.  For instance, coupling a gradient-tree
1,2
 with an array 
chip could have significant utility for optimization trials.   
8.2.2  Microfluidic Platforms for the In Meso Crystallization of Membrane Proteins 
The development of microfluidic platforms capable of preparing in meso crystallization trials was a 
significant advancement.  However, in order to further advance this technology to the stage where it could 
be used for crystallization trials with novel proteins it is necessary to optimize the design in a scaled out 
array chip format.   
In addition to these efforts, the effect of a microfluidic geometry on a protein crystallization trial has 
not been fully investigated.  It has been suggested in the literature that the geometry of the interaction 
between a mesophase bolus and the precipitant solution can have a significant impact on the 
crystallization trial,
3
 but this hypothesis remains to be tested.  The effects of geometry, however, could be 
particularly significant in very thin microfluidic chambers where relatively long lateral diffusion distances 
exist.  This chamber geometry should be optimized for the growth of a few large crystals, rather than 
potentially favoring the nucleation of a large number of small crystals due to long diffusion distances. 
The ability to prepare a large number of samples with varying compositions also has tremendous 
potential to open up new variables for crystallization screening efforts.  The nanoliter preparative scale of 
these crystallization platforms can easily be applied to the preparation of in meso crystallization trials with 
varying concentrations of protein and lipid, or combinations of different lipids.  While the role of the lipid 
during in meso crystallization has not been explored extensively, studies using different 
monoacylglycerols for the formation of the lipidic mesophase for crystallization have clearly demonstrated 
the significance of lipidic composition as a variable.
4-8
 
The preparation of lipidic mesophases on-chip can also be utilized for mechanistic studies of how in 
meso crystallization occurs.  For instance, in meso crystallization is thought to involve a local phase 
change from a cubic to a lamellar phase where crystal nucleation takes place.
3,9-16
  Crystal growth is then 
thought to occur via a lamellar conduit connecting the bulk cubic phase and the growing 
crystal.
3,5,8,10,11,14,16-19
  Microfluidic mixers could be used to prepare two different mesophase samples, one 
containing protein and the other without.  Bringing these two mesophases into contact, fluorescence 
microscopy could then be used to track the gradient diffusion of the embedded membrane proteins over 
time (Figure 8.1).  Coupling this knowledge with information about the identity and curvature of the 
various mesophases could then be used to facilitate the rational design of in meso crystallization 
experiments.  This work is continuing in the group through the efforts of Daria Khvostichenko. 
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Figure 8.1.  Schematic depiction of two coupled lipidic mixers for use in studying the diffusion of reconstituted 
membrane proteins between various lipidic mesophases.  Figure contributed by Daria Khvostichenko. 
8.3  X-ray Transparent Microfluidic Devices for In Situ Protein Crystallography 
While the ability to grow protein crystals in a microfluidic environment has inherent benefits, coupling 
of in situ analysis methods with microfluidic platforms has the potential to side-step many challenges 
associated with crystal handling and damage.  However, the integration of these devices with current X-
ray beamline setups is still a challenge.  Depending upon the experiment it will be necessary to tailor not 
only the architecture and geometry of the microfluidic device, but also the method for mounting this 
device for in situ analysis and the surrounding experimental setup.   
8.3.1  Microfluidic Platforms for Crystal Quality Screening and Structure Determination 
The results presented in Chapter 5 demonstrated a variety of device geometries for protein 
crystallization and validated a series of in situ data collection strategies ranging from the analysis of a few 
frames of diffraction data to extract information on crystal quality to the collection of an entire dataset from 
a single crystal under cryogenic conditions or by combining diffraction data from numerous crystals.  
However, these experiments were performed using model proteins such as lysozyme, thaumatin, and 
ribonuclease A.  The challenge remains to apply these methods to both novel soluble and membrane 
protein targets to truly evaluate the quality of diffraction data which can be collected from a more 
challenging system. 
8.3.2  Microfluidic Platforms for Laue Crystallography 
The potential applications for microfluidic crystallization platforms with in situ analysis capabilities in 
the field of Laue crystallography and time resolved structural studies are tremendous and could have a 
significant impact on the field.  The work presented in Chapter 6 validated the microfluidic device 
architecture for performing Laue crystallography and demonstrated several data collection strategies for 
static structure determination.  However, the next logical step in this area is to extend this work to include 
time resolved and dynamic crystallography studies.   
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A variety of studies in the field of time resolved and dynamic crystallography can be envisioned, 
including photo-activated structural studies, dynamic studies of the effects of an environmental change 
such as pH, temperature, or an applied electric field, and also ligand binding studies.  For each of these 
studies developments in the device architecture and/or capabilities can be made alongside structural 
biology efforts.  For instance, during time resolved studies where laser light is used to trigger a structural 
change, a method for preventing the scattered light from the triggering of one crystal from affecting other 
crystals within the device would be critical for the success of the experiment.  Ligand binding or pH 
studies would require the validation of a method for controllably introducing a chemical species to the 
various crystals and synchronizing the timing of fluid handling steps on the microfluidic chip with X-ray 
data collection.  Several efforts in this area are ongoing in collaboration with the BioCARS team at the 
Advanced Photon Source at Argonne National Laboratory and scientists from the University of Chicago. 
8.4  Microfluidic Platforms for the Preparation and In Situ Analysis of 
Aqueous/Lipid Phase Behavior 
As in crystallization screening experiments where microfluidics provides the benefit of a large number 
of parallel trials while using a small volume of material and efficient preparative methods, the examination 
of the phase behavior of aqueous/lipid mesophases is very sample intensive.  Scaled-out microfluidic 
chips coupled with in situ small angle X-ray analysis capabilities have tremendous potential to broaden 
the range of conditions which can be screened and the rate at which data can be collected.  However, 
further validation of these platforms is still needed. 
A logical first test of an array chip to study the phase behavior of mesophase systems would be the 
reproduction of an existing dataset.  In order to accomplish this goal, a variety of challenges need to be 
overcome, including optimization of device design and operation, and further characterization of the 
effects of radiation damage and heating due to exposure the X-ray beam.  Having achieved this 
milestone, subsequent experiments can be designed to either characterize new lipidic systems, or to try 
and understand the effect of additives and/or other contaminants on the phase behavior of an existing 
system.  On the one hand, study of a novel lipid could enable its use in future in meso crystallization 
trials.  On the other, an improved understanding of the effects of various contaminants could bring a very 
powerful understanding as to the mechanism behind in meso crystallization, and could be used to 
rationally design future crystallization trials. 
8.5  Conclusions 
In summary, the work presented here is a significant first step in a project which has tremendous 
potential for impacting the field of protein crystallography.  The development of microfluidic platforms for 
in meso membrane protein crystallization that allow for subsequent in situ analysis has overcome several 
bottlenecks for the study of these systems in microfluidic systems.  This project can continue to grow in 
many directions, taking advantage of not only the capabilities of preparing highly viscous mesophase 
samples on chip, but also a variety of strategies for on-chip crystallization and in situ analysis.  Hopefully 
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the use of these platforms in the structure determination of a novel protein target will occur in the near 
future, and their use will rapidly improve the success rates of structural biology efforts everywhere. 
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Overcoming the Challenge of Pumping Viscous 
Fluids at the Microscale
*
 
Appendix A.1  Typical Values of β for Microfluidic Channels 
Table A.2 - Table A.4 give calculated values for β for a variety of microfluidic geometries assuming a 
Young's modulus of E = 1000 MPa, a Poisson's ratio of σ = 0.5, and a value for the numerical constant  
c = 1.   
Table A.2.  Calculated values for β as a function of channel width and applied pressure assuming an initial 
channel height of h0 = 10 µm. 
  
Table A.3.  Calculated values for β as a function of channel width and applied pressure assuming an initial 
channel height of h0 = 20 µm. 
 
Table A.4.  Calculated values for β as a function of channel width and applied pressure assuming an initial 
channel height of h0 = 50 µm. 
                                                     
*
 This work has been published:  S.L. Perry, J.J.L. Higdon, and P.J.A. Kenis, Design Rules for Pumping 
and Metering of Highly Viscous Fluids, Lab on a Chip 2010 Vol. 10(22), 3112-3124. 
50 100 250 500 1000
6.89 3.4E-02 6.9E-02 1.7E-01 3.4E-01 6.9E-01
34.5 1.7E-01 3.4E-01 8.6E-01 1.7E+00 3.4E+00
68.9 3.4E-01 6.9E-01 1.7E+00 3.4E+00 6.9E+00
103 5.2E-01 1.0E+00 2.6E+00 5.2E+00 1.0E+01
138 6.9E-01 1.4E+00 3.4E+00 6.9E+00 1.4E+01
172 8.6E-01 1.7E+00 4.3E+00 8.6E+00 1.7E+01
207 1.0E+00 2.1E+00 5.2E+00 1.0E+01 2.1E+01
w  (µm)








50 100 250 500 1000
6.89 1.7E-02 3.4E-02 8.6E-02 1.7E-01 3.4E-01
34.5 8.6E-02 1.7E-01 4.3E-01 8.6E-01 1.7E+00
68.9 1.7E-01 3.4E-01 8.6E-01 1.7E+00 3.4E+00
103 2.6E-01 5.2E-01 1.3E+00 2.6E+00 5.2E+00
138 3.4E-01 6.9E-01 1.7E+00 3.4E+00 6.9E+00
172 4.3E-01 8.6E-01 2.2E+00 4.3E+00 8.6E+00
207 5.2E-01 1.0E+00 2.6E+00 5.2E+00 1.0E+01











Appendix A.2  Determination of Constants for 2nd Order Polynomial Fit for Time 
In the development of a universal relationship in Chapter 3 to relate the steady-state lag volume as a 
function of β an effective time was defined based on a 2
nd
 order polynomial scaling of the dimensionless 
diffusive time, as in Eq. (3-21).  The fit parameters A and B were obtained by matching values of the 
effective time for each value of β to the case of β = 0.001 when the lag volume parameter = 0.4 and 0.9.  
Expressions for the fit parameters A and B can be obtained from solutions to the system of two 2
nd
 order 
polynomials from Eq. (3-21) evaluated at β = 0.001 and the value of interest.  τ
*
ref refers to the value for β 
= 0.001 whereas τ
*
 refers to the value of β of interest.  The subscript (1) indicates that the time was 
evaluated for a lag time parameter Vlag/Vlagss = 0.4, while the subscript (2) indicates that the time was 
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Appendix A.3  Determination of a Graduated Mesh 
A graduated mesh was used in the numerical solution for the partial differential equation in order to 
account for the sharp changes in the slope of the function near the outlet.  To form the graduated mesh 
the change in the separation from point-to-point will be modified by a constant factor of λ such that Δxn = 
λΔxn-1.  Thus the value s of the N
th point considering an initial spacing difference of Δx0 is: 
 2 3 01 Ns x                 (A-3) 
We can also write: 
 2 3 1 0N Ns x                   (A-4) 
50 100 250 500 1000
6.89 6.9E-03 1.4E-02 3.4E-02 6.9E-02 1.4E-01
34.5 3.4E-02 6.9E-02 1.7E-01 3.4E-01 6.9E-01
68.9 6.9E-02 1.4E-01 3.4E-01 6.9E-01 1.4E+00
103 1.0E-01 2.1E-01 5.2E-01 1.0E+00 2.1E+00
138 1.4E-01 2.8E-01 6.9E-01 1.4E+00 2.8E+00
172 1.7E-01 3.4E-01 8.6E-01 1.7E+00 3.4E+00
207 2.1E-01 4.1E-01 1.0E+00 2.1E+00 4.1E+00










Subtracting Eqs. (A-3) and (A-4) gives: 
   1 01 1 Ns x              (A-5) 














         (A-6) 
Appendix A.4  Development of a Differential Equation with an Analytical Solution 
for Code Debugging 
In the course of testing the MATLAB code presented in Appendix 1F it is useful to be able to compare 
the results of the numerical solution to a partial differential equation with an exact solution.  While an 
analytical expression can be obtained for Eq. (3-17) for the case of β = 0, it is an Eigenfunction expansion 
and is inconvenient for testing purposes.  Instead it is simple to develop an expression which is bounded 
in time and which satisfies the desired boundary conditions (U = 1 at Z = 0 and U = 0 at Z = 1).   
     *1 1 expexactU Z Z Z             (A-7) 
It is then possible to force this expression to be a solution to Eq. (3-17) with β = 0 through the addition of a 
source term and a modification of the initial conditions. 











     
 
       (A-8) 
Substitution of Eq. (A-7) into Eq. (A-8) demonstrates that this expression does in fact satisfy the 
differential equation.  Evaluation of Eq. (A-8) at τ = 0 shows that U = Z2 – 2Z + 1 is an appropriate initial 
condition. 
Appendix A.5  Derivation of the Displacement of an Infinite Slab from a Point 
Pressure Source 
A detailed treatment of the theory elasticity and deformation of materials has been presented by 
Love.
1
  In Chapter 3, Eq. (3-4) describing the deformation of a channel due to pressure effects was 
developed from the theory associated with the displacement of an infinite slab resulting from a point 
pressure source.  Here the derivation of this equation is presented. 
The displacement Δh of an infinite slab resulting from a point source of pressure P located at a point 


















        (A-9) 
with 
   
2 2 2
0 0r x x y y z            (A-10) 



















         (A-12) 








           (A-13) 










            (A-14) 
While Eq. (A-14) describes the displacement as a result of a point pressure source, a distributed 
pressure source can be described as the superposition of the effects of point contributions over the area 






















            (A-16) 
For a rectangular area defined by –a ≤ x ≤ a and –b ≤ y ≤ b where xˆ  = x – x0 and ŷ = y – y0, the 
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     (A-18) 
Comparing the expression used in Eq. (3-4) with the results from Eqs. (A-16) and (A-18) shows that 
Eq. (3-4) is a general expression which can be applied to a variety of geometries.  In Eq. (3-4) the 
displacement is defined in terms of the Poisson's ratio σ, the ratio of the applied pressure to the Young's 
modulus of the material P/E, a characteristic length w, and a geometric constant c.  In the case of 
deflection over a circle the characteristic length is the radius a, and the geometric constant c = 1.  For the 
case of a rectangular geometry it is much more difficult to identify a specific the characteristic length and 
the expression for the geometric constant is more complicated.   





% This code uses the Matlab function pdepe to provide a numerical solution    
% for the nonlinear "diffusion" equation that describes pressure driven  
% laminar flow in an infinite slit that swells based on the applied  
% pressure. 
 
% The problem is coded in subfunctions PDEX1PDE, PDEX1IC, and PDEX1BC. 
% Additional subfunctions VFlowRate and Volume are coded for data analysis. 
 
% Physical parameters defined here 
Pappl = 207; % (kPa, equivalent to 30 psi) 
sigma = 0.5; % (Poisson's ratio) 
w = 100; % (µm, channel width) 
h0 = 10; % (µm, initial channel height) 
L = 1e4; % (µm, channel length) 
eta = 0.001/1000; % (kPa-s, viscosity) 
 
Vdotrigid = h0^3*w*Pappl/(12*eta*L)*1e-6; % (nL/s Vdot in a rigid channel) 
c1 = 1; % (geometric parameter, order of magnitude 1) 
beta = 1; 
 
Vdotref = L^3*Pappl/eta*1e-6; % (nL/s core variable non-dimensionalization for Vdot) 
Vref = L^3*1e-6; % (nL) core variable non-dimensionalization for volume 
 
% Define the timepoints for evaluation of the function 
tfinalND = 1; % includes a factor of gamma to make things happen at 1 
Nt = 201; % (number of time steps save for plotting) 
Ntdisplay = (Nt-1)/10; % (time interval to take for plot displays) 
 181 
dt = tfinalND/(Nt-1); 
t = (0:dt:tfinalND); 
 
% Define the number of spatial discretizations 
N = 201;  
 
% Establish x using a variable mesh 




    delta_x = x(i-1) - x(i-2); 




m = 0; % Sets the geometry as a slab 
sol = pdepe(m,@pdex1pde,@pdex1ic,@pdex1bc,x,t); 
% Extract the first solution component as u.  This is not necessary 
u = sol(:,:,1); 
u_ss = 1/beta*((x*(1-(1+beta)^4)+(1+beta)^4).^(1/4)-1); 
% u_exact = (1-x)+x.*(x-1)*exp(-tfinalND); % exact solution for debugging with beta = 
0 
 
% Evaluation of dudx 
dudx = Derivative(u,Nt,N,x); 
dudx_ss = 1/(4*beta)*(x*(1-(1+beta)^4)+(1+beta)^4).^(-3/4)*(1-(1+beta)^4); 
Error = dudx(Nt,:) - dudx_ss; 
% dudx_exact = -1 + (2*x-1)*exp(-tfinalND); % exact solution for debugging with beta = 
0 
 
% Evaluation of Vdot from dudx 
Vdot = VFlowRate(u,dudx,Nt,N,beta,Vdotrigid,Vdotref); 
% Vdot_exact = -dudx_exact; % exact solution for debugging with beta = 0 at tfinal 
% Vdot_exact_t = -(-1 + (2*x(N)-1)*exp(-t)); % exact solution for debugging with beta 
= 0 at  
 outlet 
 
% Evaluation of Total Volume Flowed 
a=1; 
Vin = Volume(Vdot,a,t); 
Vout = Volume(Vdot,N,t); 
% V_exact = -tfinalND-(2*x-1)*exp(-tfinalND)+2*x-1;% exact solution for debugging with 
beta = 0 at tfinal 
% V_exact_t = t+(2*x(N)-1)*exp(-t)-2*x(N)+1; % exact solution for debugging with beta 
= 0 at  
 outlet 
 
% Evaluation of h(z) 
h = Height(u,Nt,N,beta,h0); 
 182 
% h_exact = h0; % exact solution for debugging with beta = 0  
 
% Evaluation of the final channel volume (nL) 
Vchannel = ChannelVolume(h,x,Nt,N,w,L); 





% set the default line color order to follow a rainbow pattern starting 
% with red and ending with black 
set(0,'DefaultAxesColorOrder',[1 0 0 ; 1 0.69 0.39 ; 1 1 0 ;... 
    0 1 0 ; 0.17 0.51 0.34 ; 0.39 0.47 0.64 ; 0.08 0.17 0.55 ;... 
    0.48 0.06 0.89 ; 1 0 1 ; 0.5 0.5 0.5 ; 0 0 0]); 
 
% Plots for Debugging 
 
% figure(1) 
% subplot(3,2,1);  
% plot(x,u(1,:),'LineWidth',2); 
% title('Non-dimensionalized Pressure vs. Distance over Time') 
% xlabel('Distance'), ylabel('Pressure') 
% hold all 
% for ii=2:Ntdisplay:Nt 
%     subplot(3,2,1);  
%     plot(x,u(ii,:),'LineWidth',2); 
% end 
% subplot(3,2,1);  
% plot(x,u_exact(:),'kd'); 
% xlim([0 1]) 
% ylim([0 1]) 
% hold off 
%  
% figure(2) 
% subplot(3,2,2);  
% plot(x,dudx(1,:),'LineWidth',2); 
% title('Non-dimensionalized dP/dx vs. Distance over Time') 
% xlabel('Distance'), ylabel('dP/dx') 
% hold all 
% for ii=2:Ntdisplay:Nt 
%     subplot(3,2,2);  
%     plot(x,dudx(ii,:),'LineWidth',2); 
% end 
% subplot(3,2,2);  
% plot(x,dudx_exact(:),'kd'); 
% xlim([0 1]) 




% subplot(3,2,3);  
% plot(x,Vdot(1,:),'LineWidth',2); 
% title('Non-dimensionalized Volumetric Flowrate vs. Distance over Time') 
% xlabel('Distance'), ylabel('Volumetric Flowrate') 
% hold all 
% for ii=2:Ntdisplay:Nt 
%     subplot(3,2,3);  
%     plot(x,Vdot(ii,:),'LineWidth',2); 
% end 
% subplot(3,2,3);  
% plot(x,Vdot_exact(:),'kd'); 
% xlim([0 1]) 
% ylim([0 Vdot(2,1)*1.5]) 
% hold off 
%  
% figure(4) 
% subplot(3,2,4);  
% plot(t,Vdot(:,N),'LineWidth',2); 
% hold all 
% subplot(3,2,4);  
% plot(x,Vdot_exact_t(:),'kd'); 
% hold off 
% title('Non-dimensionalized Volumetric Flowrate at the Outlet vs. Time') 
% xlabel('Time'), ylabel('Volumetric Flowrate') 
% xlim([0 tfinalND]) 
%  
% figure(5) 
% subplot(3,2,5);  
% plot(t,V,'LineWidth',2); 
% hold all 
% subplot(3,2,5);  
% plot(x,V_exact_t(:),'kd'); 
% title('Non-dimensionalized Total Volume at the Outlet vs. Time') 
% xlabel('Time'), ylabel('Volume') 
% xlim([0 tfinalND]) 
% hold off 
%  
% figure(6) 
% subplot(3,2,6);  
% plot(x,h(1,:),'LineWidth',2); 
% title('Channel Height vs. Distance over Time') 
% xlabel('Distance'), ylabel('Channel Height (µm)') 
% hold all 
% for ii=2:Ntdisplay:Nt 
%     subplot(3,2,6);  





% xlim([0 1]) 
% hold off 
 









    subplot(3,2,1);  










title('Non-dimensionalized dP/dx at the Outlet vs. Time') 
xlabel('Time'), ylabel('dPdx') 
xlim([0 tfinalND]) 





title('Non-Dimensionalized Volumetric Flowrate vs. Distance over Time') 
xlabel('Distance'), ylabel('Volumetric Flowrate') 
hold all 
for ii=2:Ntdisplay:Nt 
    subplot(3,2,3);  
    plot(x,Vdot(ii,:),'LineWidth',2); 
end 
xlim([0 1]) 






title('Non-dimensionalized Volumetric Flowrate at the Outlet vs. Time') 
xlabel('Time'), ylabel('Volumetric Flowrate') 
xlim([0 tfinalND]) 













title('Channel Height vs. Distance over Time') 
xlabel('Distance'), ylabel('Channel Height (µm)') 
hold all 
for ii=2:Ntdisplay:Nt 
    subplot(3,2,6);  






% Exporting data to Excel 
u_out = [x' u']; 
dudx_out = [x' dudx']; 
Vdot_out = [x' Vdot']; 
Vdot_end_out = [t' Vdot(:,1) Vdot(:,N)]; 
V_end_out = [t' Vin Vout]; 
h_out = [x' h']; 
Vchannel_out = [t' Vchannel']; 
Error_out = [x' Error']; 
 
filename=['Beta-' num2str(beta) '.xls']; 
filename=['Output.xls']; 
 
warning off MATLAB:xlswrite:AddSheet 
xlswrite(filename, beta, 'Beta', 'B1'); 
 
warning off MATLAB:xlswrite:AddSheet 
xlswrite(filename, 't', 'ND Pressure', 'B1'); 
xlswrite(filename, 'd', 'ND Pressure', 'A2'); 
xlswrite(filename, t, 'ND Pressure', 'B2'); 
xlswrite(filename, u_out, 'ND Pressure', 'A3'); 
 
xlswrite(filename, 't', 'ND dPdx', 'B1'); 
xlswrite(filename, 'd', 'ND dPdx', 'A2'); 
xlswrite(filename, t, 'ND dPdx', 'B2'); 
xlswrite(filename, dudx_out, 'ND dPdx', 'A3'); 
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xlswrite(filename, 't', 'ND Vdot', 'B1'); 
xlswrite(filename, 'd', 'ND Vdot', 'A2'); 
xlswrite(filename, t, 'ND Vdot', 'B2'); 
xlswrite(filename, Vdot_out, 'ND Vdot', 'A3'); 
 
xlswrite(filename, 't', 'ND Vdot ends', 'A1'); 
xlswrite(filename, '1', 'ND Vdot ends', 'B1'); 
xlswrite(filename, 'N', 'ND Vdot ends', 'C1'); 
xlswrite(filename, Vdot_end_out, 'ND Vdot ends', 'A2'); 
 
xlswrite(filename, 't', 'ND V ends', 'A1'); 
xlswrite(filename, '1', 'ND V ends', 'B1'); 
xlswrite(filename, 'N', 'ND V ends', 'C1'); 
xlswrite(filename, V_end_out, 'ND V ends', 'A2'); 
 
xlswrite(filename, 't', 'Channel Height', 'B1'); 
xlswrite(filename, 'd', 'Channel Height', 'A2'); 
xlswrite(filename, t, 'Channel Height', 'B2'); 
xlswrite(filename, h_out, 'Channel Height', 'A3'); 
 
xlswrite(filename, 't', 'Channel Volume', 'A1'); 
xlswrite(filename, 'V', 'Channel Volume', 'B1'); 
xlswrite(filename, Vchannel_out, 'Channel Volume', 'A2'); 
 
xlswrite(filename, 'x', 'dudx Error', 'A1'); 




function [c,f,s] = pdex1pde(x,t,u,DuDx) 
 
% Physical parameters defined here 
beta = 1; 
 
c = 1; 
f = (1+beta*u)^3*DuDx; 
% s = (-2+x-x^2)*exp(-t); % source term for debugging with beta = 0 




function u0 = pdex1ic(x) 
 
% Physical parameters defined here 
beta = 1; 
 
u0 = 0; % initial condition of P = 0 
% u0 = x^2 - 2*x + 1; % initial condition for debugging with beta = 0 
% u0 = 1/beta*((x*(1-(1+beta)^4)+(1+beta)^4).^(1/4)-1); % initial condition of P = Pss 
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% ------------------------------------------------------------------------- 
 
function [pl,ql,pr,qr] = pdex1bc(xl,ul,xr,ur,t) 
 
pl = ul-1; % u = 1 at x = 0 
ql = 0; 
% pl = 0; % u = 0 at x = 0 
% ql = 1; % dudx = 0 at x = 0 
pr = ur; % u = 0 at x = 1 
qr = 0; 
   
% ------------------------------------------------------------------------- 
 
function dudx = Derivative(u,Nt,N,x) 
 
for tt = 1:Nt 
  
    % Differentiation done with parabolic fit for derivative such that 
    % u = ax^2+bx+c and dudx = 2ax+b because of unequal mesh spacings. 
    % A first point fit is used for the inlet, a center point fit is used 
    % for the interior points, and a 3rd point fit is used for the outlet. 
     
    % For the interior points 
    for ii = 2:N-1 
        x1 = x(ii-1); 
        x2 = x(ii); 
        x3 = x(ii+1); 
        b1 = ((u(tt,ii)-u(tt,ii+1))*(x1^2-x2^2)-(u(tt,ii-1)-u(tt,ii))*... 
            (x2^2-x3^2))/((x2-x1)*(x2^2-x3^2)+(x2-x3)*(x1^2-x2^2)); 
        a1 = (u(tt,ii-1)-u(tt,ii)+b1*(x2-x1))/(x1^2-x2^2); 
        dudx(tt,ii) = 2*a1*x2+b1; 
    end 
     
    % For the inlet condition 
    x1 = x(1); 
    x2 = x(2); 
    x3 = x(3); 
    b1 = ((u(tt,2)-u(tt,3))*(x1^2-x2^2)-(u(tt,1)-u(tt,2))*(x2^2-x3^2))/... 
        ((x2-x1)*(x2^2-x3^2)+(x2-x3)*(x1^2-x2^2)); 
    a1 = (u(tt,1)-u(tt,2)+b1*(x2-x1))/(x1^2-x2^2); 
    dudx(tt,1) = 2*a1*x1+b1; 
     
    % For the outlet condition 
    x3 = x(N); 
    x2 = x(N-1); 
    x1 = x(N-2); 
    bN = ((u(tt,N-1)-u(tt,N))*(x1^2-x2^2)-(u(tt,N-2)-u(tt,N-1))*(x2^2-x3^2))/... 
        ((x2-x1)*(x2^2-x3^2)+(x2-x3)*(x1^2-x2^2)); 
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    aN = (u(tt,N-2)-u(tt,N-1)+bN*(x2-x1))/(x1^2-x2^2); 
    dudx(tt,N) = 2*aN*x3+bN; 





function Vdot = VFlowRate(u,dudx,Nt,N,beta,Vdotrigid,Vdotref) 
 
for tt = 1:Nt 
 
    for xx = 1:N 
        Vdot(tt,xx) = -Vdotrigid/Vdotref*(1+beta*u(tt,xx))^3*dudx(tt,xx); 





function V = Volume(Vdot,N,t) 
 
% Integration done using the trapezoid rule 
% Result is gamma*V-ND 




function h = Height(u,Nt,N,beta,h0) 
h(Nt,N) = zeros; 
 
for tt = 1:Nt 
     
    for xx = 1:N 
        h(tt,xx) = h0*(1+beta*u(tt,xx)); 




function Vchannel = ChannelVolume(h,x,Nt,N,w,L) 
h_integ(N)=zeros; 
z=x*L; 
%Integration done using the trapezoid rule 
for tt = 1:Nt 
     
    for xx = 1:N 
        h_integ(xx) = h(tt,xx); 
        Vchannel(tt) = w*trapz(z,h_integ)*1e-6; 




(1) Love, A. E. H. A Treatise on the Mathematical Theory of Elasticity; 4th ed.; Cambridge University 
Press: Cambridge, 1934. 
 
